

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mazindol	[3H]imidazo[2,1-a]isindol-5-ol 5-[4-chlorophenyl]-2,5-dihydro- [CAS]	22232-71-9	US 3763178	Anorectic/Aniobesity	Obesity
Mazipredone MC-5723		13085-08-0	US 6043269	Cardiovascular	Unspecified
MCC-478	(2-amino-6-(4-methoxyphenylthio)-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) ester)				
MCI-154	3(2H)-Pyridazinone, 4,5-dihydro-6-[4-(4-pyridylamino)phenyl]-, monohydrochloride [CAS]	98326-32-0 98326-33-1	EP 145019	Cardiotonulant	Infection, hepatitis-B virus
m-Cresyl Acetate		122-46-3			Heart failure
MDAM	Gamma-Methylene-10-deazaaminopterin			Anticancer, antimetabolite	Cancer, general
MDI-101			US 4885311	Antiacne	Acne
MDI-403		403849-94-5	US 4677120	Antiacne	Acne
MDL-100907	4-Piperidinemethanol, Alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-, (R)- [CAS]	139290-65-6		Hypnotic/Sedative	Sleep disorder, general
mebendazole	methyl-5-benzoylbenzimidazole-2-carbamate	31431-39-7	GB 1307306	Anthelmintic	
mebeverine	Benzoic acid, 3,4-dimethoxy-, 4-[ethyl][2-(4-methoxyphenyl)-1-methylethyl]amino]butyl ester [CAS]	3625-06-7		Antispasmodic	Irritable bowel syndrome
Mebhydroline		524-81-2			
Mebrofenin		78266-06-5			
Mebutamate		64-55-1			
mecamylamine	Bicyclo[2.2.1]heptan-2-amine, N,2,3,3-tetramethyl- [CAS]	60-40-2		Neurological	Unspecified
Mechlorethamine		51-75-2			
Mechlorethamine Oxide		302-70-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mecillinam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[((hexahydro-1H-azepin-1-yl)methylene)amino]-3,3-dimethyl-7-oxo-[2S-(2Alpha,5Alpha,6Beta,)-]-[CAS]	322887-01-7 322887-03-9	GB 1293590	Penicillin, injectable	Infection, general
Mecilizine		569-65-3			
Meclocycline	Benzoic acid, 2-[(2,6-dichloro-3-methylphenyl)amino]-, monosodium salt [CAS]	2013-58-3			
meclofenamate				Antiarthritic, other	Arthritis, osteo
Meclofenamic Acid		644-62-2			
Meclofenoxate		644-62-2			
Mecloqualone		51-68-3			
Mecysteine		340-57-8			
Medazepam		18598-63-5			
medifoxamine	Ethanamine, N,N-dimethyl-2,2-diphenoxy-[CAS]	12/6/2898 32359-34-5	FR M5498	Antidepressant	
Medrogestone		977-79-7			
Medronic Acid	Pregn-4-ene-3,20-dione, 17-(acetoxy)-6-methyl-[6Alpha)	1984-15-2 71-58-9 520-85-4			
medroxyprogesterone				Formulation, fixed-dose combinations	Contraceptive, female
Medrysone		2668-66-8			
Mefenamic Acid		61-68-7			
Mefenorex		17243-57-1			
Mefexamide		1227-61-8			
mefloquine	4-Quolinemethanol, Alpha-2-piperidinyl-2,6-bis(trifluoromethyl)-, (R*, S*)-(±)-[CAS]	51773-92-3 53230-10-7 69191-18-0	GB 1594282	Antimalarial	
Mefruside		7195-27-9			
Megestrol		595-33-5			
Meglumine		22154-43-4 131-49-7			
meglutol	2-hydroxy-2-methyl-1,3-propandicarboxylic acid	503-49-1	US 3629449	Hypolipaemic/Antiatherosclerosis	Hyperlipidaemia, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
melagatran	Glycine, N-[{1R)-2-[(2S)-2-[[4-(aminominnomehyl)phenyl]methyl]amino]-2-oxobutyl]-[1-azetidinyl]-2-oxethyl]- [CAS]	159776-70-2	WO 9616671	Antithrombotic	Thrombosis, general
	N-[{3R)-1,2,3,4-Tetrahydroisoquinolinium-3-ylcarbonyl]-{[1R)-1-(4-chlorobenzyl)-2-f4-cyclohexyl}-4-{[1H-1,2,4-triazol-1-ylmethyl]piperidin-1-yl}-2-oxoethylamine(1-melanocortin-4-agonist)			Anorectic/Antiobesity	Obesity
Melarsoprol		494-79-1			
Melengestrol	Alanine, 3-(3,4-dihydroxyphenyl)-methyleneester [CAS]	5633-18-1			
melevodopa		7101-51-1	EP 252290	Antiparkinsonian	Parkinson's disease
Melinamide		14417-88-0			
Melitracen		5118-29-6			
meloxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-1,1-dioxide- [CAS]	71125-38-7	US 4233299	Antiarthritic, other	Arthritis, rheumatoid
melperone	1-Butanone, 1-(4-fluorophenyl)-4-(4-methyl-1-piperidinyl)- [CAS]	1622-79-3 3575-80-2	BE 651144	Neuroleptic	
Melphalan		148-82-3			
	Benzenemethanol, 2-chloro-Alpha-{{((1,1-dimethylethyl)amino)methyl)-4-hydroxy-, (R)-, (R*)}-2-3-dihydroxybutanedioate (1:1) (salt) [CAS]	134885-37-5	EP 420120	Labour inhibitor	Labour, preterm
meluidazine	Tricyclo[3.3.1.13.7]decan-1-amine, 3,5-dimethyl [CAS]	41100-52-1 19982-08-2	EP 392059	Cognition enhancer	Dementia, AIDS-related
memantine	Acetamide, 2-[[{5R,6S)-6-[(1R)-1-hydroxyethyl]-2-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-en-3-ylmethyl]methyl]amino]- [CAS]	195874-55-6	WO 9406803	Beta-lactam antibiotic	Infection, general
MEN-10700					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
MEN-10755	5,112-Naphthacenedione, 7-[[4-O-(3-amino-2,3,6-trideoxy- α -L-Lyxohexopyranosyl)-2,6-dideoxy- α -D-lyxohexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-(hydroxyacetyl)-hydrochloride, (7S,9S)- [CAS]	169317-77-5	WO 9509173	Anticancer, antibiotic	Cancer, breast
Menadiol		481-85-6			
Menadione		58-27-5			
Menadoxime		573-01-3			
Menbutone		3562-99-0			
Menogaril		71628-96-1			
MENT	7Alpha-Methyl-19-nortestosterone			Formulation, transdermal, systemic	Contraceptive, male
Menthol	Cyclohexanol, 5-methyl-2-(1-methylethyl)-[CAS]	1490-04-6 89-78-1		Formulation, dermal, topical	Pruritus
Menthyl Valerate		89-47-4			
Meobentine		46464-11-3			
Meparffynol		77-75-8			
meparticin	Parficitin, methyl ester [CAS]	11121-32-7	US 3780173	Antifungal	Infection, Candida, general
Mepazine		60-89-9			
Mepenzolate Bromide		76-90-4			
Meperidine		57-42-1			
Mephenesin		59-47-2			
Mephenoxalone		70-07-5			
Mephentermine		100-92-5			
Mephenytoin		50-12-4			
Mephobarbital		115-38-8			
Mepindolol		23694-81-7			
Mepitostane	N-(2-(6-Dimethylphenyl))-1-methyl-2-piperidinocarboxamide	21362-69-6 96-88-8		Formulation, modified-release, >24hr	Pain, post-operative
Mepivacaine					
Mepixanox		17854-59-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Neprednison		1247-42-3			
Neprobamate		57-53-4			
meproscliarin	Bufa-4,20,22-trienolide, 3-[(6-deoxy-4-O-methyl-Alpha-L-mannopyranosyloxy)-14-hydroxy-, (3S)- [CAS]	33396-37-1	DE 1910207	Cardiostimulant	Heart failure
meptazinol	Pheno-3-(3-ethylhexahydro-1-methyl-1H-azepin-3-yl)- [CAS]	54-240-58-8 59263-76-2	GB 1285025	Analgesic, other	Pain, general
mequitazine	10H-Phenothiazine, 10-(1-azabicyclo[2.2.2]oct-3-ylmethyl)- [CAS]	29216-28-2	GB 1250534	Antiallergic, non-asthma	
Meralelin		4386-35-0			
Meralluride		8069-64-5			
Merbromin		129-16-8			
Mercaptomerin		21259-76-7			
Mercumallylic Acid		86-36-2			
Mercuric Chloride, Ammoniated		10124-48-8			
Mercuric Oleate		1191-80-6			
Mercuric Oxycyanide		1335-31-5			
merimepodib	Carbamic acid, ((3-(((3-methoxy-4-(5-oxazolyl)phenyl)amino)carbonyl)amino)phenyl)methyl- (3S)-tetrahydro-3-furanylester [CAS]	198821-22-6	US 5807876	Antiviral, other	Infection, hepatitis C virus
meropenem	1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[(5-[(dimethylamino)carbonyl]-3-pyrrolidinyl)thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, (4R-[3(3S*,5S*),4Alpha,5B,6B(R*)]- [CAS]	96036-03-2	EP 126387	Beta-lactam antibiotic	Infection, respiratory tract, lower
Mersalyl		492-18-2			
Mesalamine		89-57-6			
mesalazine	Benzoic acid, 5-amino-2-hydroxy- [CAS]	89-57-6	WO 5541170	Formulation, oral, other	Colitis, ulcerative
Mesna		19767-45-4			
Mesoridazine		5588-33-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Mestanolone		521-11-9			
Mesterolone		1424-00-6			
Mestranol		72-33-3			
Mesulfen		135-58-0			
Metaciazepam		84031-17-4			
Metampicillin		6489-97-0			
Metapramine		21730-16-5			
Metaproterenol		586-06-1			
Metaraminol		54-49-9			
Metazocine		3734-52-9			
metergoline	Carbamic acid, [(8S)-1,6-dimethylergolin-8-yl]methyl-, phenylmethoxy ester [CAS]	17692-51-2 21631-37-8 2706-42-5	GB 1401935	Antiprolactin	Amenorrhoea
metformin	imidodicarbonimidic diamide, N,N-dimethyl-[CAS]	657-24-9		Formulation, modified-release, <=24 hr	Diabetes, Type II
Methacholine		62-51-1			
Methacycline		914-00-1			
Methadone		76-99-3			
Methafurylene		531-06-6			
Methamphetamine		537-46-2			
Methandriol		521-10-8			
Methandrostenolone		72-63-9			
Methantheline		53-46-3			
Methapyrilene		91-80-5			
Methaqualone		72-44-6			
Metharbital		50-11-3			
Methazolamide		554-57-4			
Methdilazine		1982-37-2			
Methenamine		100-97-0			
Methenolone		153-00-4			
Mestestrol		130-73-4			
Methetoin		5696-06-0			
Meticilllin		132-92-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Methimazole		60-56-0			
Methiodal		126-31-8			
Methionic Acid		503-40-2			
Methionine		63-68-3			
Methisazone		1910-68-5			
Methitural		467-43-6			
Methixene		2/2/4969			
Methocarbamol		532-03-6			
Methohexitol		22151-68-4			
Methotrexate	L-Glutamic acid, N-[4-[(2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]-[CAS]	59-05-2	US 2512572	Anticancer, antimetabolite	Cancer, general
Methotriprazine		60-99-1			
Methoxamine		390-28-3			
Methoxsalen		298-81-7			
Methoxyflurane		76-38-0			
Methoxyphenamine		93-30-1			
Methoxypromazine		61-01-8			
Methscopolamine		155-41-9			
Methsuximide		77-41-8			
Methylclothiazide		135-07-9			
Methyl Blue		28983-56-4			
Methyl Nicotinate		93-60-7			
Methyl Propyl Ether		557-17-5			
Methyl Salicylate		119-36-8			
Methyl tert-Butyl Ether		1634-04-4			
Methylbenzethonium Chloride		25155-18-4			
Methylcobalamin		13422-55-4			
methyldopa	[L-Tyrosine, 3-hydroxy-Alpha-methyl-[CAS]	555-30-6		Formulation, modified-release, <=24hr	Hypertension, general
Methylene Blue		61-73-4			
Methylergonovine		113-42-8			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Methylhexanamine	2-Piperidineacetic acid, Alpha-phenyl-, methyl ester [CAS]	105-41-9 113-45-1 298-59-9		Formulation, modified-release, multi	Attention deficit disorder
Methylprednisolone	Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-11-hydroxy-6-methyl-17-(1-oxopropoxy)-, (6Alpha, 11beta)- [CAS]	83-43-2			
methylprednisolone aceponate	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-[[8-[methyl(2-sulfoethyl)amino]-1,8-dioxaooctyl]oxy]-monosodium salt, (6Alpha, 11beta)- [CAS]	86401-95-8	EP 72547	Antipruritic/inflamm, allergic	Pruritus
methylprednisolone suleptanate		90350-40-6	JP 59137500	Antistress	Asthma
Methylthiouracil		56-04-2			
Methyltriенolone		965-93-5			
Methyprylon		125-64-4			
Methysergide		361-37-5			
Metazinic Acid		13993-65-2			
metipranolol	Phenol, 4-[2-hydroxy-3-[(1-methylethyl)amino]propoxy]-2,3,6-trimethyl-1-acetate [CAS]	22664-55-7	GB 1206148	Antihypertensive, adrenergic	
metoclopramide	Benzamide, 4-amino-5-chloro-N-[2-(diethylaminoethyl)-2-methoxy- [CAS]	364-62-5		Formulation, modified-release, <=24hr	Gastro-oesophageal reflux
Metocurine Iodide		7601-55-0			
Metofenazine		388-51-2			
metolazone	6-Quinazolinesulfonamide, 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo- [CAS]	17560-51-9	US 4517179	Antihypertensive, diuretic	
Metoplimazine		14008-44-7			
Metopon	2-Propanol, 1-[4-(2-methoxyethyl)phenoxy]-3-[(1-methylethyl)aminol, (+/-)- [CAS]	143-52-2 51384-51-1 56392-17-7 37350-58-6			
metoprolol				Formulation, modified-release, other	Hypertension, general
Metralindole		54188-38-4			
Metrizamide		31112-62-6			
Metrizoic Acid		1949-45-7			
Metron S		13946-02-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Metyrapone		54-36-4			
Metyrosine		672-87-7			
Mexazolam		31868-18-5			
Mexenone		1641-17-4			
Mexiletine		31828-71-4			
Mefloccillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-[[[1-(methylsulfonyl)-2-oxo-1-imidazolidinyl]carbonyl]amino]phenylacetyl [2Alpha,6S(S*)]- [CAS]	42057-22-7 51481-65-3	GB 1301961	Penicillin, injectable	Infection, general
MFH-244	Benzene carboximidic acid, 3,4,5-trihydroxy-, ethyl ester, hydrochloride	72539-76-5 95933-76-9	US 4623659	Cardiovascular	Reperfusion injury
minanserin	Dibenzocyclo[1,2-az]azepine, 1,2,3,4,10,14b-hexahydro-2-methyl-[CAS]	21535-47-7 24219-97-4	GB 1173783	Antidepressant	Depression, general
Mibepradil		1166044-53-2			
Miboplatin		103775-75-3			
Micafungin		235114-32-6			
mitconazole	1H-Imidazole, 1-(2,4-dichlorophenyl)-2[2,4-dichlorophenyl)methoxy]ethyl]	22916-47-8		Formulation, modified-release, other	Infection, Candida, general
Micronomicin		52093-21-7			
midaxifylline	1H-Purine-2,6-dione, 8-(1-aminocyclopentyl)-3,7-dihydro-1,3-dipropl-[CAS]	151159-23-8	US 5378844	Cardiovascular	Unspecified
midazolam	4H-Imidazo[1,5-a][1,4]benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl-[CAS]	59467-70-8 59467-94-6	US 4280957	Anaesthetic, injectable	
midecamycin	Leucomycin V, 3,4B-dipropanoate [CAS]	35457-80-8	US 3761588	Macrolide antibiotic	Infection, general
midecamycin acetate	Leucomycin V, 3B,9-diacetate 3,4B-dipropanoate [CAS]	55881-07-7	JP 49124087	Macrolide antibiotic	Infection, general
midestine	2-Thiophene carboxylic acid, S-[1-methyl-2-oxo-2-[tetrahydro-2-oxo-3-(thienyl)amino]ethyl] ester [CAS]	94149-41-4	EP 120534	COPD treatment	Emphysema, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
midodrine	Acetamide, 2-amino-N-[2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]- [CAS]	42318-56-0 42794-76-3	EP 164571	Urological	Incontinence
midostaurin	Benzamide, N-(2,3,10,11,12,13-hexahydro-1H,9H-dimidolo[1,2,3-gh:3'2',1'-im]pyrrol[3,4-j][1,7]benzodiazolin-11-yl)-N-methyl-, (9Alpha,10B,11B,13A)ipha-[CAS]	120685-11-2	EP 296110	Anticancer, other	Cancer, leukaemia, acute myelogenous
miapristone	Estra-4,9-dien-3-one, 11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(1-propynyl)-, (11B,17B)- [CAS]	84371-65-3	EP 57115	Abortifacient	Abortion
miglitol	3,4,5-Piperidinetriol, 1-(2-hydroxyethyl)-2-(hydroxymethyl)-, (2R-(2Alpha,3B,4Alpha,5B))- [CAS]	72432-03-2	EP 55431	Antidiabetic	Diabetes, Type I
miglustat	3,4,5-Piperidinetriol, -butyl-2-(hydroxymethyl)-(2R-(2Alpha, 3B, 4Alpha, 5B)) [CAS]	72599-27-0	DE 2758025	Metabolic and enzyme disorders	Gaucher's disease
mildronate	Hydrazinium, 2-(2-carboxyethyl)-1,1,1-trimethyl-, inner salt [CAS]	76144-81-5	WO 8001068	Cardiotonutant	Heart failure
milnacipran	Cyclopropanecarboxamide, 2-(aminomethyl)-N,N-diethyl-1-phenyl-, cis-(+-)[CAS]	101152-94-7 92623-85-3	US 4478836	Antidepressant	Depression, general
Miloxacin	[3,4'-Bipyrindine]-5-carbonitrile, 1,6-dihydro-2-methyl-6-oxo- [CAS]	37065-29-5 78415-72-2	US 4313951	Cardiotonutant	Heart failure
miriznone	Ethanaminium, 2-[(hexadecyloxy)hydroxyphosphinyl]oxy-N,N,N-trimethyl-, hydroxide, inner salt [CAS]				
mitofosine	53949-20-5 58066-85-6	EP 225608	Anticancer, other	Cancer, skin, general	
minaprine	25905-77-5 25933-17-7	GB 1345880	Antidepressant	Depression, general	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
minocycline	2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, [4S-(4Alpha,4aAlpha,5aAlpha,12aAlpha)]-[CAS]	10118-90-8		Formulation, optimized, microparticles	Infection, oral
minodronic acid	Phosphonic acid, (1-hydroxy-2-imidazol[1,2-a]pyridin-3-ylethylidene)bis-, [CAS]	180064-38-4	EP 354806	Anticancer, other	Cancer, myeloma
minoxidil	2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide [CAS]	38304-91-5	US 4139619	Vasodilator, peripheral	Hypertension, general
Miokamycin	Pyrazinof[2,1-al]pyrido[2,3-cl]benzazepine, 1,2,3,4,10,14b-hexahydro-2-methyl-[CAS]	85650-52-8 61337-67-5	GB 1543171	Antidepressant	Depression, general
mitazapine	Prost-13-en-1-oic acid, 11,16-dihydroxy-16-methyl-9-oxo-, methyl ester, (11Alpha,13E)-(±)- [CAS]	59122-46-2 59122-48-4	US 4301146	Prostaglandin	Ulcer, gastric
misoprostol	Erythromycin, 8,9-didehydro-N-demethyl-9-deoxy-6,11-dideoxy-6,9-epoxy-12-O-methyl-N-(1-methylethyl)-11-oxo-, (2E)-2-butenedioate (2:1) [CAS]	154802-96-7	WO 9324509	Gastroprotective	Gastro-oesophageal reflux
mitemcinal	Calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinyl carbonyl)propionate, dihydrate-[CAS]	145525-41-3	EP 507534	Antidiabetic	Diabetes, Type II
mitiglinide			488-41-5		
Mitobronitol			459-86-9		
Mitoguazone					
mitolactol	Galactitol, 1,6-dibromo-1,6-dideoxy- [CAS]	10318-26-0	US 3993781	Anticancer, alkylating	Cancer, cervical

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mitomycin	Azirino[2',3':3,4]pyrrol[1,2-ajindole-4,7-dione, 6-amino-8-[(aminocarbonyloxy)methyl]-1,2,8,8a-hexahydro-8a-methoxy-5-methyl-[1aS-(1aAlpha,8B,8aAlpha,8bAlpha)]- [CAS]	50-07-7		Formulation, parenteral, other	Cancer, stomach
Mitotane	9,10-Anthracenodione, 1,4-dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]ethyl]amino]- [CAS]	65271-80-9 70476-82-3	US 4197249	Anticancer, other	Cancer, breast
mitoxantrone	9,10-Anthracenodione, 1,4-dihydroxy-5,8-bis[2-[(2-hydroxyethyl)amino]ethyl]amino]- [CAS]	65271-80-9 70476-82-9		Formulation, optimized, liposomes Antiviral, other	Cancer, general Infection, hepatitis-B virus
MV-210	(3'-Fluoro-2'-3'-dideoxy) guanosine)				
mirvacurium	isoquinolinium, 2,2'[{1,8-dioxo-4-octene-1,8-diy]bis[oxy-3,1-propanediyl]}bis[1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-{[3,4,5-trimethoxyphenyl)methyl}- dichloride, [R-(R*)-R*(E)]- [CAS]	106861-44-3	EP 181055	Muscle relaxant	Anaesthesia, adjunct
Mivazerol	4(1H)-Pyrimidinone, 2-[1-[1-[4-fluorophenyl)methyl]-1H-benzimidazol-2-yl]4-piperidiny]methylamino]- [CAS]	108612-45-9	EP 217700	Antiallergic, non-asthma	Rhinitis, allergic, general
Mizoribine	(R)-N-(3-quinuclidinyl)-7-oxo-4,7-dihydropyrano[3,2-b]pyridine-6-carboxamide hydrochloride	50924-49-7			
MKC-733		194093-42-0	JP 09216888	Gastrokinetic	Gastro-oesophageal reflux
MLN-519	6-Oxa-2-azabicyclo[3.2.0]heptane-3,7-dione, 1-[(1S)-1-hydroxy-2-methylpropyl]-4-propyl- (1R,4R,5S)- [CAS]	211866-70-5	WO 9915183	Neuroprotective	Ischaemia, cerebral
MLN-576	4-Methoxy-benzol[alphaphenazine-11-carboxylic acid (2-(dimethylamino)-1-(R)-methylene)-amide			Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
moclobemide	Benzamide, 4-chloro-N-[2-(4-morpholinyl)ethyl]- [CAS]	71320-77-9	EP 326023	Antidepressant	Depression, general
modafinil	Acetamide, 2-[{diphenylmethyl}sulfanyl]- [CAS]	68693-11-8	DE 280625	Psychostimulant	Narcolepsy
moexipril	3-Isoquinolinecarboxylic acid, 2-[2-[(1-(ethoxycarbonyl)-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-dimethoxy- (3S-(2(R*(R*)),3R*)- [CAS]	103775-10-6 103775-14-0	US 4344949	Anthypertensive, renin system	Hypertension, general
Mofarotene		125533-88-2			
Mofebutazone		2210-63-1			
Mofegiline		119386-96-8			
mofezolac	5-Isoxazoleacetic acid, 3,4-bis(4-methoxyphenyl)- [CAS]	78967-07-4	EP 26928	Analgesic, NSAID	Pain, post-operative
MOL-6131	N-[4-(aminomethyl)benzyl]-8(S)-[1-14-[2-(4-aminophenyl)-acetamido]butyryl]piperidin-4-yl]-2-(naphthalen-1'-ylmethyl)-1,3-dioxo-2,3,5,8-tetrahydro-1H-[1',2,4]triazolo[1,2-a]pyridazine-5(R)-carboxamide			Antasthma	Asthma
Molindone		7416-34-4			
mosidomine	Sydnone imine, N-[(4-morpholinyl)-3-[(4-morpholinyl)-acetamido]butyryl]piperidin-4-yl]- [CAS]	25717-80-0	US 3769283	Vasodilator, coronary	
metametasone	Pregna-1,4-diene-3,20-dione, 9,21-dichloro-11,17-dihydroxy-16-methyl-, (11B,16A)alpha- [CAS]	105102-22-5 83919-23-7	EP 57401	Antipuritic/inflamm, allergic	Psoriasis
Monatepil		103377-41-9			
Monobenzzone		103-16-2			
monolaurin	Dodecanoic acid, monoester with 1,2,3-propanetriol [CAS]	27215-38-9	US 4885282	Dermatological	Ichthyosis
montelukast	Cyclopropaneacetic acid, 1-[[1'-3-[2-[(7-Chloro-2-quinoliny)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl-, [CAS]	151767-02-1 138966-92-8			Asthma
Monteplase		122007-85-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Moperone		1050-79-9			
Mopidamol		13665-88-8			
Moprolol	Carbamic acid, [10-[3-(4-morpholinyl)-1-oxopropyl]-10H-phenothiazin-2-yl]-, ethyl ester [CAS]	5741-22-0			
Moracizine		29560-58-5 31883-05-3	US 3864487	Antiarrhythmic	Tachycardia, ventricular
Morazone		6536-18-1			
Moxicizine		31883-05-3			
Moroxydine		3731-59-7			
Morphazinamide		952-54-5			
morpheine	Morphinan-3-6-diol 7-8-didehydro-4,5-epoxy-17-methyl- (5Alpha,6Alpha)-, [CAS]	6055-06-7 64-31-3		Formulation, parenteral, other	Pain, cancer
morpheine-6-glucuronide	morpheine-6-glucuronide			Formulation, inhalable, systemic	Pain, general
mosapramine	Spiro[imidazo[1,2-a]pyridine-3,(2H),4-piperidin]2-one, 1-[3-(3-chloro-10,1-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl]hexahydro-, (+/-)- [CAS]	89419-40-9 98043-60-8	US 4337260	Neuroleptic	
mosapride	Benzamide, 4-amino-5-chloro-2-ethoxy-N-((4-((4-fluorophenyl)methyl)-2-morpholinyl)methyl)- [CAS]	112885-41-3 112885-42-4	EP 243859	GI inflammatory/bowel disorders	Gastritis
motexafin gadolinium	Gadolinium, bis(acetato-kappaO)(9,10-diethyl-2,2-bis(2-(2-(2-methoxy)ethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,16,16,13-dinitriolo-1,18-benzodiazacyclodeicosine-5,14-dipropanoato-kappaN1, kappaN18, kappaN23, kappaN24, kappaN25), (PB-7-11-2352'4) [CAS]		246252-06-2	Radio/chemosensitizer	Cancer, brain
Motretinide		56281-36-8			
Moveltipril		85890-54-8			
Moxalactam		64982-97-2			
Moxastine		3572-74-5			
Moxaverine		10539-19-2			
Moxestrol		34816-55-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
moxifloxacin	3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(octahydro-6H-pyrido[3,4-b]pyridin-6-yl)-4-oxo-, hydrochloride (4aS-cis)- [CAS]	186826-86-8 151096-09-2	DE 19546249	Quinolone antibacterial	Infection, respiratory tract, general
mosixlyte	Pheno[4R]-{2-[dimethylaminoethoxy]}-2-methyl-5-(1-methylethyl)-, acetate (ester), [CAS]	964-52-3 54-32-0		Male sexual dysfunction	Impotence
monoxidine	5-Pyrimidinamine, 4-chloro-N-[4,5-dihydro-1H-imidazol-2-yl]-6-methoxy-2-methyl- [CAS]	75438-57-2	DE 2849537	Antihypertensive, other	Hypertension, general
M-PGA	(-)-(S)-2-Methyl-2-(1-oxo-2,3-dihydro-1H-isindol-2-yl)pentanedioic acid		US 571291	Anticancer, other	Cancer, general
MP1-5010	Platinum diamminedichloro-, (SP-4-2) + (R)-4-[1-hydroxy-2-(methylamino)-ethyl]-1,2-benzenediol		US 6224883	Formulation, parenteral, other	Cancer, head and neck
MP1-5020	2,4(1H,3H)-Pyrimidinedione, 5-fluoro- [CAS]	51-21-8 198076-81-2	US 5750146	Formulation, parenteral, other	Cancer, breast
MPL			US 6060481	Immunostimulant, other	Vaccine adjunct
MRS-1754				Antiesthma	Asthma
MS-209	1-Piperazineethanol, 4-(diphenylacetyl)-Alpha-[5-(quinolonyloxy)methyl]-, (2E)-2-butenedioate(2:3) (salt) [CAS]	158681-49-3		Radio/chemosensitizer	Cancer, breast
MS-275	N-(2-Aminophenyl)-4-[N-(pyridin-3-yl-methoxy carbonyl)aminomethyl]benzamide			Anticancer, antimetabolite	Cancer, lung, general
MS-325		201688-00-8	EP 839805	Neuroleptic	Schizophrenia
MS-377					
Mupirocin		12650-69-0			
Muscarine		300-54-9			
Muzolimine		55294-15-0	US 61753591	Hepatoprotective	Unspecified
MX-1013					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
mycophenolate mofetil	4-Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, 2-(4-morpholinyl)ethyl ester, (E)- [CAS] 128794-94-5	116680-01-4 128794-94-5	WO 9119498	Immunosuppressant	Transplant rejection, general
Myrophine	4-hexanoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (E)- [CAS]	37415-62-6 24230-93-1		Formulation, oral, enteric-coated	Transplant rejection, general
N-(Hydroxymethyl)nicotinamide		467-18-5			
N,N,N',N'-Tetraethylphthalimide		3569-99-1			
N ₂ -Formylsulfisomidine		83-81-8			
N ⁴ -β-D-Glucosylsulfanilamide		795-13-1			
N ⁴ -Sulfanilylsulfanilamide		53274-53-6			
Nabilone	2-Butanone, 4-(6-methoxy-2-naphthalenyl)- [CAS]	547-52-4			
nabumetone		51022-71-0			
N-acetylcysteine	L-Cysteine, N-acetyl- [CAS]	42924-53-8 616-91-1	GB 1476721	Anti-inflammatory	Arthritis, osteo
N-Acetylmethionine		65-52-7		Anticancer, other	Cancer, general
nadifloxacin	1H,5H-Benzol[<i>b</i>]quinolizine-2-carboxylic acid, 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-, (+/-)- [CAS]	124858-35-1	US 4399134	Quinolone antibacterial	Acne
nadolol	2,3-Naphthalenediol, 5-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,2,3,4-tetrahydro- [CAS]	4220-33-9	US 4346106	Antihypertensive, adrenergic	
Nadoxolol		54063-51-3			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
naftamostat	Benzoic acid, 4-[aminoinomethyl]amino]-, 6-(aminoinomethyl)-2-naphthalenyl ester-[CAS]	80261-32-7 81525-10-2 82956-11-4	EP 450232	GI inflammatory/bowel disorders	Pancreatitis
nafarelin	Luteinizing hormone-releasing factor (pig), 6-f3-(2-naphthalenyl)-D-alanine-[CAS]	76932-56-4 86220-42-0	EP 21234	Releasing hormones	Endometriosis
Nafcilin		147-52-4			
Nafronyl		31329-57-4			
naftidrofuryl	2-Furanpropanoic acid, tetrahydro- α - α -(1-naphthalenylmethyl)-, 2-(diethylamino)ethyl ester	31329-57-4		Formulation, modified-release, other	Unspecified
naftifine	1-Naphthalenemethanamine, N-methyl-N-(3-phenyl-2-propenyl)-, (E)- [CAS]	65472-88-0 65473-14-5	US 4282251	Antifungal	Infection, dermatological
naftopidil	1-Piperazineethanol, 4-(2-methoxyphenyl)- α -(1-naphthalenyloxy)methyl- [CAS]	57149-07-2	US 3997666	Antihypertensive, adrenergic	Hypertension, general
nabuphine	Morphinan-3,6,14-triol, 17-(cyclobutylmethyl)-4,5-epoxy-, (5Alpha,6Alpha)- [CAS]	20594-83-6 23277-43-2	US 3393197	Analgesic, other	Pain, general
Nalidixic Acid	Morphinan-3,14-diol, 17-(cyclpropylmethyl)-4,5-epoxy-6-methylene-, (5Alpha)-[CAS]	389-08-2			
nalmefene		55006-26-9	JP 56167687	Dependence treatment	Poisoning, drug
Nalorphine		62-67-9			
naltrexone	Morphinan-6-one, 17-allyl-4,5Alpha-epoxy-3,14-dihydroxy-, hydrochloride [CAS]	357-08-4 465-65-6		Septic shock treatment	
naltrazone	Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5Alpha)-[CAS]	16590-41-3 16576-29-2	US 3332950	Dependence treatment	Addiction, narcotic/opiate
NAMI	Imidazolium trans(imidazole)(dimethylsulfoxide)tetrachlororuthenate (III)			Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
inamidil	Guanidine, N-cyano-N'-(4-cyanophenyl)-N'-(1R)-1,2,2-trimethylpropyl)[CAS]	220641-11-2		Dermatological	Alopecia, general
Nandrolone		434-22-0			
Naphazoline		835-31-4			
Naphthalene		91-20-3			
naproxen betaine	Methanaminium, 1-carboxy-N, N, N-trimethyl-salt with (R)-6-methoxy-Alpha-methyl-2-naphthaleneacetic acid (1:1), sodium salt [CAS]	104124-26-7	US 4672077	Antiarthritic, other	Arthritis, rheumatoid
naproxen	2-Naphthaleneacetic acid, 6-methoxy-Alpha-methyl-, [CAS]	26159-34-2	GB 1211134	Analgesic, NSAID	Pain, general
naratriptan	1H-Indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)- [CAS]	22204-53-1	EP 303507	Antimigraine	Migraine
Narceine		121679-13-8			
Narcobarbital		131-28-2			
Natamycin	D-phenylalanine, N-((4-(1-methylethyl)cyclohexyl)carbonyl), trans-[CAS]	125-55-3			
nateglinide		7681-93-8			
N-Butyldeoxynojirimycin		105816-04-4	EP 196222	Antidiabetic	Diabetes, Type II
N-Butylscopolammonium Bromide		72599-27-0			
NC-503		149-64-4			
NC-531					
NCX-1000					
NCX-4016	Benzoic acid, 2-(acetoxy)-, 2-((nitrooxy)methyl)phenyl ester [CAS]	US 5643562	Anti-inflammatory	Amyloidosis	
NCX-456	Benzoic acid, 5-amino-2-hydroxy-, 4-(nitrooxy)butyl ester [CAS]	US 5643562	Cognition enhancer	Alzheimer's disease	
		WO 0061604	Hepatoprotective	Cirrhosis, hepatic	
		WO 9716405	Symptomatic antidiabetic	Insulin-related metabolic syndrome	
		256499-26-0	GI inflammatory/bowel disorders	Inflammatory bowel disease	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
NCX-950	Alpha-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzodimethanol nitrate				Asthma
n-Docosanol		661-19-8			
NE-100	Benzeneethanamine, 4-methoxy-3-(2-phenylethoxy)-N,N-dipropryl-, hydrochloride [CAS]	149409-57-4	WO 9307113	Neuroleptic	Schizophrenia
Nealbarbital		561-83-1			
nebivolol	2H-1-Benzopyran-2-methanol, Alpha,Alpha'-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro]-, (2R*)(R*(S*))-(1+)-118457-14-0 [CAS]	99200-09-6	EP 145067	Antihypertensive, adrenergic	Hypertension, general
neostigmine	NT-[4-(4-Dimethylcyclohexyl)-L-isoglutamine	163000-63-3	EP 0688312	Cognition enhancer	Unspecified
Nebracetam	Platinum, diamminiumhydroxylacetato(2-)O ₂] ²⁺ , (SP-4-3)- [CAS]	95734-82-0	EP 216362	Anticancer, alkylating	
nedaplatin	4H-Pyran[3,2-d]quinoline-2,8-dicarboxylic acid, 9-ethyl-6,9-dihydro-4,6-dioxo-10-propyl- [CAS]	69049-73-6 69049-74-7	EP 555718	Antis asthma, Ophthalmological	Rhinitis, allergic, general, Ocular disorder, general
nedocromil					
nefazodone	3H-1,2,4-Triazol-3-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-, [CAS]	82732-99-6 83386-66-9	US 4338317	Antidepressant	Depression, general
nefracetam	1-Pyrrolidineacetamide, N-[2,6-dimethylphenyl]-2-oxo- [CAS]	77191-36-7	US 4341790	Cognition enhancer	Dementia, senile, general
nefopam	1H-2,5-Benzodioxazine, 3,4,5,6-tetrahydro-5-methyl-1-phenyl- [CAS]	13669-70-0 23327-57-3	US 3487153	Analgesic, NSAID	
Negamycin	3-Isoquinolinecarboxamide, N-(1,1-dimethylfatty)decahydro-2-(2-hydroxy-3-((3-hydroxy-2-methylbenzoyl)amino)-4-(phenylthio)butyl)-, (3S-(2(2S',3S*)-3Alpha,4aB,8aB))-, [CAS]	33404-78-3			Infection, HIV/AIDS
Nemonapride		75272-39-8			
Neostigmine		59-99-4			-

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nepadutant	Cyclo[3-amino-L-alanyl-L-leucyl-N-[2-(acetamino)-2-deoxy-β-D-glucopyranosyl]-L-asparaginyl-L-Alpha-aspartyl-L-tryptophyl-L-phenylalanyl], (4-1)-lactam [CAS]	183747-35-5 202807-80-5	WO 9628467	Antiasthma	Asthma
neramexane	1,3,3,5-pentamethylcyclohexylamine	219810-59-0		Dependence treatment	Addiction, alcohol
neridronic acid	Phosphonic acid, (6-amino-1-hydroxyhexylidene)bis- [CAS]	79778-41-9		Musculoskeletal	Osteogenesis imperfecta
Nerifolin		466-07-9			
N-Ethylamphetamine	1H-Imidazole, 1-[2-(methylthio)-1-[2-(pentyloxy)phenyl]ethenyl]-, monohydrochloride, (E)- [CAS]	457-87-4 130773-02-3 130726-68-0	EP 446540	Antifungal	Infection, Candida, general
neticonazole	D-Streptamine, O-3-deoxy-4-C-methyl-3-(methylamino)-β-L-arabinopyranosyl-(1-6)-O-[2,6-diamino-2,3,4,6-tetrahydro-Alpha-D-glycero-hex-4-enopyranosyl-(1-4)]-2-deoxy-56391-56-1 N-ethyl- [CAS]	56391-57-2	GB 1473733	Aminoglycoside antibiotic	Infection, general
nefamilicin	6H-Dipyrido[3,2-b;3'-e][1,4]diazepin-6-one, 11-cyclopropyl-5,11-dihydro-4-methyl- [CAS]	129618-40-2	EP 429987 WO 9635689	Antiviral, anti-HIV Anxiolytic	Infection, HIV/AIDS Anxiety, general
NGD-98-2					
Nialamide		51-12-7			
Niaprazine		27367-90-4			
Nicametate		3099-52-3			
nilcaraven	3-Pyridinecarboxamide, N,N'-(1-methyl)-1,2-ethanediyi)bis- [CAS]	7945-30-4	EP 29602	Neuroprotective	Haemorrhage, subarachnoid
nicardipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 2-[methyl(phenoxy)methyl]aminooethyl ester [CAS]	54527-84-3 55585-32-5	US 3985758	Neuroprotective	Hypertension, general
nicergoline	Ergoline-8-methanol, 10-methoxy-1,6-dimethyl-(8/b)-, 5-bromo-3-pyridinecarboxylate(ester)	27848-84-6		Formulation, modified-release, other	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Niceritrol		5868053			
Niclosamide		50-65-7			
Nicoclonate		10571-59-2			
Nicoturanoate		15351-13-0			
Nicomol		27959-26-8			
Nicomorphine		639-48-5			
nicorandil	3-Pyridinecarboxamide, N-[2-(nitrooxy)ethyl]- [CAS]	65141-46-0	US 4792564	Vasodilator, coronary	Hypertension, general
Nicotinamide		98-92-0			
nicotine	Pyridine, 3-(1-methyl-2-pyrrolidinyl)-, (S)- [CAS]	54-11-5	Formulation, inhalable, other	Addiction, nicotine	
Nicotinic Acid		59-67-6			
Nicotinic Acid Benzyl Ester		94-44-0			
Nicotinyl Alcohol		100-55-0			
nifedipine	4-(2'-nitrophenyl)-2,6-dimethyl-3,5-dicarbomethoxy-1,4-dihydropyridine	21829-25-4	GB 1173862	Vasodilator, coronary	Hypertension, general
nifeekalant	2,4(1H,3H)-Pyrimidinedione, 6-[[2-[2-hydroxyethyl][3-(4-nitrophenyl)propyl]amino]ethyl]amino]-1,3-dimethyl-, [CAS]	1300336-43-0 130056-51-8	EP 369627	Antiarrhythmic	Arrhythmia, general
Nifenalol		7413-36-7			
Niflumic Acid		4394-00-7			
Nifuratel		4936-47-4			
Nifurfoline		3363-58-4			
Nifuroxazide		965-52-6			
Nifuroxime		6236051			
Nifurpirinol		13411-16-0			
Nifurprazine		1614-20-6			
Nifturtimox		23256-30-6			
Nifurtoinol		1088-92-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
niflurizide	2-Thiophene-carboxylic acid, 5-nitro-, [3-(6-nitro-2-furyl)-2-propenyl]idene)hydrazide [CAS]	39978-42-2	US 3847911	Antidiarrhoeal	Infection, GI tract
NIK-254	Gentamicin, sulfate (salt) [CAS]	1405-41-0		Formulation, other	Infection, general
Nikethamide	2,4-imidazolidinedione, 5,5-dimethyl-[3-[4-nitro-3-(trifluoromethyl)phenyl]-[CAS]]	59-26-7			
nitamidine	3,5-Pyridinedicarboxylic acid, 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3-methyl-5-(1-methylethyl) ester [CAS]	63612-50-0	US 4472382	Anticancer, hormonal	Cancer, prostate
nivaldipine	Methanesulfonanide, N-(4-nitro-2-phenoxyphenyl)- [CAS]	75530-68-6	US 4338322	Antihypertensive, other	Hypertension, general
nimesulide	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, 2-methoxyethyl 1-methylethyl ester [CAS]	51803-78-2	US 3840597	Anti-inflammatory	Pain, general
Nimetazepam		2011-67-8			
nimodipine	Urea, N-[4-amino-2-methyl-5-pyrimidinylmethyl]-N-(2-chloroethyl)-N-nitroso-[CAS]	66085-59-4	EP 533014	Neuroprotective	
Nimorazole		6506-37-2			
nimustine	42471-28-3	1374344	Anticancer, alkylating	Cancer, brain	
Ninopterin	55661-38-6				
NIP-142	N-[4-(S)-(Cyclopropylamino)-3-(R)-hydroxy-2,2-dimethyl-7-nitro-3,4-dihydro-2H-1-benzopyran-6-y]-4-methoxybenzenacetamide	2179-16-0			Fibrillation, atrial
NIP-531	N-[3,5-Bis(trifluoromethyl)benzyl]benzimidazol-2-yl-amino]propyl-N-methylurea hydrochloride		WO 9804542	Antiarrhythmic	
niperotidine	N-[2-[[5-[(dimethylamino)methyl]furfuryl]thio]ethyl]-2-nitro-N-piperonyl-1-ethenediamine	84845-75-0		Antipruritic/antiflammn, allergic	Exzema, atopic
		GB 2104071	Antiucer		Ulcer, GI, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
nipradilol	2H-1-Benzopyran-3-ol, 3,4-dihydro-8-[2-hydroxy-3-(1'-methylethyl)amino]propoxy]-, 3-nitrate [CAS]	81486-22-8 86247-86-1	EP 42299	Formulation, mucosal, topical	Glaucoma
Niridazole	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-, methyl 2-methylpropyl ester- [CAS]	61-57-4			
nisoldipine	Benzamide, 2-(acetoxyoxy)-N-(5-nitro-2-thiazolyl)- [CAS]	63675-72-9	GB 1516793	Antihypertensive, other	Hypertension, general
nitazoxanide	1,3-Cyclonexanedione, 2-[2-nitro-4-(trifluoromethyl)benzoyl]- [CAS]	55981-09-4	US 5387598	Protozoacide	Infection, GI tract
nitisinone	1,3-Propanediamine, N,N-dimethyl-N'-(1-nitro-9-acridinyl)- [CAS]	104206-65-7 4533-39-5 6514-85-8	EP 186118 FR 1458183	Metabolic and enzyme disorders Anticancer, other	Cirrhosis, hepatic Cancer, ovarian
Nitrazepam	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, ethyl methyl ester- [CAS]	146-22-5			
nitrendipine	(1,1'-Biphenyl)-4-acetic acid, 2-fluoro-Alpha-methyl-, 4-(nitrooxy)butyl ester [CAS]	39562-70-4	GB 1355951	Antihypertensive, other	Hypertension, general
nitroflurbiprofen	158336-71-6	EP 670825	Urological		Incontinence
Nitrofurantoin		67-20-9			
Nitrofurazone		59-87-0			
nitroglycerin	1,2,3-Propanetriol, trinitrate [CAS]	55-63-0		Formulation, transdermal, patch	Angina, general
Nitromersol		133-58-4			
nitronaproxen	2-Naphthaleneacetic acid, 6-methoxy-Alpha-methyl 4-(nitrooxy)butyl ester (AlphaS)- [CAS]	163133-43-5	WO 9509831	Analgesic, NSAID	Pain, post-operative
nitroxazepine	Dibenz[b,f][1,4]oxazepin-11(10H)-one, 10-[3-(dimethylamino)propyl]2-nitro-monohydrochloride [CAS]	16398-39-3	NL 6608671	Antidepressant	
Nitroxoline		4008-48-4			
nizatidine	1,1-Ethenediamine, N-[2-[[2-(dimethylamino)methyl]4-(thiazolylmethyl)ethoxy]N'-methyl-2-nitro- [CAS]	76663-41-2	EP 49618	Antilicer	Ulcer, duodenal

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Nizofenone	3-(2-methylcarboxymethyl)-6-methoxy-8-hydroxy-isocoumarin	54533-85-6			
NM-3	4-Bromo-5-(3-pyridylmethylamino)-6-[3-(4-chlorophenyl)propoxy]-3(2H)pyridazinone hydrochloride		JP 08176138	Anticancer, other	Cancer, general
NM-702				Antithrombotic	Peripheral vascular disease
N-Methylphendrine		552-79-4			
N-Methylepinephrine		554-99-4			
N-Methylglucamine		6284-40-8			
NN-414	6-chloro-3-(1-methylcyclopropylamino)-4H-thieno[3,2-e][1,2,4]thiadiazine-1,1-dioxide			Antidiabetic	Diabetes, Type II
NNC-05-1869	(R)-1-(3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-propyl)-3-piperidine carboxylic acid				Symptomatic antidiabetic
Nogalamycin		1404-15-5			Neuropathy, diabetic
nolatrexed	4(1H)-Quinolinone, 2-amino-6-methyl-5-(4-pyridyliothio), [CAS] 147149-76-6	152346-68-4	WO 9320055	Anticancer, antimetabolite	Cancer, liver
nolomirole	Propanoic acid, 2-methyl-, 5,6,7,8-tetrahydro-6-(methylamino)-1,2-naphthalenediyI ester, hydrochloride, (+/-)-[CAS] 138531-51-8				Heart failure
nolopitantum	1-Azoniatricyclo[2.2.2]octane, 1-[2-[3-(3,4-dichlorophenyl)-1-[3-(1-methylethoxy)phenyl]acetyl]-3-piperidinyl]ethyl-4-phenyl-chloride, (S)-[CAS] 153050-21-6		EP 591040	GI inflammatory/bowel disorders	Inflammatory bowel disease
nonegestrol	19-Norpregna-4,6-diene-3,20-dione, 17-(acetoxy)-6-methyl- [CAS]	58662-20-3	DE 2622533	Menstruation disorders	Menstrual disorder, general
Nomifensine		24526-64-5			
Nopryl sulfanamide		576-97-6			
Norbolethon		1235-15-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Nordazepam		1088-11-5			
Nordefrin		6539-57-7 (unspecified); 74812-63-8 (R*, S*)-(±)- form			
Nordihydroguaiaretic Acid		27686-84-6 (meso-form); 500-38-9 (unspecified)			
Norelgestromin, Ethynodiol Estradiol					
Norepinephrine		51-41-2			
Norethandrolone		52-78-8			
Norethindrone		68-22-4			
Norethyndrel		68-23-5			
Norenefine		536-21-0			
Norfloxacin	3-Quinolonecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)- [CAS] 70458-96-7	US 4146719	Quinolone antibacterial	Infection, general	
Norgesterone		13563-60-5			
Norgestimate		35189-28-7			
Norgestrel		6533-00-2			
Norgestriene		848-21-5			
Norlevorphanol		1531-12-0			
Normethadone		467-85-6			
Normethandrone		514-61-4			
Normorphine		466-97-7			
Norphenazone		89-25-8			
Norpipanone		561-48-8			
Norpseudoephedrine		492-39-7			
Nortriptyline		72-69-5			
Norvinisterone		6795-60-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Noscapine		128-62-1			
Novembichin		1936-40-9			
Novobiocin		303-81-1			
Noxiptilin		3362-45-6			
Noxythiolin		15599-39-0			
NS-1209	Butanoic acid, 2-[[5-[4-[(dimethylamino)sulfonyl]phenyl]-1,2,6,7,8,9-hexahydro-8-methyl-2-oxo-3H-pyrrolo[3,2-h]isquinolin-3-ylidene]amino]oxy]-3-hydroxy- [CAS] 254751-28-5	WO 9426747	Antiepileptic	Epilepsy, general	
NS-1231	5-(4-chlorophenyl)-6,7,8,9-tetrahydro-1H-pyrido-(3,2-h)naphthalene-2,3-dione-3-oxime			Neuroprotective	Ischaemia, cerebral
NS-126	2-Methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid	US 5063222	Antiallergic, non-asthma	Rhinitis, allergic, general	
NS-220	NS 2330 [CAS]	402856-42-2		Hypolipaemic/Antiatherosclerosis	Atherosclerosis
NS-2330		US 6030785	Cognition enhancer		Alzheimer's disease
NSGA inhibitors		US 6030785	Antiviral, other		Infection, hepatitis-C virus
NS-7	Pyrimidine, 4-(4-fluorophenyl)-2-methyl-6-[[5-(1-piperidinyl)pentyl]oxy]-monohydrochloride [CAS] 178429-67-9	WO 9607641	Neuroprotective		Ischaemia, cerebral
NS-8	2-Amino-5-(2-fluorophenyl)-4-methyl-1H-pyrrrole-3-carbonitrile			Urological	Incontinence
NSC-330507	17-Allylaminogeldanamycin				
NSC-619534	2-chloroethyl phenyl selenone			Anticancer, antibiotic	Cancer, general
NSC-697726	2,5-diaziridinyl-3-[hydroxymethyl]G-methyl-1,4-benzquinone			Anticancer, alkylating	Cancer, general
N-Sulfanilyl-3,4-xyliamide		120-34-3		Anticancer, antibiotic	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
NU-6027	2,4-Pyrimidinediamine, 6-(cyclohexylmethoxy)-5-nitroso- [CAS] 2,4,6[1H,5H]-Pyrimidinetrione, 5-ethyl-5-sec-pentyl-, 2-oxime [CAS]	220036-08-8		Anticancer, other	Cancer, general
NV-07	([3R,4aR,10aR]-1,2,3,4,4a,5,10,10a-Octahydro-6-methoxy-1-methyl-benz[1]quinoine-3-carboxylic acid-4-(4-nitrophenoxy)piperazine amide, hydrogen maleate	53745-16-7	US 6455032	Antipruritic/inflamm., non-allergic	Keratosis
NVP-SRA880	(S)-(+)-2-[4-(2-fluorobenzoyloxy)benzylamino]propanamide methansulfonate			Neurological	Unspecified
NW-1029	CPI 22 [CAS]	168021-79-2	US 5780510	Analgesic, other	Pain, general
NXY-059	1-imidazolidineacetic acid, 3-[(3-nitrophenyl)methyl]-2,4,5-trioxo- [CAS]	447-41-6		Neuroprotective	Ischaemia, cerebral
Nyldrin	5-hydroxy-1-methylimidazolidine-2,4-dione	128043-99-2	EP 363198	Symptomatic antidiabetic	Neuropathy, diabetic
NZ-314	OC 108 [CAS]	1'14-90-9	EP 412940	Urological	Renal failure
Obidoxime Chloride	Methanone, 2-pyridiny][7-(4-pyridiny)pyrazolo[1,5-a]pyrimidin-3-yl]- [CAS]	162602-62-2		Vasoprotective, topical	Venous insufficiency
OC-108	ocinapron	96604-21-6	EP 129847	Anxiolytic	Generalized anxiety disorder
Octabenzone		1843-05-6			
Octacaine		13912-77-1			
Octamoxin		4684-87-1			
Octaverine		549-68-8			
Octetidine	1-Octanamine, N,N'-[1,10-decanediylidene]bis-[CAS]	70775-75-6	WO 8705501	Stomatological	Periodontitis
Octodrine		71251-02-0			
Octopamine		86767-75-1			
Octotamine		543-82-8			
		104-14-3			
		137-86-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
octreotide	L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-trypophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-cyclic (2-7)-disulfide, [R-(R*,R*)]- [CAS]	83150-76-9		Formulation, fixed-dose combinations	Cancer, general
Octyl Methoxycinnamate		5466-77-3			
ofloxacin	7H-Pyrido[1,2,3-de]1,4-benzoxazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-(+/-) [CAS]	82419-36-1	EP 47005	Quinolone antibacterial	
o-iodohippurate		133-17-5			
olanzapine	10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl) [CAS]	132539-06-1	EP 454436	Neuroleptic	Schizophrenia
Oleandrin		465-16-7			
Oleic Acid		112-80-1			
olmesartan medoxomil	1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-(2-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl-(5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester [CAS]	144689-63-4	EP 503785	Antihypertensive, renin system	Hypertension, general
olopatadine	11-[{Z}-3-(Dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-acetic acid, monohydrochloride	113806-05-6 140462-76-6	EP 235796	Ophthalmological	Conjunctivitis
olpadronate	Monosodium 3-dimethylamino-1-(hydroxypropylidene)-1,1-bisphosphonate	63132-39-8	WO 9619998	Osteoporosis treatment	Osteoporosis
olsalazine	Benzoic acid, 3,3'-azobis[6-hydroxy-[CAS]	15722-48-2 53200-51-4	US 4559330	GI inflammatory/bowel disorders	Colitis, ulcerative
olitipraz	3H-1,2-Dithiole-3-thione, 4-methyl-5-pyrazinyl-[CAS]	64224-21-1	DE 2705641	Anticancer, other	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
OM-294DP	2-[3(R)-[Dodecanoyloxy]tetradecanamido]-N-[4-[3(R)-hydroxytetradecanamido]o-5-(phosphonoxy)pentyl]-4-(phosphonoxy)butyramide			Anticancer, immunological	Unspecified
Omacor	ethyl (5Z,8Z,11Z,14Z,17Z)-eicos-5,8,11,14,17-pentaenoate + ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docos-4,7,10,13,16,19-hexaenoate	81926-94-5 86227-47-6		Hypolipidaemic/Antiatherosclerosis	Hypertriglyceridaemia
onapatriptan	7H-Pyrido(2,1-b)(1,3)thiazepine-7-carboxylic acid, octahydro-4-(2-mercapto-1-oxo-3-phenylpropylamino)-5-oxo, (4S-(4AlphadR),7Alpha,10aS)- [CAS]	167305-00-2	US 5503272	Antihypertensive, renin system	Hypertension, general
omeprazole	1H-Benzimidazole, 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfanyl]- [CAS]	73590-58-6	US 4255431	Antitulcer	Ulcer, GI, general
omiloxetine	Ethanone, 2-[{3(R),4S}-3-{[(3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl}-1-(4-fluorophenyl)], -rel-[CAS]	176894-09-0		Antidepressant	Depression, general
omoconazole	1H-Imidazole, 1-[2-[2-(4-chlorophenoxy)ethoxy]-2-(2,4-dichlorophenyl)-1-methylethoxy]-, (Z)- [CAS]	74512-12-2	EP 8804	Antifungal	Infection, dermatological
Onapristone	4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-[{(2-methyl-1H-imidazol-1-yl)methyl}- [CAS]	96346-61-1			
ondansetron	Benzoic acid, 4-[(1E)-3-[(2-ethoxy-2-oxoethyl)2-propenylamino]-2-methyl-3-oxo-1-propenyl]-, 4-(aminoinomethyl)phenyl ester, monomethanesulfonate [CAS]	99614-01-4 99614-02-5	US 4847281	Antiemetic	Chemotherapy-induced nausea and vomiting
ONO-3403		181586-07-2		GI inflammatory/bowel disorders	Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ONO-4128	1,4,9-Triazaspiro(5,5)undecane-2,5-dione, 1-butyl-3-(cyclohexylmethyl)-9-((2,3-dihydro-1,4-benzodioxin-6-yl)methyl)- [CAS]	342394-93-8		Antiviral, anti-HIV	Infection, HIV/AIDS
ONO-8815 Ly	L-lysine (Z)-7-[{(1R,2R,5R)-5-chloro-3-hydroxy-2-[(E)-(S)-4-(1-ethyl(cyclobutyl))-4-hydroxy-1-butenyl]cyclopentyl}-5-heptenoate				
ONT-093			US 5756527	Labour inhibitor Radio/chemosensitizer	Labour, preterm Cancer, general
OPC-14523	(21H)-Quinolinone, 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4-dihydro-5-methoxy- [CAS]	145969-30-8	EP 512525	Antidepressant	Depression, general
OPC-31260	Benzamide, N-[4-[(5-(dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]phenyl]-2-methyl-[1]carbonyl]phenyl]-2-methyl-[1]carbonyl]phenyl]-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl]-N-isopropylacetamide	137975-06-5	WO 9105549	Urological	Unspecified
OPC-51803	(5R)-2-[{2-chloro-4-[(1-pyridinyl)benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepin-5-yl}-N-isopropylacetamide			Antidiabetic	Diabetes, insipidus
OPC-6535	2-Pyridin carboxylic acid, 6-[2-(3,4-diethoxyphenyl)-4-thiazolyl]- [CAS]	145739-56-6	WO 9209586	GI inflammatory/bowel disorders	Inflammatory bowel disease
Opiniazide	2-(4-trifluoromethylphenyl)-N-methyl[1-phenyl-2-(1-pyridinyl)ethyl]acetamide	2779-55-7			
opioid analgesics				Analgesic, other	Pain, general
Opipramol		315-72-0			
Orazamide		2574-78-9			
orazipone	2,4-Pentanedione, 3-[(4-methylsulfonyl)phenyl)methylene]- [CAS]	137109-78-5	EP 440324	Antisthma	Unspecified
Org-12962	Piperazine, 1-[6-chloro-5-(trifluoromethyl)-2-pyridinyl]-, monohydrochloride [CAS]	210821-63-9		Antidepressant	Depression, general
Org-24448			US 6166008	Neuroleptic	Schizophrenia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
aztreavancin	Vancomycin, 22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-L-alpha-L-arabinohexopyranosyl)-N ³ -(4'-chloro[1,1'-biphenyl]-4-yl)methyl-[4"-R]- [CAS]	171099-57-3	US 5840684	Peptide antibiotic	Infection, dermatological
orlistat	L-Leucine, N-formyl-, 1-[3-hexyl-4-oxo-2-octanoyl]methyl)dodecyl ester, [2S-[2Alphar(R*)],3S]- [CAS]	96829-58-2	EP 129748	Anorectic/Antiobesity	Obesity
ormeloxifene	Pyrrolidine, 1-[2-{p-[7-methoxy-2,2-dimethyl-3-phenyl-4-chromanyl)phenoxy}ethyl]-, trans- [CAS]	31477-60-8	DE 2329201	Female contraceptive	Contraceptive, female
Ornidazole		16773-42-5			
Onnipressin		3397-23-7			
Ornithine		70-26-8			
oromprostil	Prost-13-en-1-oic acid, 11,15-dihydroxy-17,20-dimethyl-6,9-dioxo-, methyl ester, (11Alpha,13E,15S,17S)- [CAS]	70667-26-4	US 4278688	Prostaglandin	Ulcer, gastric
Orotic Acid		65-86-1			
Orphenadrine		83-98-7			
Orthocaine		5336-25-4			
Osalmid		526-18-1			
osanetant	Acetamide, N-[1-[3R]-1-benzoyl-3-(3,4-dichlorophenyl)-3-piperidinyl]propyl]-4-phenyl-4-piperidinyl]N-methyl- [CAS]	160492-56-8	EP 673928	Neuroleptic	Schizophrenia
ossterone	2-Oxapregna-4,6-diene-3,20-dione, 17-(acetoxymethyl)-6-chloro- [CAS]	105149-00-6	EP 193871	Prostate disorders	Benign prostatic hyperplasia
oseltamivir	1-Cyclohexene-1-carboxylic acid, 4-(acetylamino)5-amino-3-(1-ethylpropoxy)-ethyl ester, (3R-(3Alpha,(4B,5Alpha)- [CAS]	199618-13-0	WO 9626933	Antiviral, other	Infection, influenza virus
OSI-7836	4'-Thio-β-D-arabinofuranosylcytosine			Anticancer, antimetabolite	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
OSI-7904	Pentanediolic acid, 2-[5-[(1,2-dihydro-3-methyl-1-oxobenzof[fl]quinazolin-9-yl)methyl]amino]-1,3-dihydro-1-oxo-2H-isindol-2-yl]-(S)- [CAS]	133987-54-5	WO 9119700	Formulation, optimized, liposomes	Cancer, general
ospemifene	Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenylbutenyl]phenoxy]- [CAS]	128607-22-7	WO 9607402	Menopausal disorders	Osteoporosis
otilonium bromide	Ethanaminium, N,N-diethyl-N-methyl-2-[[4-[2-(octyloxy)benzoyl]amino]benzoyloxy]bromide [CAS]	26095-59-0	GB 1181406	Antispasmodic	Irritable bowel syndrome
Ouabain		630-60-4			
Oxaceprol		33996-33-7			
Oxacillin		66-79-5			
Oxflozane		26629-87-8			
oxaliplatin	Platinum, (1,2-cyclohexanediamine-N,N')ethanedicato(2-)O,O]-, [SP-4-2-(1R,trans)]- [CAS]	61825-94-3	EP 393575	Anticancer, alkylating	Cancer, colorectal
Oxalyt-C	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt [CAS]	28060-67-5	DE 2249274	Urological	
Oxamarin		15301-80-1			
Oxametacaine		27035-30-9			
Oxamniquine		21738-42-1			
oxandrolone	2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5Alpha,17Beta)- [CAS]	53-39-4	US 3128833	Reproductive/gonadal, general	Sex-chromosome abnormality, Turner's syndrome
Oxantel		36631-26-7			
Oxapropranolium	2-Oxazolepropanoic acid, 4,5-diphenyl-[CAS]	541-66-2			
oxaprozin	2H-Benzimidazol-2-one, 1-[3-[4-(diphenylmethyl)-1-piperazinyl]propyl]-1,3-dihydro- [CAS]	21256-18-8	GB 1206403	Antiarthritic, other	Arthritis, osteo
oxatamide	60607-34-3	GB 1579365	Antiallergic, non-asthma	Rhinitis, allergic, general	
oxazepam	7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one	604-75-1		Formulation, oral, orally-disintegrating	Anxiety, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
oxazolam	Oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one, 10-chloro-2,3,7,11b-tetrahydro-2-methyl-11b-phenyl- [CAS]	27167-30-2	US 3772371	Anxiolytic	
oxcarbazepine	5H-Dibenz[b,f]azepine-5-carboxamide, 10,11-dihydro-10-oxo- [CAS]	28721-07-5 29331-92-8	DE 2011087	Antiepileptic	Epilepsy, general
Oxeladin		468-61-1			
Oxendolone		33765-68-3			
Oxethazaine		126-27-2			
Oxetorone		26020-55-3			
oxiconazole	Ethanone, 1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)-, O-[2,4-dichlorophenyl)methyl]oxime, (Z)- [CAS]	6421-45-6	GB 1514870	Antifungal	Infection, fungal, general
Oxidronic Acid		15468-10-7			
Oxiniacic Acid		2398-81-4			
Oxiracetam		62613-82-5			
oxitropium	3-Oxa-9-azoniatricycle[3.3.1.02,4]nonane, 9-ethyl-7-(3-hydroxy-1-oxo-2-phenylpropoxy)-9-methyl-, bromide, [7(S)-[Alpha].2B,4B,5Alpha,7B]- [CAS]	30286-75-0	GB 1178305	Antisthma	
Oxolamine		959-14-8			
Oxolinic Acid		14698-29-4			
Oxophenarsine		538-03-4			
Oxprenolol		6452-71-7			
Oxygenzone		131-57-7			
oxybutynin	Benzeneacetic acid, Alpha-cyclohexyl-Ester- [CAS]	5633-20-5		Formulation, modified-release, other	Incontinence
Oxycinchophen		485-89-2			
oxycodeone	Morphinan-6-one, 4,5-epoxy-14-hydroxy-3-methoxy-17-methyl-, (5Alpha)- [CAS]	76-42-6		Formulation, transmucosal, nasal	Pain, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Oxyfedrine	Octane, 1-bromo-1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-hepta deafluoro- [CAS]	15687-41-9			
Oxymestosterone		423-55-2		Haematological	Surgery adjunct
Oxymetazoline		145-12-0			
Oxymetholone	Androstan-3-one, 17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5Alpha,17Beta)- [CAS]	1491-59-4			
Oxymethurea	(5Alpha)-4,5-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one [CAS]	434-07-1		Hormone	Anaemia, general
oxymorphone	(5Alpha)-4,5-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one [CAS]	140-95-4		Formulation, modified-release, immediate	Pain, general
Oxypendyl		76-41-5			
Oxypertine		5585-93-3			
Oxyphenbutazone		153-87-7			
Oxyphencyclimine		129-20-4			
Oxyphenisatin		125-53-1			
Oxyphenonium		115-33-3			
Oxypinocamphone		50-10-2			
oxypurinol	1H-Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione [CAS]	10136-65-9		Antigout	Hyperuricaemia
Oxytetracycline		2465-59-0			
ozagrel	2-Propenoic acid, 3-[4-(1H-imidazo[1-ylmethyl]phenyl)-, (E)- [CAS]	79-57-2			
P-(Benzylsulfonamido)benzoic Acid		78-71-43-3			
P-100	82571-53-7	GB 2025946	Antithrombotic		Vasospasm, cerebral
P-1202	536-95-8				
P32/98		US 6313177	Antiviral, anti-HIV		Infection, HIV/AIDS
PA-324		US 6034267	Dermatological	Keratosis	
				Antidiabetic	Diabetes, Type II
		WO 9701562	Antimycobacterial		Infection, tuberculosis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PACAP 38	Pituitary adenylyl cyclase-activating peptide-38 [CAS]	128605-20-2	US 5128242	Neuroprotective	Nerve injury, general
paclitaxel	5R,20-Epoxy-1-Aalpha,4,7beta,10beta,13Aalpha-hexahydrotax-11-en-9-one-4,10-diacetate-2-benzoate-13-(Alpha-phenylhippurate)	33069-62-4			
PADRE	1H-isooindol-1-one, 2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxohexyl) - (R)- [CAS]	133737-32-3	US 6413935	Formulation, optimized, nanoparticles Immunostimulant, other	Cancer, breast Vaccine adjunct
pagoclone			US 4960779	Anxiolytic	Panic disorder
PAI inhibs			WO 9404512	Antithrombotic	Thrombosis, venous
palindore	8H-1,4-dioxinof[2,3-e]indol-8-one,2,3,7,9-tetrahydro-2-[(phenyl)methyl]amino[methyl]-, 2(S), (2E)-2-butendiolate (1:1)	189681-71-8			
Palivizumab		188039-54-5		Neuroleptic	Schizophrenia
palonosetron	3aS-2-[(S)-1-Azabicyclo[2.2.2]oct-3-yl]-2,3,3a,4,5,6-hexahydro-1-oxo-1H-benz[d]isoquinoline hydrochloride	135729-62-3	US 5202333	Antiemetic	Chemotherapy-induced nausea and vomiting
Pambrom		606-04-2			
Pamaquine		491-92-9			
panicogrel	1H-Pyrrole-1-acetic acid, 2-[4,5-bis(4-methoxyphenyl)-2-thiazolyl]- ethyl ester [CAS]	101001-34-7	EP 159677	Antithrombotic	Thrombosis, cerebral
panidronate	(3-Amino-1-hydroxypropylidene)diphosphonic acid-[CAS]	40391-99-9		Formulation, implant	Hypercalcaemia of malignancy
p-Aminobenzoic Acid		150-13-0			
p-Aminohippuric Acid		61-78-9			
p-Aminopropiophenone		70-69-9			
p-Aminosalicylic Acid		65-49-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Panavir	4,4'-isopropylidenedifluorobis-2,6-di- butylphenol			Neuroprotective	Vasospasm, cerebral
Pancuronium		15500-66-0			
Panipenem		87726-17-8			
Pantethine		16816-67-4			
pantoprazole	1H-Benzimidazole, 5-(difluoromethoxy)-2- [(3,4-dimethoxy-2-pyridiny)methyl]sulfanyl]- [CAS]	102625-70-7	EP 166287	Antilulcer	Ulcer, duodenal
Pantothenic Acid		79-83-4			
Papain					
Papaverine		58-74-2			
paracetamol	Acetamide, N-(4-hydroxyphenyl)- [CAS]	103-90-2		Formulation, oral, other, modified- release	Pain, general
Parafutizide		1580-83-2			
Paraldehyde		123-63-7			
Paramethadione		115-67-3			
Paramethasone		53-33-8			
Paranyline		1729-61-9			
Parathyroid Hormone		9002-64-6			
parecoxib	Propanamide, N-((4-(5-methyl-3-pienyl-4- isoxazolyl)phenyl)sulfonyl)-, sodium salt [CAS]	198470-85-8	WO 9738986	Analgesic, NSAID	Pain, post-operative
Parethoxycaine		94-23-5			
Pargyline		555-57-7			
paricalcitrol	19-Nor-9,10-secoergosta-5,7,22-triene- 1,3,25-triol, (1Alpha,3beta,7E,22E)- [CAS]	131918-61-1	EP 387077	Hormone	Hyperparathyroidism
paramomycin	O-2-Amino-2-deoxy-Alpha-D- glucopyranosyl-(1-4)-O-[O-2,6-diamino-2,6- dideoxy- β -L-idopyranosyl-(1-3)- β -D- ribofuranosyl-(1-5)]-2-deoxy-D-streptamine	7542-37-2		Protozoacide	Infection, leishmaniasis
paroxetine	Piperidine, 3-[(1,3-benzodioxol-5- yloxy)methyl]-4-(4-fluorophenyl)-, (3S- trans)- [CAS]	611869-08-7	EP 223403	Antidepressant, formulation, oral, orally- disintegrating	Depression, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Paroxypropione		70-70-2			
Parsalmide		30653-83-9			
PaTriN-2	4-Bromophenylguanine			Radio/chemosensitizer	Cancer, melanoma
Pazinaclone		103255-66-9			
	7H-Pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid, 10-(1-aminoacylpropyl)-9-fluoro-2,3-dihydro-3-methyl-7-oxo-, (S)-[CAS]	127045-41-4 127046-45-1 136905-87-8	DE 3913245	Quinolone antibacterial	Infection, general
P-Bromoacetanilide		103-88-8			
PC-NSAIDs		US 4918063	Formulation, other		Arthritis, general
	6-(2,6-Dichlorophenyl)-2-[4-(diethylaminoethoxy)-phenylamino]-8-pyridof[2,3-D]pyrimidine-7-one				
Pecilocin		19504-77-9			
	3-Quinoliniccarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-[CAS]	70456-92-3	GB 1599915	Quinolone antibacterial	Infection, urinary tract
pefloxacin	Somatotropin (18-aspartic acid, 21-asparagine, 120-lysine, 167-asparagine, 168-alanine, 171-serine, 172-arginine, 174-serine, 179-threonine (human), pegylated [CAS]				
pegvisomant	218820-50-9			Somatostatin	Acromegaly
Pelletierine		4396-1-4			
	L-Glutamic acid, N-[4-(2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrrol[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-, disodium salt [CAS]				
penetrexed	4H-Pyrido[1,2,3- <i>a</i>]pyrimidin-4-one, 9-methyl-3-(1H-tetrazol-5-yl)- [CAS]	137281-23-3 150399-23-8	US 5248775	Anticancer, antimetabolite	Cancer, mesothelioma
pemirolast		69372-19-6	US 4457932	Antiasthma	Asthma
Pemoline		2152-34-3			
Pempidine		79-55-0			
PEN-203			US 5955446	Antiviral, other	Infection, human papilloma virus
Penamecillin		983-85-7			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
penbutolol	2-Propanol, 1-[2-(2-cyclopentyloxy)phenoxyl]amino]-,(S)- sulfate [(1,1-dimethylethyl)(amino)-,(S)- sulfate (2:1)] (salt) [CAS]	38363-32-5 38363-40-5	GB 1215751	Antihypertensive, adrenergic	
peniclovir	6H-Purin-6-one, 2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)butyl]- [CAS]	39809-25-1	JP 60058982	Antiviral, other	Infection, herpes simplex virus
Penethamate		808-71-9			
perfluridol	4-Piperidinol, 1-[4-(4-bis(4-fluorophenyl)butyl)-4-(4-chloro-3-(trifluoromethyl)phenyl)phenyl]- [CAS]	26864-56-2	DE 2040231	Neuroleptic	
Penicillamine		52-67-5			
Penicillin G		61-33-6			
Penicillin G Benzathine		1538-09-6			
Penicillin G Procaine		6130-64-9			
Penicillin N		525-94-0			
Penicillin O		87-09-2			
Penicillin V		87-08-1			
Penimepicycline		4599-60-4			
Pentuss		US 4221778	Formulation, modified-release, other	Rhinitis, allergic, general	
Pentaerythritol Chloral		78-12-6			
Pentaerythritol		2209-86-1			
Dichlororohydrin					
Pentaerythritol		597-71-7			
Pentagastrin		5534-95-2			
Pentagestrone		7001-56-1			
Pentalyle	Starch, 2-hydroxyethyl ether [CAS]	9005-27-0	US 5407428	Plasma substitute	Surgery adjunct
Pentamethonium		541-20-8			
pentamidine	Benzene-carboximidamide, 4,4'-(1,5-pentanediylibis(oxy))bis- [CAS]	100-33-4			Infection, Pneumocystis jiroveci prophylaxis
Pentazocine		359-83-1			
Pentetate		12111-24-9			
Pentetic Acid		67-43-6			
Pentetreotide		138661-02-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Penthienate		60-44-6			
Pentifylline		1028-33-7			
Pentigetide		62087-72-3			
Pentisomide		78833-03-1			
Pentobarbital		76-74-4			
Pentolinium		52-62-0			
Pentorex		434-43-5			
pentosan	Xyjan, [CAS]	37319-17-8	US 5180715	Urological	Inflammation, urinary tract
pentostatin	Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydro-, (R)- [CAS]	53910-25-1	US 3923785	Anticancer, antimetabolite	Cancer, leukaemia, hairy cell
pentoxifylline	1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(5-oxohexyl)- [CAS]			Neuroprotective	Amyotrophic lateral sclerosis
Pentoxyfylline		147-61-5			
Pentrinitrol		1607-17-6			
Pentylene tetrazole		54-95-5			
perlonycin	Bleomycinamide, N1-[3'[(1-phenylethyl)amino]propyl]- (S)- [CAS]	68247-85-8	US 4195018	Anticancer, antibiotic	
Perazine		84-97-9			
Perflubron		423-55-2			
Perfosfamide		62435-42-1;			
	39800-16-3 (unspecified)				
pergolide	Ergoline, 8-[(methylthio)methyl]-6-propyl-, (83)-, monomethanesulfonate- [CAS]	66104-23-2	US 4797405	Antiparkinsonian	Parkinson's disease
Perhexiline		6621-47-2			
Pericyazine		2622-26-6			
perifosine	Piperidinium, 4-[[hydroxy(octadecyloxy)phosphoryl]oxy]-1,1-dimethyl-, inner salt [CAS]	157716-52-4	EP 594999	Anticancer, other	Cancer, prostate
perillyl alcohol	1-Cyclohexene-1-methanol, 4-(1-methylethoxy)- [CAS]	536-59-4	US 5110832	Anticancer, other	Cancer, breast
Perimethazine		13093-88-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
perindopril	1H-Indole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)butyl]amino]-1-oxopropyl]octahydro- [2S-[1R*(R*)]-2Alpha,3aBeta-7aBeta]- compd. with 2-methyl-2-propanamine (1:1) [CAS]	107133-36-8 8284-16-0 95153-31-4	EP 49658	Antihypertensive, renin system	Hypertension, general
Periodyl		53586-99-5			
perisoxal	1-Piperidineethanol, Alpha-(5-phenyl-3-isoxazolyl)-, 2-hydroxy-1,2,3-propanetricarboxylate (2:1) (salt) [CAS]	2135-25-5 2056-44-9	JP 04217925	Anti-inflammatory	
Perlapine		197-11-3			
Permethrin		52645-53-1			
perospipone	1H-Isoindole-1,3(2H)-dione, 2-[4-(1,2-benzisotiazol-3-yl)-1-piperazinyl]butylhexanhydro-, cis- [CAS]	129273-38-7 150915-41-6	CA 2167004	Neuroleptic	Schizophrenia
Perphenazine		58-39-9			
Petroleum Benzin		8030-30-6			
PH-10		US 6331286	Antipsoriasis		Psoriasis
Phanquinone		84-12-8			
Pharmaprojects No. 4994		WO 9638482	Immunological		Unspecified
Pharmaprojects No. 5325		WO 9703986	Neuroleptic		Schizophrenia
Pharmaprojects No. 5972		WO 0204426	Antisthma		Asthma
Pharmaprojects No. 6362	(R)-N-[4-(2-[[2-Hydroxy-2-(3-pyridinyl)ethyl]aminolethyl]phenyl)-4-[4-(trifluoromethyl)phenyl]thiazol-2-yl]benzenesulfonamide	US 6057346	Antiviral, anti-HIV		Infection, HIV/AIDS
Pharmaprojects No. 6446				Anorectic/Antiobesity	Obesity
Pharmaprojects No. 6590		WO 0206223	Psychostimulant		Attention deficit disorder
Pharmaprojects No. 6656		US 6455026	Genomics-based drug discovery		Cancer, brain
Pharmaprojects No. 6691		US 6299900	Formulation, other		Pain, general
Pharmaprojects No. 6743					Infection, general
				Antibacterial, other	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Pharmacaine	1,2,3,4,10,14b-Hexahydro-6-methoxy-2-methylbenzof[c]pyrazinol[1,2-a]azepin	620-99-5		Antidepressant	Depression, general
Phenacetin		63-98-9			
Phenadoxone		62-44-2			
Phenallymal		467-84-5			
Phenamet		115-43-5			
Phenazocine		3819-34-9			
Phenazopyridine		127-35-5			
Phenbutamide		136-40-3			
Phencyclidine		3149-00-6			
Phendimetrazine		77-10-1			
Phenelzine		634-03-7			
Phenesterine		51-71-8			
Phenetharital		3546-10-9			
Phenetichillin		357-67-5			
Pheneturide		132-93-4			
Phenformin		90-49-3			
Phenglutarimide		114-86-3			
Phenindamine		1156-05-4			
Phenindione		82-88-2			
Pheniprazine		83-12-5			
Pheniramine		55-52-7			
Phenmetrazine		86-21-5			
Phenobarbital		134-49-6			
Phenobutiodil		50-06-6			
Phenocoll		554-24-5			
Phenoctide		103-97-9			
Phenolphthalein		78-05-7			
PhenolphthaoI		77-09-8			
		81-92-5			

Table IV

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Phenyltoloxamine		92-12-6			
Phenyramidol	2,4-imidazolidinedione, 5,5-diphenyl- [CAS]	553-69-5			
phenytoin		57-41-0		Formulation, oral, other	Epilepsy, general
Phephenylate		510-34-9			
Phloroglucinol		108-73-6			
Pholcodine		509-67-1			
Pholedrine		370-14-9			
Phosphocreatine		67-07-2			
Phosphocysteamine		5746-40-7			
Phosphorylcholine		107-73-3			
Phthalylsulfacetamide		131-69-1			
Phthalylsulfathiazole		85-73-4			
p-Hydroxyephedrine		365-26-4			
Phylloquinone		84-80-0			
Physostigmine		57-47-6			
Phytic Acid		83-86-3			
Pi-88	D-Mannose, O-6-O-phosphono-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-3)-O-Alpha-D-mannopyranosyl-(1-2)- hydrogen sulphate [CAS]	185077-23-0		Anticancer, other	Cancer, melanoma
Piberaline	2H-(1,3)Oxazine(3,2- α)-indole-10-carboxamide, N-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro- [CAS]	39640-15-8			
piboserod		152811-62-6	WO 9318036	Antiarrhythmic	Fibrillation, atrial
Piclorex		62510-56-9			
Picloxydine		5636-92-0			
Picoperine		21755-66-8			
Picosulfate		10040-45-6			
Picotamide		32828-81-2			
Picumast		39577-19-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pidotimod	4-Thiazolidinecarboxylic acid, 3-[5-oxo-2-pyrroldinyl]carbonyl]- [CAS]	121808-62-6	EP 276752	Immunomodulator, anti-infective	Infection, respiratory tract, lower
Pifarnine	Benzeneacetamide, 3-benzoyl- <i>Alpha</i> -methyl-N-(4-methyl-2-pyridinyl)- [CAS]	56208-01-6			
piketoprofen		60576-13-8	GB 1436502	Anti-inflammatory, topical	
Pildralazine	2(3H)-Furanone, 3-ethylidihydro-4-[(1-methyl-1 <i>H</i> -imidazol-5-yl)methyl]-, (3 <i>S</i> -cis)- [CAS]	64000-73-3			
pilocarpine		92-13-7		Formulation, implant, Stomatological	
Pileplex	2-Propenoic acid, 2-methyl-, dodecyl ester, polymer with 2-propenoicacid, compd. with (3 <i>S</i> -cis)-3-ethylidihydro-4-[(1-methyl-1 <i>H</i> -imidazol-5-yl)methyl]-2(3 <i>H</i>)-furanone [CAS]	62783-28-2	DE 2636559	Formulation, mucosal, topical	Glaucoma
pilsicainide	1 <i>H</i> -Pyrazoline-7- <i>a</i> (5 <i>H</i>)-acetamide, N-(2,6-dimethylphenyl)tetrahydro-, monohydrochloride [CAS]	88069-49-2 88069-67-4	US 4564624	Antiarrhythmic	Arrhythmia, general
Pimecrolimus	15,19-Epoxy-3 <i>H</i> -pyrido[2,1-c](1 <i>H</i>)oxaazacyclotriosine-1,7,20,21(4 <i>H</i> ,23 <i>H</i>)-tetrone, 3-(2-(4-chloro-3-methoxycyclohexyl)-1-methyllethoxy)-8-ethyl-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26 <i>a</i> -hexadecahydro-5,19-dihydroxy-14,16-dimethoxy-4,10,12,18-tetramethyl-(3 <i>S</i> -(3 <i>R</i>)(1 <i>S</i> *-3 <i>S</i> *,4 <i>R</i>)), 4 <i>S</i> *,5 <i>R</i> *,8 <i>S</i> *,9 <i>E</i> *,12 <i>R</i> *,14 <i>R</i> *,5 <i>S</i> *,16 <i>R</i> *,18 <i>S</i> ,19 <i>S</i> *,26 <i>a</i> <i>R</i> *)- [CAS]	534-84-9			
Pimecrolimus		137071-32-0	EP 626385	Antipruritic/inflamm, allergic	Eczema, atopic
Pimeffylline	Acetic acid, [2-[focihydro-5-hydroxy-6-(3-hydroxy-5-methyl-1-nonenyl)-2-pentenyl]ethoxy]- methyl ester, [<i>2R</i> -(2 <i>Alpha</i> ,3 <i>Alpha</i> ,4 <i>Alpha</i> (1 <i>E</i> ,3 <i>S</i> *,5 <i>S</i> *, <i>5B</i> ,6 <i>A</i>)-[CAS]]	10001-43-1			
pimiprost		139403-31-9		Dermatological	Ulcer, general
Piminodine		13495-09-5			
Pimobendan		74150-27-9			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pimozone	2H-Benzimidazol-2-one, 1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-[CAS]	2062-78-4	FR M3695	Neuroleptic	
Pinacidil	Morpholinium, 4-[(2-bromo-4,5-dimethoxyphenyl)methyl]-4-[2-[2-(6,6-dimethylbicyclo[3.1.1]hept-2-yl)ethoxy]ethyl]-, [CAS]	85571-64-8			
pinaverium		5325-94-8 59995-65-2	EP 406743	Antispasmodic	Irritable bowel syndrome
pinazepam	2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl-1-(2-propynyl)-[CAS]	52463-83-9	DE 2339790	Anxiolytic	
Pindolol	2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl], monohydrochloride (+/-)- [CAS]	13523-86-9			
pioglitazone	111025-46-8 112529-15-4	EP 193256	Antidiabetic		
Pipacycline		1110-80-1			
Pipamazine		84-04-8			
Pipamperone		1893-33-0			
Pipazethate		2167-85-3			
Pipebuzone		27315-91-9			
Pipecurium		52212-02-9			
pipecuronium	Piperazinium, 4,4'-[[2B,3Alpha,5Alpha,16B,17B]-3,17-dimethyl-, [CAS]	52212-02-9 68359-57-5	GB 1398050	Muscle relaxant	Anaesthesia, adjunct
pipemidic acid	Pyrido[2,3-d]pyrimidine-6-carboxylic acid, 8-ethyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)- [CAS]	51940-44-4	GB 1451911	Anitbacterial, other	Infection, urinary tract
Pipenzolate Bromide		125-51-9			
Piperacetazine		3819-00-9			
	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[[[(4-ethyl-2,3-dioxo-1-piperazinyl)carbonyl]amino]phenylacetyl]aminol-3,3-dimethyl-7-oxo-[2S-[2Alpha,5Alpha,6Beta(S*)]-] [CAS]	59703-84-3 61477-96-1	GB 1508062	Penicillin, injectable	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Piperazine Adipate		142-88-1			
Piperidone		77-03-2			
Piperidolate		82-98-4			
Piperilate		4546-39-8			
piperine analogues			WO 002544	Dermatological	Vitiligo
Piperocaine		136-82-3			
Piperonal		120-57-0			
Piperoxan		59-39-2			
Piperylone		25-31-4-6			
Pipobroman		54-91-1			
Piposulfan		2608-24-4			
	Hexadecanoic acid, 2-[1-[2-[(dimethylamino)sulfonyl]-10H-phenothiazin-10-yl]propyl]-4-piperidiny]ethyl ester [CAS#37517-26-3]	37517-26-3 39860-99-6	US 4782077	Neuroleptic	
Pipoxolan		18174-58-8			
Pipradrol		467-60-7			
pirazozolin	Acetic acid, [3-ethyl-4-oxo-5-(1-piperidinyl)-2-thiazolidinylidene]-, ethyl ester [CAS#17243-64-0]	17243-64-0	US 3971794	GI inflammatory/bowel disorders	Motility dysfunction, GI, general
Piracetam		7491-74-9			
	5,12-Naphthacenedione, 10-[[3-amino-2,3,6-trideoxy-4-O-(tetrahydro-2H-pyran-2-yl)-Alpha-L-lyxo-hexopyranosyl]oxy]-7,8,10-trihydro-6,8,11-trihydroxy-8-(hydroxymethyl)-1-methoxy-[8S-[8Alpha,10Alpha(S')]]-[CAS#72496-41-4]	72496-41-4	US 4303785	Anticancer, antibiotic	Cancer, breast
Pirazolac		71002-09-0			
pirbuterol	2,6-Pyridinedimethanol, Alpha6-[[1-dimethyl(ethyl)amino)methyl]-3-hydroxy-, monoacetate (salt) [CAS#38629-10-6 38677-81-5 65652-44-0]	38629-10-6 38677-81-5 65652-44-0	US 3786160	Antitussive	Asthma
Pirenoxine		1043-21-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pirenezepine	6H-Pyrido[2,3-b][1,4]benzodiazepin-6-one, 5,11-dihydro-11-[(4-methyl-1-piperazinyl)acetyl]- [CAS]	28797-61-7 29898-97-1	FR 1505795	Anticancer	
piretanide	Benzoic acid, 3-(aminosulfonyl)-4-phenoxy-5-(1-pyrrolidinyl)- [CAS]	55837-27-9	US 4010273	Antihypertensive, diuretic	Hypertension, general
pirfenidone	2(1H)-Pyridinone, 5-methyl-1-phenyl-[1-CAS]	53179-13-8		Respiratory	Fibrosis, pulmonary
piribedil	Pyrimidine, 2-[4-(1,3-Benzodioxol-5-ylmethyl)-1-piperazinyl]- [CAS]	3605-01-4	US 3299067	Vasodilator, peripheral	Parkinson's disease
Piridocaine		87-21-8			
Piropibrate		55285-45-5			
Piriramide		302-41-0			
Pirtrexim		72732-56-0			
pirindole	1H-Purazino[3,2,1-ik]carbazole, 2,3,8a,4,5,6-hexahydro-8-methyl- [CAS]	16154-78-2 60762-57-4	SU 276060	Antidepressant	Depression, general
pirmenol	(2-Pyridinemethanol, Alpha-[3-(2,6-dimethyl-1-piperidinyl)propyl]-Alpha-phenyl-, cis-(+)- [CAS]	6147-94-9 63252-19-7	US 4112103	Antiarrhythmic	Tachycardia, supraventricular
Piroctone		50650-76-5			
Piroheptine		163378-21-5			
Promidic Acid		19562-30-2			
piroxicam	2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridinyl-, 1,1-dioxide [CAS]	36322-90-4	US 3862319	Anti-inflammatory	
piroxicam betadex	β-Cyclodextrin, compd. with 4-hydroxy-2-methyl-N-2-pyridinyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide- [CAS]	121696-62-6 96684-39-8	EP 153998	Formulation, other	Pain, musculoskeletal
piroxicam cinnamate	2-Propenoic acid, 3-phenyl-, 2-methyl-3-[(2-pyridinylamino)carbonyl]-2H-1,2-benzothiazin-4-yl ester, S,S-dioxide [CAS]	87234-24-0	EP 79639	Antiarthritic, other	Inflammation, general
Pirozadil		54110-25-7			
Piprofen		31733-07-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pitavastatin	6-Heptenoic acid, 7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]-3,5-dihydroxy-, calcium salt (2:1), [S-(R*, S*-E)]- [CAS] 69542-93-4	147526-32-7	EP 304063	Hypolipaemic/Antiatherosclerosis	Hyperlipidaemia, general
pivagabine	N-trimethylacetyl-4-aminobutyric acid				Anxiety, general
pivaloyloxymethyl	Butanoic acid, (2Z)-dimethyl-1-oxopropoxymethyl ester [CAS]	122110-53-6	EP 302349	Anticancer, other	Cancer, lung, non-small cell
Pivalylbenzhydrazine		306-19-4			
Pivampicillin		33817-20-8			
pivampicillin/pivmecillinam		98445-47-7		Penicillin, oral	Infection, genera
Pivcefalexin		63836-75-9			
pivmecillinam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[(hexahydro-1H-azepin-1-yl)methylene]amino-3,3-dimethyl-7-oxo-(2,2-dimethyl-1-oxopropoxy)methyl ester, [2S-(2Alpha, 5Alpha, 6Beta)-] [CAS] 32886-97-8	GB 1293590	Penicillin, oral		Infection, genera
pixantrone	Benz[1]isoquinoline-5,10-dione, 6,9-bis[(2-aminoethyl)amino]-, (2Z)-2-butenedioate(1:2) [CAS] 144675-97-8	EP 503537	Anticancer, other		Cancer, lymphoma, non-Hodgkin's
pizotifen	4-(9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-yldene)-1-methylpiperidine	15574-96-6	DE 2346747	Antimigraine	
Pizotyline		15574-96-6			
PK-166	Phenol, 4-(4-((1R)-1-phenylethyl)amino)-1H-pyrrolo(2,3-d)pyrimidin-6-yl)- [CAS] 187724-61-4				
p-Lactophenetide		539-08-2			
Platibride		63394-05-8			
plasminogen activator	Plasminogen activator [CAS] 105913-11-9	EP 151996	Fibrinolytic		Infarction, myocardial
Plasmocid		551-01-9			
Platotonin		3571-88-8			
Plaunotol		64218-02-6			
PLD-118	Cyclopentanecarboxylic acid, 2-amino-4-methylene-, (1R,2S)- [CAS] 198022-65-0	EP 805145	Antifungal		Infection, Candida, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PLD-147	(OC-6-4)-Bis(acetato)(1-adamantylamine)amine-dichloroplatinum (IV)			Anticancer, alkylating	Cancer, general
pleconaril	1,2,4-Oxadiazole, 3-(3,5-dimethyl-4-(3-(3-methyl-5-isoxazolyl)propoxy)phenyl)-5-(trifluoromethyl)- [CAS] 153168-05-9	US 5464848	Antiviral, other	Infection, respiratory tract, general	
Picamycin		18378-89-7			
p-Methyldiphenhydramine		19804-27-4			
PMS-601			WO 0001677	Antiviral, anti-HIV	Infection, HIV/AIDS
Pneumococcal Vaccine, Diphtheria Conjugate					
Pneumococcal Vaccine, Polyvalent	N-[{(5s)-3-[4[(1,1-dioxido-4-thiomorpholinyl)3,5-difluorophenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide}			Antibiotic, other	Infection, general
PNU-288034					
Podophyllotoxin	Zinc, bis[N-3-alanyl-L-histidinato-N3,OAlpha], (T-4)- [CAS] 518-28-5	EP 107667-60-7	Antileuk		
polaprezinc		303380			
Poldine Methylsulfate		545-80-2			
Policresulen		9011-2-3			
Polidexide		9064-92-0			
polidocanol	Polyethylene glycol monododecyl ether 3035-99-0 9002-92-0		Vasoprotective, systemic	Venous insufficiency	
Poliovirus Vaccine Inactivated					

Table IV

API Generic Name poly-ADPRT inhibitors	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Polyestradiol Phosphate		28014-46-2	WO 9845253	Anticancer, other	Cancer, general
Polyphenon E	Polyphenon E [CAS]	188265-33-0		Antiviral, other	Infection, human papilloma virus
Polythiazide		346-18-9			
parfimer	Photofrin [CAS]	87806-31-3	US 4882234	Anticancer, other	Cancer, lung, non-small cell
Porfiromycin		801-52-5			
	D-threo-Pentitol, 2,5-anhydro-1,3,4-trideoxy-2-C-(2,4-difluorophenyl)-4-((4-(4-(4-(11S,2S)-1-ethyl-2-hydroxypropyl)-1,5-dihydro-5-oxo-4H-1,2,4-triazol-4-yl)phenyl)-1-piperazinyl)phenoxy)methyl)-1'(1H-1,2,4-triazol-1-yl)- [CAS]	171228-49-2	US 5714490	Antifungal	Infection, fungal, general
Posafirelin	Potassium chloride (KCl) [CAS]	78664-73-0			
potassium chloride		7447-40-7			
Potassium Gluconate		299-27-4		Formulation, oral, enteric-coated	
Potassium		1321-14-8			
Guaiacolsulfonate					
Potassium p-Aminobenzoate		138-84-1			
Potassium		7722-64-7			
Permanganate					
Povidone		9003-39-8			
Povidone-Iodine		25655-41-8			
PP-117	3-Pyridinemethanol, hydrofluoride [CAS]	62756-44-9	DE 2633028	Formulation, oral, other	Unspecified
PR-2699	(-)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-1-imidazolylacetonitrile			Antifungal	Infection, fungal, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
PR-608	(S)-(-)-1-[4-(4-fluorophenyl)butyl]-4-(2-hydroxy-3-phenylaminopropyl)piperazine trihydrochloride			Antiparkinsonian	Parkinson's disease
Practolol		6673-35-4			
Prajmaline		35080-11-6			
Pralidoxime		51-15-0			
pranacasan	6H-Pyridazino(1,2-a)(1,2-diazepine-1-carboxamide, N-((2R,3S)-2-ethoxytetrahydro-5-oxo-3-furyl)octahydro-9-(1-isoquinolimylcarbonyl)amino)-6,10-dioxo,(1S,9S)-[CAS]	192755-52-5		Antiarthritic, immunological	Arthritis, rheumatoid
pramipexole	2,6-Benzothiazolediamine, 4,5,6,7-tetrahydro-N6-propyl-, (S)-[CAS]	104632-26-0	EP 186087	Antiparkinsonian.	Parkinson's disease
pramiracetam	1-Pyrrolidineacetamide, N-[2-[bis(1-methylethyl)amino]ethyl][2-oxo-, monohydrochloride [CAS]	68497-62-1 72869-16-0 75733-50-5	US 4145347	Cognition enhancer	Amnesia
Pramiverin		14334-40-8			
pramlintide	1,2-Dithia-5,8,11,14,17-pentaazacycloicosane, cyclic peptide deriv. [CAS]	151126-32-8	US 5124314	Antidiabetic	Diabetes, Type I
Pramoxine		140-65-8			
pranidipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-, methyl 3-phenyl-2-propenyl ester, (E)- [CAS]	99522-79-9	EP 173126	Antihypertensive, other	Hypertension, general
Pranlukast		103177-37-3			
pranoprofen	5H-[1]Benzopyranol[2,3-b]pyridine-7-acetic acid, Alpha-methyl- [CAS]	52549-17-4		Formulation, mucosal, topical	Ocular disorder, general
prasterone	Androst-5-en-17-one, 3-Hydroxy-, (3β)-[CAS]	53-43-0		Labour inducer	
pratosartan	4(3H)-Cycloheptimidazolone, 5,6,7,8-tetrahydro-2-propyl-3-[2-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-y][methyl]- [CAS]	153304-05-8	US 5409947	Antihypertensive, renin system	Hypertension, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
pravastatin	1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-8, delta-6-trifluoroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, monosodium salt, [1S, [1Alpha][3BetaS*, deltaS*], 2Alpha, 6Alpha, 8Beta(R*)] .8aAlpha]- [CAS]	81093-37-0 81131-70-6	US 4346227	Hypolipemic/Antiatherosclerosis	Atherosclerosis
Prazepam	4H-Pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- [CAS]	2955-38-6 55268-74-1	US 4001411	Schistosomicide	
praziquantel	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazoliny)-4-(2-furylcarbonyl)- [CAS]	19216-56-9 19237-84-4	US 4092315	Antihypertensive, adrenergic	Hypertension, general
Prednicarbate		73771-04-7			
prednimustine	Pregna-1,4-diene-3,20-dione, 21-[4-[bis(2-chloroethyl)amino]phenyl]-1-[oxobutoxy]-11,17-dihydroxy-, (11S)- [CAS]	29069-24-7	GB 1272841	Anticancer, alkylating	
Prednisolone		50-24-8			
Prednisolone 21-Diethylaminoacetate	Pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-21-[3-(7,11-trimethyl-1-oxo-2,6,10-dodecatetraenyl)oxy], [11S,21(2E,6E)]- [CAS]	5626-34-6			
prednisolone farnesi		118244-44-3	EP 332143	Antiarthritic, other	Arthritis, rheumatoid
Prednisolone Sodium Phosphate		125-02-0			
Prednisone		53-03-2			
Prednival		15180-00-4			
Prednylidene		599-33-7			
pregabalin	Hexanoic acid, 3-(aminomethyl)-5-methyl, (S)- [CAS]	148553-50-8		Antiepileptic	Epilepsy, general
Pregnan-3 α -ol-20-one	Estra-4,9-dien-3-one, 17-(2-hydroxy-1-oxopropyl)-17-methyl-, [17S (S)]- [CAS]	128-20-1			
Premarin + trimegestone		74513-62-5		Menopausal disorders	Hormone replacement therapy

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
prenalterol	Phenol, 4-[2-hydroxy-3-[(1-methylethyl)aminolpropoxy]-hydrochloride, (S)-[CAS]	57526-81-5 61260-05-7	GB 1470059	Cardiotonic	
Prenoxydiazine		982-43-4			
Prenylamine		390-64-7			
	Cuprate(1-), (N2-(N-glycy-L-histidyl)-L-lysinoato(N2-(N-glycy-L-histidyl)-L-lysinoato(2-))-, hydrogen, [CAS]	130120-57-9			
Prizidinol	prezatide	511-45-5		Veterinary	
Prifinium		4630-95-9			
Prilocaine		721-50-6			
Primaquine		90-34-6			
Primidone		125-33-7			
Prinomastat		192329-42-3	US 5614599	Antiviral, anti-HIV	Infection, HIV prophylaxis
PRO-2000			57-66-9		
Probenecid		23288-49-5			
Probucol	Benzamide, 4-amino-N-[2-(diethylamino)ethyl]-[CAS]	51-76-9 614-39-1		Formulation, other	Arrhythmia, general
procainamide		59-46-1			
Procaine		671-16-9			
Procarbazine	2(1H)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[(1-methylethyl)amino]butyl], monohydrochloride [CAS]	59828-07-8 60443-76-6 72332-33-3	GB 1496766	Antitumor	Nausea and vomiting, general
procaterol	10H-Phenothiazine, 2-chloro-10-[3-(4-methyl-1-piperazinyl)propyl], (Z)-2-butenedioate	58-38-8 84-02-6		Formulation, oral, other	
procloperazine					
procodazol					
Procyclidine	1H-Benzimidazole-2-propanoic acid [CAS]	23249-97-0 77-37-2	ES 407882	Anticancer, immunological	Cancer, general
Procymate		13931-64-1			
Prodipine		31314-38-2			
Proflavine		92-62-6			
Progabide		62666-20-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
progesterone	Pregni-4-en-3,20-dione [CAS]	57-83-0		Formulation, transmucosal, systemic	Amenorrhoea
proglumetacin	1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-4-[3-((4-(benzoylamino)-5-(dipropylamino)-1,5-dioxpentyloxy)propyl)-1-piperazinyl]ethyl ester, (+/-)- [CAS]	57132-63-3 59209-40-4	GB 1467568	Antiflammatory	Inflammation, general
proglumide	Pentanoic acid, 4-(benzoylamino)-5-(dipropylamino)-5-oxo-, (+/-)- [CAS]	6620-60-6	DE 1518125	Antidiarrhoeal	Ulcer, gastric
Proheptazine		77-14-5			
Prolaactin		9002-62-4			
Prolintane		493-92-5			
Prolonium		123-47-7			
Promazine		58-40-2			
Promedol		64-39-1			
Promegestone	Estra-1,3,5(10)-triene, 17-methoxy-3-propoxy-, (17 β)- [CAS]	34184-77-5			
promestriene		39219-28-8	GB 1337198	Reproductive/gonadal, general	Acne
Promethazine		60-37-7			
Pronethalol	Glycine, N,N-diethyl-, 4-(acetamino)phenyl ester [CAS]	54-80-8 66332-85-2 66332-86-3	US 4127671	Formulation, parenteral, other	
propacetamol	1-Propanone, 1-[2-[2-hydroxy-3-(propylamino)propoxy]phenyl]-3-phenyl-[CAS]	54063-53-5	GB 1307455	Antiarrhythmic	Fibrillation, ventricular
propafenone					
Propagermanium		12758-40-6			
Propallylona		545-93-7			
Propamidine		104-32-5			
propane-1,2-diol	1,2-propanediol	57-55-6		Formulation, dermal, topical	Infection, fungal, general
Propanidid		1421-14-3			
Propantheline		50-34-0			
Proparacaine		499-67-2			
Propaty		2921-92-8			
propenidazole	Ethyl trans-Alpha-acetyl-1-methyl-5-nitroimidazole-2-acrylate	76448-31-2	Antifungal		Infection, trichomoniasis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
propentofylline	1H-Purine-2,6-dione, 3,7-dihydro-3-methyl-1-(5-oxohexyl)-7-propyl- [CAS]	55242-55-2	GB 1470220	Neuroprotective	Ischaemia, cerebral
Propicillin		551-27-9			
Propiomazine		362-29-8			
Propionic Acid		79-09-4			
propionyl L-carnitine	1-Propanaminium, 3-carboxy-N,N,N-trimethyl-2-(1-oxoproxy)-, chloride, (R)- [CAS]	119793-66-7 20084-19-1	GB 2008578	Vasodilator, peripheral	Peripheral vascular disease
Propipocaine		3670-68-6			
Propiram		15686-91-6			
propiverine	2,2-diphenyl-2-(1-propoxy)acetic acid (1-methyliperoxy-4-yl) ester hydrochloride	54556-98-8 60569-19-9		Urological	Incontinence
Propizepine		10321-12-7			
protofo	Phenol, 2,6-bis(1-methylethyl)- [CAS]	207-54-8	US 4056635	Anaesthetic, injectable	Anaesthesia
Propoxycaine		550-83-4			
Propoxyphene		469-62-5			
propranolol	2-Propanol, 1-[1-(1-methylethyl)amino]-3-(1-naphthalenyl oxy)- [CAS]	318-98-9 525-66-6		Formulation, modified-release, <=24hr	Hypertension, general
Propylhexedrine		101-40-6			
Propylidone		587-61-1			
Propythiouracil		51-52-5			
Propyphenazone		479-92-5			
Proquazone		22760-18-5			
Proscillaridin		466-06-8			
Prostacyclin		35121-78-9			
Prostaglandin E₁		745-65-3			
Prostaglandin E₂		363-24-6			
Prostaglandin F_{2α}		551-11-1			
Prosultamine		59-58-5			
Protein C		60202-16-6			
Protheobromine		50-39-5			
Prothipendyl		303-69-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Protiofate		58416-00-5			
Protonamide		142222-60-7			
protizinic acid	10H-Phenothiazine-2-acetic acid, 7-methoxy-Alpha,10-dimethyl-, (+/-) [CAS]	13799-03-6	US 3450698	Anti-inflammatory	
Protoanemonin		108-28-1			
ProtokyloI		136-70-9			
Protoporphyrin IX		553-12-8			
Prototriptiline		438-60-8			
Pro-Urokinase		82657-92-9			
Proxazole		5696-9-3			
Proxibarbal		2537-29-3			
proxigermanium	Propanoic acid, 3,3'-(1,3-dioxo-1,3-digermoxanediyl)bis- [CAS]	12758-40-6	FR 2005110	Antiviral, other	Infection, hepatitis-B virus
Proxyphylline		603-00-9			
Prozapine		3426-8-2			
PruCalopride		179474-81-8			
prulifloxacin	1H,4H-[1,3]Thiaze[3,2-a]quinoline-3-carboxylic acid, 6-fluoro-1-methyl-7-[4-[(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl]-1-piperazinyl]-4-oxo- [CAS]	123447-62-1	EP 315828	Quinolone antibacterial	Infection, respiratory tract, general
Pseudococaine	Benzene[methanol, Alpha-[1-(methylamino)ethyl], hydrochloride, [S-(R*,R')]-, mixt. with (E)-2-[1-(4-methylphenyl)-3-(1-pyridinyl)-1-propenyl]pyridine monohydrochloride [CAS]]	478-73-9			
pseudoephedrine + triplidine	Benzene[methanol, Alpha-[1-(methylamino)ethyl], [S-(R*,R')]- [CAS]]	90-82-4, 8054-27-1, 345-78-8		Formulation, modified-release, other	Rhinitis, allergic, general
pseudoephedrine		520-52-5		Formulation, oral, other	Infection, respiratory tract, general
Psilocybin	Benzonitrile, 4-[3-(4-hydroxybutyl)-4-dimethyl-2,5-dioxo-1-imidazolidinyl]-2-(trifluoromethyl)- [CAS]	154992-24-2		Dermatological	Alopecia, general
PSK-3841					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
p-Sulfanilylbenzylamine		4393-19-5			
Pt-141			US 6051555	Male sexual dysfunction	Impotence
Pteropterin		89-38-3			
Puromycin		53-79-2			
	1-Methylpropyl 2-mercaptopimidazoly disulfide				
Px-12					
Pyrantel		15686-83-6			
Pyrazinamide		98-96-4			
Pyridinol Carbamate		1882-26-4			
Pyridostigmine Bromide		101-26-8			
Pyridoxal 5-Phosphate		54-47-7			
Pyridoxine		58-56-0			
Pyrilamine		91-84-9			
Pyrimethamine		58-14-0			
Pyrinoline		1740-22-3			
Pyrisuccideanol		33605-94-6			
Pyritthione		1121-30-8			
Pyritthydione		77-04-3			
Pyritinol		1098-97-1			
Pyrocatechol		120-80-9			
Pyrogallol		87-66-1			
Pyronaridine		74847-35-1			
Pyrovalerone		3563-49-3			
Pyroxylan		9004-70-0			
Pyrrobutamine		91-82-7			
Pyrrocaine		2210-77-7			
Pyrolnitrin		1018-71-9			
Pyrvinium Pamoate		3546-41-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
quazepam	2H-1,4-Benzodiazepine-2-thione, 7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)- [CAS]	36735-22-5	US 3845039	Hypnotic/Sedative	Insomnia
Quercetin		117-39-5			
quetiapine	Ethanol, 2-[2-(4-dibenzof[b,f]1,4-thiazepin-11-yl-1-piperazinyl)ethoxy], (E)-2-butenedioate (2:1) (salt) [CAS]	111974-69-7 111974-72-2	EP 240228	Neuroleptic	Schizophrenia
Quinacillin		1596-63-0			
quinacrine	N-[6-Chloro-2-methoxy-9-acridinyl]-N,N-diethyl-1,4-pentanediamine + 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl-	83-89-6			
quinagolide	Sulfamide, N,N-diethyl-N-(1,2,3,4,4a,5,10,10a-octahydro-6-hydroxy-1-propylbenzof[g]quinolin-3-yl)-(3Alpha,4aAlpha,10aS)-(+-)- [CAS]	87056-78-8 94424-50-7 97805-49-7	EP 77754	Antiprolactin	Hyperprolactinaemia
quinapril	3-Isoquinolinecarboxylic acid, 2-[2-[(1-ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2R*(R*)],3R]- [CAS]	82586-55-8 85441-61-8 90243-99-5	EP 49605	Antihypertensive, renin system	Hypertension, general
quinaprilat	3-Isoquinolinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-, [3S-[2R*(R*)],3R]- [CAS]	82768-85-2	EP 46953	Antihypertensive, renin system	Hypertension, general
Quinapyramine		20493-41-8			
Quinbolone		2487-63-0			
Quinestradil		1169-79-5			
Quinestrol		152-43-2			
Quinetazine		73-49-4			
quinfarmide	2-Furancarboxylic acid, 1-(dichloroacetyl)-1,2,3,4-tetrahydro-6-quindolinyl ester [CAS]	62265-68-3	US 3997542	Antabicidic	
quinidine	Cinchonan-9-ol, 6-methoxy-, (9S)-, sulfate (1:1) (salt) [CAS]	56-54-2		Formulation, modified-release, other	Arrhythmia, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Quinine		130-95-0			
Quinocide		525-61-1			
Quinupramine		31721-17-2			
Quinupristin	cis-2,3,3a,8-tetrahydro-N,N-dimethylidibenz[c,f]isoxazolo[2,3-a]azepine-2-methanamine	120138-50-3			
R-107500			WO 9614320	Anxiolytic	Anxiety, general
R-667	1H-Benzimidazole, 2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl]sulfanyl], sodium salt-[CAS]	117976-89-3 117976-90-6	EP 268956	Antitulcer	Ulcer, gastric
rabeprazole	Glycine, N-[2-[(acetylthio)methyl]-1-oxo-3-phenylpropyl]-, phenylmethyl ester, (+/-)-[CAS]	112573-72-5 81110-73-8	EP 38758	Antidiarrhoeal	Diarrhoea, general
raeacetotril		510-53-2			
Racemethorphan	Methanone, [β-hydroxy-2-(4-hydroxyphenyl)benzop[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxyphenyl]-, hydrochloride [CAS]	82640-04-8 84449-90-1	EP 62503	Osteoporosis treatment	Osteoporosis
raloxifene	L-glutamic acid, N-[[5-[[1,4-dihydro-2-methyl-4-oxo-6-quinoxolinyl)methyl]methylamino]-2-thienyl]carboxylic acid, [CAS]	112687-68-0	EP 239362	Anticancer, antimetabolite	Cancer, colorectal
raltrexed	9H-Carbazole-9-propanoic acid, 3-[[4-fluorophenyl]sulfonyl]aminol-1,2,3,4-tetrahydro-, (R)- [CAS]	116649-85-5	EP 242518	Antiallergic, non-asthma	Rhinitis, allergic, perennial
Ramatroban		3615-24-5			
Ramifenazone	Cyclopentenylpyrrole-2-carboxylic acid, 1-[2-[[1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, [2S-[(R*)]-2Alpha,3aBeta,6aBeta]-[CAS]	87269-97-4 87333-19-5	EP 79022	Antihypertensive, renin system	Heart failure
ramipril	Methanone, (1-methyl-1H-indol-3-yl)(4,5,6,7-tetrahydro-1H-benzimidazol-5-yl)-, monohydrochloride, (R)- [CAS]	132907-72-3 132036-88-5	EP 381422	Antiemetic	Nausea and vomiting, general

Table IV

API Generic Name Ranom project No. 1097	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Ranimustine		58994-96-0	US 5730992	Dermatological	Unspecified
ranitidine	1,1-Ethenediamine, N-[2-[[5-((dimethylamino)methyl)-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-[CAS]	663-57-35-5	US 4128658	Antulcer	Ulcer, duodenal
ranitidine bismuth citrate	1,2,3-Propanetricarboxylic acid, 2-hydroxy-bismuth(3+) salt (1:1), compd. with N-(2-(((5-((dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitroethenenediamine (1:1)- [CAS]	128345-62-0	EP 533281	Antulcer	Ulcer, duodenal
ranolazine	1-Piperazineacetamide, N-[2-(6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (+/-)- [CAS]	95635-55-5 95635-56-6	EP 126449	Antianginal	Angina, general
Ranpirnase		133-37-96-9			
Rapacuronium	1H-Inden-1-amine, 2,3-dihydro-N-2-propynyl-, (R)-, [CAS]	156137-99-4			
rasagiline		161735-79-1	US 5457133	Antiparkinsonian	Parkinson's disease
Raubasine		483-04-5			
rauconazole	Benzonitrile, 4-[2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]- [CAS]	182760-06-1		Antifungal	Infection, meningitis, general
raxofelast	2-Benzofuranacetic acid, 5-(acetoxy)-2,3-dihydro-4,6,7-trimethyl-, (+)- [CAS]	128232-14-4	US 4998350	Symptomatic antidiabetic	Nephropathy, diabetic
razoxane	2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyli)bis- [CAS]	21476-67-1, 21476-87-5	GB 1234935	Anticancer, other	Cancer, general
RC-529	Tetradecanoic acid (1R)-1-(2-((2-((2-deoxy-3-O-((3R)-1-oxo-3-((1-oxotetradecyl)oxy)tetradecyl)amino)-4-O-phosphono-β-D-glucopyranosyloxy)ethyl)amino)-2-oxoethyl)dodecyl ester, compd. with N,N-diethyllethanamine (1:1) [CAS]				
rebamipide	4-Quinolinepropionic acid, Alpha-[4-chlorobenzoyl]amino]-1,2-dihydro-2-oxo-[CAS]	90098-04-7	DE 3324034	Antulcer	Vaccine adjunct

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rebimastat	L-Valinamide, N-((2S)-2-mercaptopro-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N(3,3-dimethyl-[CAS])	259188-38-0		Anticancer, other	Cancer, lung, non-small cell
reboxetine	Morpholine, 2-[(2-ethoxyphenoxy)phenylmethyl]-, (R*,S*)-[CAS]	71620-89-8, 98769-81-4	US 4229449	Antidepressant	Depression, general
Remacemide	1-Piperidinepropanoic acid, 4-((methoxycarbonyl)-4-((1-oxopropyl)phenylamino)-methyl ester-[CAS]	132539-07-2, 132875-61-7	EP 383579	Analgesic, other	Pain, general
remifentanil	Tricyclo[3.1.13.7]decane-2-carboxylic acid, 2-[1-(-7-chloro-4-quinolonyl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-y]carbonylaminoo-[CAS]	146362-70-1	EP 699438	Neuroleptic	Schizophrenia
Remoxipride	Benzamide, 4-amino-N-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy-[CAS]	80125-14-0			
renzapride	Benzoic acid, 2-ethoxy-4-[2-[3-methyl-1-[2-(1-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]-, (S)-[CAS]	109872-41-5 88721-77-1	JP 58188885	Gastroprokinetic	Irritable bowel syndrome
repaglinide	2(R)-4-isobutylphenylpropionic methanesulfonamide L-lysine salt	135062-02-1	WO 9300337	Antidiabetic	Diabetes, Type II
repertaxin L-lysine salt	1,2-Benzisothiazol-3(2H)-one, 2-(4-((3,4-dihydro-2H-1-benzopyran-2-y)methylamino)butyl)-, 1,1-dioxide, monohydrochloride [CAS]		WO 0024710	Cardiovascular	Reperfusion injury
repinotan	4H-Pyran-3(2-c)quinoline-2-carboxylic acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-3-methylbutyl ester [CAS]	144480-29-0 144480-77-8	US 5137901	Neuroprotective	Ischaemia, cerebral
repinast		73080-51-0	US 4298610	Antiasthma	
Reposal		3625-25-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
reprotoleol	1H-Purine-2,6-dione, 7-[3-[[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino]propyl]-3,7-dihydro-1,3-dioxo-5,7-dimethyl-[CAS]	13055-82-8 54063-54-6	FR M5969	Antisthma	Asthma
Rescimetol		73573-42-9			
Rescinnamine		24815-24-5			
Reserpiline		131-02-2			
Reserpine		50-55-5			
Resibufogenin		465-39-4			
resiquimod	1H-Imidazo[4,5-c]quinoline-1-ethanol(ethoxymethyl)-Alpha, Alpha-dimethyl-[CAS]	144875-48-9	US 5389640	Antiviral, other	Infection, hepatitis-C virus
Resorcinol		108-46-3			
Reteplase		133652-38-7			
retigabine	Carbamic acid, (2-amino-4-(((4-fluorophenyl)methyl)amino)phenyl)-, ethyl ester [CAS]	150812-12-7	DE 4200259	Antiepileptic	Epilepsy, general
retinoic acid	Retinoic acid [CAS]	302-79-4			Cancer, leukaemia, acute myelogenous
Revimid	[1,1'-Biphenyl]-4-acetic acid, 2-fluoro-Alpha-methyl		US 6281230	Anticancer, other	Cancer, myeloma
R-flurbiprofen		5104-49-4		Anticancer, other	Cancer, prostate
<i>Rho (D) Immune Globulin (Human)</i>					
Rho-kinase inhibitors			WO 0156988	Antisthma	Unspecified
ribavirin	1H-1,2,4-Triazole-3-carboxamide, 1,3-D-ribofuranosyl-[CAS]	36791-04-5	US 4211771	Antiviral, other	Infection, haemorrhagic fever
Riboflavin		146-17-8			
ribostamycin	D-Streptamine, O-2,6-diamino-2,6-dideoxy-Alpha-D-glucopyranosyl-(1-4)-O-[β-D-ribofuranosyl-(1-5)]-2-deoxy-[CAS]	25546-65-0	GB 1254883	Aminoglycoside antibiotic	Infection, general
Ricinoleic Acid		141-22-0			
Ridogrel		110140-89-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rifabutin	Rifamycin XIV, 1',4-didehydro-1-deoxy-1,4-dihydro-5-(2-methylpropyl)-1-oxo-[CAS]	72359-06-9	US 4219478	Antimycobacterial	Infection, Mycobacterium avium complex
rifalazil	Rifamycin VIII, 1',4-didehydro-1-deoxy-1,4-dihydro-3'-hydroxy-5-[4-(2-methylpropyl)-1-123791-92-0 piperazinyl]-1-oxo- [CAS]	132633-12-2	EP 366914	Antimycobacterial	Infection, tuberculosis
rifametane	Rifamycin, 3-[[1-(diethylamino)ethylidene]hydrazono]methyl-1-[CAS]	94168-98-6	EP 119571	Antimycobacterial	Infection, general
Rifamide	Rifamycin, 3-[[4-methyl-1-piperazinyl]imino]methyl-, mixt. with 5-[(3,4,5-trimethoxyphenyl)methyl]-2,4-pyrimidinediamine [CAS]	2750-76-7			
rifampicin + trimethoprim		61498-94-0			
Rifampin		13292-46-1			
Rifamycin SV	Rifamycin, 3-[[4-cyclopenty-1-piperazinyl]imino]methyl- [CAS]	6998-60-3			
rifapentine	Rifamycin, 3-[[4-cyclopenty-1-piperazinyl]imino]methyl- [CAS]	61379-65-5	DE 2606218	Antibiotic, other	Infection, tuberculosis
rifaximin	Epoxypentadeca[1,11,13]trienimino]benzofuro[4,5-e]-pyrido[1,2-a]benzimidazolo-1,15(2H)-dione, 25-(acetoxy)-5,6,21,23-tetrahydroxy-27-methoxy-2,4,11,16,20,22,24,26-octamethyl- [2S-(2R*,16Z,18E,20R*,22S*,23S*,25R*,26S*,27R*,28E)]				
rifaximin cream	4-deoxy-4'-methylpyridof[1',2'-1,2]imidazo[5,4-c]rifamycin SV	80621-81-4	GB 2079270	Antibiotic, other	Infection, GI tract
Rilmazafone		80621-81-4	BE 888895	Formulation, dermal, topical	Infection, dermatological
	99593-25-6				
rilmendine	2-Oxazolamine, N-(dicyclopropylmethyl)-4,5-dihydro- [CAS]	54187-04-1 54249-57-9	DE 2362754	Antihypertensive, adrenergic	Hypertension, general
riluzole	2-Benzothiazolamine, 6-(trifluoromethoxy)- [CAS]	1744-22-5	EP 50551	Neuroprotective	Amyotrophic lateral sclerosis
Rimantadine		13392-28-4			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rimazolum	4H-Pyrid[1,2-alpyrimidinium, 3-(ethoxy carbonyl)-6,7,8,9-tetrahydro-1,6-dimethyl-4-oxo-, [CAS]	28610-84-6 35615-72-6	DE 2461349	Analgesic, NSAID	
rimexolone	Androsta-1,4-dien-3-one, 11-hydroxy-16,17-dimethyl-17-(1-oxopropyl)-, (11 β ,16 α Alpha,17 β)- [CAS]	49697-38-3	DE 2301317	Ophthalmological	Inflammation, ocular
Rimiterol	1H-Pyrazole-3-carboxamide, 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-1-piperidinyl-, monohydrochloride [CAS]	158681-13-1	US 5624941	Anorectic/Antiobesity	Obesity
rimonabant	1,3-Benzenediol, 2,4,6-triiodo- [CAS]	19403-92-0	US 3755251	Antiviral, other	
Rio doxo		77287-05-9			
Rioprostil					
risendronate	Phosphonic acid, (1-hydroxy-2-(3-pyridinyl)ethyleneglyb-, monosodium salt	115436-72-1	EP 304961	Osteoporosis treatment	Paget's disease
Risedronic Acid		105462-24-6			
risperidone	4H-Pyrido[1,2-alpyrimidin-4-one, 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl- [CAS]	106266-06-2	EP 196132	Neuroleptic, formulation, optimized, microencapsulate	Schizophrenia
Ritanserin		87051-43-2			
Ritipenem		84845-57-8			
ritodrine	Benzene methanol, 4-hydroxy-Alpha-[1-[2-(4-hydroxyphenyl)ethyl]amino]ethyl]-, (R*,S*)- [CAS]	23239-51-2 26652-09-5	US 3410944	Labour inhibitor	Labour, preterm
ritonavir	2,4,7,12-Tetraazatridecan-13-oic acid, 10-hydroxy-2-methyl-5-(1-methylethyl)-1-[2-(1-methylethyl)-4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-, 5-thiazoly-l-methyl ester, (5S-(5R*,8R*,10R*,11R*)- [CAS]	155213-67-5	WO 9414436	Antiviral, anti-HIV	Infection, HIV/AIDS
Rituximab		174722-31-7			
rivastigmine	Carbamic acid, ethylmethyl-, 3-[1-(dimethylamino)ethyl]phenyl ester, (S)- [CAS]	123441-03-2 12901-54-8	DE 3805744	Cognition enhancer	Alzheimer's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
izatiriptan	1H-Indole-3-ethanamine, N,N-dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-, [CAS]	145202-66-0 159776-67-7	EP 497512	Antimigraine	Migraine
RJR-2403	3-Buten-1-amine, N-methyl[4-(3-pyridinyl)-(3E)-, (2E)-2-butenedioate (1:1) [CAS]	183288-99-5		Cognition enhancer	Alzheimer's disease
RNA Stealth Nucleosides	5-Formyluridine			Antiviral, other	Infection, hepatitis-C virus
Ro-0094889	2',3'-Di-O-acetyl-5'-vinylcytidine			Anticancer, antimetabolite	Cancer, general
Ro-61-1790	2-Pyridinesulfonamide, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-[2-(1H-tetrazol-5-yl)-4-pyridinyl]-4-pyrimidinyl]-5-methyl-, [CAS]	180384-56-9	WO 9619459	Cardiovascular	Haemorrhage, subarachnoid
Rociverine	Pyrrolidinium, 1-[(2S,3Alpha,5Alpha,16B,17B)-17-(acetoxy)-3-hydroxy-2-(4-morpholinyl)androstan-16-yl]-1-(2-propenyl)-, bromide-, [CAS]	53716-44-2			
rocuronium		104855-17-6. 104884-91-5 119302-91-9 143556-00-3	EP 287150	Muscle relaxant	Muscle spasm, general
rofecoxib	2(5H)-Furanone, 4-(4-(methylsulfonyl)phenyl)-3-phenyl-, [CAS]	162011-90-7	US 5474895	Analgesic, NSAID	Arthritis, osteo
roflumilast	Benzamide, 3-(cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)-, [CAS]	162401-32-3	WO 9501338	COPD treatment	Chronic obstructive pulmonary disease
rolitamycin	Leucomycin V, 4B-butanolate 3B-propanoate [CAS]	74014-51-0	US 4242504	Macrolide antibiotic	Infection, general
Rolipram		61413-54-5			
Rolitetracycline		751-97-3			
Romurtide		78113-36-7			
Ronifibrate		42597-57-9			
ropinirole	2H-Indol-2-one, 4-[2-(dipropylamino)ethyl]-1,3-dihydro-, monohydrochloride-, [CAS]	91374-20-8 91374-21-9	EP 266033	Antiparkinsonian	Parkinson's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
ropivacaine	2-Piperidinecarboxamide, N-[2,6-dimethylphenyl]-, (S)- [CAS] 84057-95-4	98717-15-8	EP 239710	Anaesthetic, local	Anaesthesia
Roquinimex	Cyclopentaneheptanoic acid, 2-hexyl-5-hydroxy- [CAS]	84088-42-6			
rosaprostol		56695-65-9	GB 1523355	Prostaglandin	
Rosaramicin		35834-26-5			
Rose Bengal		632-68-8			
rosiglitazone	2,4-Thiazolidinedione, 5-[(4-(2-(methyl-2-pyridylamino)ethoxy)phenyl)methyl]-, (Z)-2-butenedioate (1:1) [CAS] 155141-29-0	122320-73-4	US 5002953	Antidiabetic	Diabetes, Type II
rosoxacin	3-Quinoliniccarboxylic acid, 1-ethyl-1,4-dihydro-4-oxo-7-(4-pyridinyl)- [CAS] 40034-42-2	40034-42-2	US 3753993	Quinolone antibacterial	Infection, gonorrhoea
rostaporphin	Tin, dichloroethyl 3,4,20,21-tetrahydro-4,9,14,19-tetraethyl-1,8,19-dihydro-3,8,13,18-tetramethyl-2-phorbinecarboxylato(2-)kappaN23,kappaN24,kappaN25,kappaN26], (OC-6-13)- [CAS] 11494-17-6			Ophthalmological	Macular degeneration
rosuvastatin	6-Heptenoic acid, 7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy- (S-(R*, S*-)(E)) [CAS] 147098-20-2	147098-20-2	JP 2648897	Hypolipidaemic/Antiatherosclerosis	Hyperlipidaemia, general
rotigotine	[propyl[2-(2-thienyl)ethyl]amino]-, (S)- [CAS] 99755-59-6	99755-59-6	US 4564628	Antiparkinsonian	Parkinson's disease
Rofaxate		92071-51-7			
Roxarsone		121-19-7			
roxatidine	Acetamide, 2-(acetyl oxy)-N-[3-(1-piperidinylmethyl)phenoxy]propyl-, [CAS] 78628-28-1	93793-83-0	EP 24510	Antitulcer	Ulcer, gastric
roxifiban	L-Alanine, 3-((3-(4-(aminomethyl)phenyl)-4,5-dihydro-5-isoxazolyl)acetyl)amino)-N-(butoxycarbonyl)-, methyl ester, (R)-, [CAS] 176022-59-6				Thrombosis, general
Roxindole		112192-04-8			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
roxithromycin	Erythromycin, 9-[O-[(2-methoxyethoxy)methyl]oxime] [CAS]	80214-83-1 80214-86-4	EP 33255	Macrolide antibiotic	Infection, general
RPR-109881A	Benzene propanoic acid, β -(((1,1-dimethyllethoxy)carbonyl)amino)-[Alpha-hydroxy-(1S,2S,4S,7R,8aR,9aS,10aR,12aS,12bR)-7,12a-bis(acetoxyoxy)-1-(benzoyloxy)-1,3,47,8,9,9a,10,10a,12,12a,12b-dodecahydro-2-hydroxy-5,13,13-trimethyl-8-oxo-2,6-methano-2H-cyclodecen(3,4)cyclopropane (4/5) benz (1,2-b) oxet-4-yl ester, dihydrate Alpha R, beta S [CAS]	192573-38-9		Anticancer, other	Cancer, lung, general
R-roscovitine	4,9-Ethano-3aH-benz[f]isoindole-3a-carboxylic acid, 1,2,3,4,9,9a-hexahydro-2-[2-(2-methoxyphenyl)-1-oxo-2-propenyl]-9-(4-methylphenyl)-, (3aR,4S,9S,9aR)-rel-[CAS]	210282-69-2	WO 9829390	Anticancer, other	Cancer, general
RS-0406	N,N'-bis(3-hydroxyphenyl)pyridazine-3,6-diamine		US 6316456	Anticancer, other	Cancer, lung, non-small cell
RSR-13		131179-95-8			Alzheimer's disease
Rubijervine	1H-Pyran(3',4',6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-10-nitro-, (S)- [CAS]	79-58-3			
rubitecan	9H,18H-5,21,12,17-Dimethyldibenzo[e,k]pyrrolo[3,4-h](1,4,13)oxadiazacyclohexadecine-18,20(19H)-dione, 9-((dimethylamino)methyl)-6,7,10,11-tetrahydro-, (S)- [CAS]	91421-42-0	US 6485514	Anticancer, other	Cancer, pancreatic
rufoxistaurin			169939-94-0		
Rufinamide			106308-44-5	Symptomatic antidiabetic	Retinopathy, diabetic

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
rufloxacin	7H-Pyrido[1,2,3-de]-1,4-benzothiazine-6-carboxylic acid, 9-fluoro-2,3-dihydro-10-(4-methyl-1-piperazinyl)-7-oxo- [CAS] 101363-10-4 102052-47-1 106017-08-7	EP 165375	Quinolone antibacterial		Infection, general
rupatadine	5H-Benzo[5,6]cycloheptal[1,2-b]pyridine, 8-chloro-6,11-dihydro-11-[1-[(5-methyl-3-pyridinyl)methyl]-4-piperidinylidene], trihydrochloride- [CAS]	155611-76-6	EP 0577957	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Rutin		153-18-4			
RWJ-54428	5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 7-[(2Z)-(2-amino-5-chloro-4-thiazolyl)(hydroxymethyl)acetyl]amino]-3-[(3-[(2-aminoethyl)thio]methyl)-4-pyridinyl]thio]-8-oxo-, (6R,7R)- [CAS] 189448-35-9	WO 9713772	Cephalosporin, injectable		Infection, beta-lactamase resistant
S-0139	Olean-12-en-28-oic acid, 27-[3-[5-hydroxy-2-[(4-methoxy-1,4-dioxo-2-buteny)amino]phenyl]-1-oxo-2-propenyl]oxy]-3-oxo- [CAS] 193969-54-9	WO 9727314	Cardiovascular		Ischaemia, cerebral
S-15535	Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-(2,3-dihydro-1H-inden-2-yl)- [CAS] 146988-34-7		Cognition enhancer		Cognitive disorder, general
S-18886	1-Naphthaleneprpanic acid, 6-((4-chlorophenyl)sulfonylamino)-5,6,7,8-tetrahydro-2-methyl [CAS] 165537-73-5		Antithrombotic		Thrombosis, general
S-24730	7-chloro-6-sulfamoyl-2-(1H)-quinoleinone-3-phosphonic acid			Neuroprotective	Unspecified
S-3578	7B-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-ethoxyminoacetamido]-3-(1-(N-methylaminopropyl)-1H-imidazo[4,5-b]pyridinium-4-methyl-3-cephem-4-carboxylate monosulfate			Cephalosporin, injectable	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
S-36496	2-[N-[4-(4-Chlorophenyl)sulfonyl]amino]butyl]-N-[3-[{(4-isopropylthiazol-2-y)methoxy]benzyl}sulfamoyl]benzoic acid			Antiasthma	Asthma
S-36527	2-[N-[4-(4-Chlorophenyl)sulfonyl]amino]butyl]-N-[3-[2-(4-cylobutylthiazol-2-y)ethyl]benzyl}sulfamoyl]benzoic acid			Antiasthma	Asthma
S-5751	(1R,2R,3S,5S)-7-[2-(5-Hydroxybenzothiophen-3-ylcarboxamido)-6,6-dimethylbicyclo[3.1.1]hept-3-yl]-5(Z)-heptenoic acid				
S-3510	Imidazolo[4,5-d]pyran-4,3-b]pyridine, 1,6,7,9-tetrahydro-2-(3-isoxazolyl)-, phosphate (1:1) [CAS]	151466-23-8	EP 556008	Antiallergic, non-asthma Cognition enhancer	Allergy, general Alzheimer's disease
S-3921	2-Naphthalene carboxylic acid, 1-(3,4-dimethoxyphenyl)-3-(3-ethyl-1-oxopentyl)-4-hydroxy-6,7,8-trimethoxy-, methyl ester [CAS]	151165-98-7	WO 9303155	Hypolipaemic/Antiatherosclerosis	Hypercholesterolaemia
Sabcomeline		159912-53-5			
Sabeluzole		104383-17-7			
S-Adenosylmethionine		29908-03-0			
safinamide	(S)-(+)-2-[4-(3-fluorobenzoyloxy)benzylamino]propanamide methansulfonate	133865-89-1	AU 711309	Antiepileptic	Epilepsy, general
Salacetamide		487-48-9			
Salazosulfadimidine		2315-84-			
salbutamol	1,3-Benzodihydro-1,1-dimethyl(ethyl)amino)methyl]-4-hydroxy-[CAS]	18559-94-9	EP 451745	Formulation, inhalable, topical, dry powder	Asthma
Salicin		138-52-3			
Salicyl Alcohol		90-01-7			

Table IV

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
saredutant	Benzamide, N-[4-[4-(acetylamino)-4-phenyl-1-piperidinyl]-2-(3,4-dichlorophenyl)butyl]-N-methyl-, (S)- [CAS] 142001-63-6	EP 474561	Antiasthma	Asthma	
sarizotan	3-Pyridinemethanamine, N-[(3,4-dihydro-2H-1-benzopyran-2-yl)methyl]-5-(4-fluorophenyl)- [CAS] 177975-08-5			Antiparkinsonian	Parkinson's disease
sarpogrelate	Butanediol acid, mono[2-(dimethylamino)-1-[2-[2-(3-methoxyphenyl)ethyl]phenoxy)methyl]ethyl]ester [CAS]	125926-17-2	EP 398326	Antithrombotic	
Satigrel	Platinum, bis(acetato-O)amininedichloro(cyclohexanamine)-(OC-6-3)- [CAS]	111753-73-2			
satraplatin	N-[3-[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl-nitrobenzamide, HCl	129580-63-8	EP 328274	Anticancer, alkylating	Cancer, prostate
Satumomab	N-[3-[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl-4-nitrobenzamide, HCl	144058-40-2			
SB-237376	[5-(2-phenylamino-4-pyrimidiny)-4-(4-fluorophenyl)-1-(4-piperidiny)imidazole			Antiarrhythmic	Fibrillation, atrial
SB-238039				Anticancer, other	Cancer, general
SB-277011	trans-N-[4-[2-(6-Cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolonecarboxamide				
Scarlet Red	85-83-6		Neuroleptic	Schizophrenia	
SCH-00013	Benzonitrile, 4-[2-[3,6-dihydro-4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-1-(2H-pyridinyl)-1-hydroxyethyl]- [CAS] 217983-18-3	EP 618204	Cardiotonic	Heart failure	
Sch-23863	(2-[10,11-Dihydro-5-ethoxy-5H-dibenzo[a,d] cyclohepten-S-yl]-N,N-dimethyl-ethanamine			Immunosuppressant	Inflammation, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sch-57790	1-Piperazineacetontitifile, 4-cyclohexyl-alpha-[4-[S]-{4-methoxyphenyl)sulfinylphenyl}]-[CAS] 7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 2-(2-furanyl)-7-(3-phenylpropyl)- [CAS]	221660-80-6		Cognition enhancer	Alzheimer's disease
Sch-63390		174648-45-4		Antiparkinsonian	Parkinson's disease
Sicilarenin		465-22-5			
Scopolamine		51-34-3			
Scopolamine N-Oxide		97-75-6			
scopolamine	Benzeneacetic acid, Alpha-(hydroxymethyl)-, 9-methyl-3-oxa-9-azatricyclo[3.3.1.0 ^{2,4}]non-7-yl ester, [7(S)-1(Alpha,2Beta,4Beta,5Alpha,7S)- [CAS]	51-34-3	US 4262003	Formulation, transdermal, other	Nausea and vomiting, general
SCS technology	9,10-Secocholesta-5,7,10(19)-triene-3,24,25-triol, (3Beta,5Z,7E,24R)- [CAS]	55721-11-4	US 6046188	Antiasthma	Unspecified
secalciferol	1H-imidazole-1-ethanol, Alpha,2-dimethyl-5-nitro- [CAS]	3366-95-8	EP 301167	Osteoporosis treatment	Osteodystrophy
secnidazole		FR M3270		Protozoacide	
Secobarbital		309-43-3			Infection, trichomiasis
selagine	Benzeneethanamine, N,Alpha-dimethyl-N-2-propynyl-, (R)- [CAS]	1461-51-9	GB 1153578	Antiparkinsonian	
Selenomethionine		1464-42-2			
Sematilide		101526-83-4			
Semotiadil		116476-13-2			
sesocalcitol	1,3-Cyclohexanediol, 5-((1-(6-ethyl-6-hydroxy-1-methyl-2,4-octadienyl)octahydro-7a-methyl-4H-inden-4-ylidene)ethylidene)-4-methylene-, [(R-(1Alpha)(R*-2E,4E),3aE,4E(1R*,3S*,5Z),7aAlpha)-] [CAS]	134404-52-7	WO 9100855	Anticancer, other	Cancer, liver
Sepimostat		103926-64-3			
seratrodast	Benzeneheptanoic acid, zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, (+/-)- [CAS]	112665-43-7	EP 232089	Antiasthma	Asthma

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sertaconazole	1H-imidazole, 1-[2-[(7-chlorobenzotriphenyl)ethyl]-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-[CAS]	99392-32-2	EP 151477	Antifungal	Infection, dermatological
serindole	2-imidazolidinone, 1-[2-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]-1-piperidinyl]ethyl]- [CAS]	106516-24-9	EP 392959	Neuroleptic	Schizophrenia
sertraline	1-Naphthalenamine, 4-[3-(4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, (1S-cis)- [CAS]	7959-97-0 79617-96-2 79617-97-3	EP 30081	Antidepressant	Depression, general
Sefastine	2-Propen-1-amine polymer with (chloromethyl)oxirane, hydrochloride [CAS]	64294-95-7			
sevelamer	Propane, 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)- [CAS]	152751-57-0 52757-95-6	US 5496545	Urological	Renal failure
sevoflurane	2H-1,4-Benzothiazine-2-acetic acid, 3,4-dihydro-3-oxo-4-((4,5,7-trifluoro-2-benzothiazolyl)methyl)- [CAS]	28523-86-6	DE 1954268	Anaesthetic, inhalation	Anaesthesia
SG-210	Cyclobutanemethanamine, 1-(4-chlorophenyl)-N,N-dimethyl-Alpha-(2-methylpropyl)- [CAS]	143162-65-6		Symptomatic antidiabetic	Neuropathy, diabetic
sibutramine	(4aS-(4aAlpha,6aAlpha,11bAlpha,13aR)*13bAlpha,1,2,3,4,4a,5,6a,11b,13b-decahydron-4,4,6a,9-tetramethyl-13H-benzo[furo[2,3,4-mr]]xanthen-11-ol	106650-56-0 84485-00-7	GB 2098602	Anorectic/Antidiabesity	Obesity
siccanin	Piperazine, 1-[(3-(4,7-dihydro-1-methyl-5-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methyl-, 2-hydroxy-1,2,3-propanetricarboxylate- (1:1)	22733-60-4	JP 37003548	Antifungal	
sildenafil	1H-Indole-7-carboxamide, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-(2,2,2-trifluoroethoxy)phenoxyl]amino]propyl]- [CAS]	171599-83-0 139755-83-2	WO 9428902	Male sexual dysfunction	Impotence
silodosin					
Silver Lactate		128-00-7	EP 600675	Urological	Dysuria

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Silver Picrate	N'-2-pyrimidinylsulfamiamide monosilver salt	146-84-9 22799-08-2 68-35-9			
Silver sulfadiazine				Anti-infective, other	Infection, general
Simetride		154-82-5			
Simfibrate		14929-11-4			
simvastatin	Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester, [1S-[1Alpha,3Alpha,7S,8S(2S',4S')]-[CAS]]	79902-63-9	US 4444784	Hypolipidaemic/Antitherosclerosis	Hyperlipidaemia, general
Sincalide		25726-32-3			
Sintropium Bromide		79467-19-9			
Sisomicin		32385-11-8			
sitafloxacin	3-Quinolinecarboxylic acid, 7-(7-amino-5-azaspiro[2.4]hept-5-yl)-8-chloro-6-fluoro-1-(2-fluorocyclopentyloxy)-1,4-dihydro-4-oxo-, [1R-[1Alpha(S*),2Alpha]]-, hydrate	127254-12-0	EP 341493	Quinolone antibacterial	Infection, general
sitemaquine	1,6-Hexanediamine, N,N-diethyl-N-[6-methoxy-4-(methyl-8-quinoindyl)-[CAS] 57695-04-2			Protozoacide	Infection, leishmaniasis
siltaxsentan	N-(4-Chloro-3-methyl-5-isoxazolyl)-2-[4-(methyleneedioxy)-o-tolyl]acetyl]-3-thiophenesulfonamide	184036-34-8	US 5464853	Antihypertensive, other	Hypertension, pulmonary
sivelestat	Glycine, N-[2-[[4-(2,2-dimethyl-1-oxopropoxy)phenyl]sulfonyl]aminobenzoyl]-[CAS]	127373-66-4	EP 347168	Respiratory	Systemic inflammatory response syndrome
SLA-6017	Butanamide, 2-[[4-(fluorophenyl)sulfonyl]amino]-N-[(1S)-1-formyl-3-methylbutyl]-, (2S)-[CAS] 190274-53-4				Cataract
SL-65-11498	6-Fluoro-9-methyl-2-phenyl-4-pyrrolidin-1-ylcarbonyl)-2,3-dihydro-1H-pyridof[3,4-b]indole-1-one		EP 607076	Anxiolytic	Anxiety, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SLV-306	(3S,2'R)-3-[1'-[2'-(Ethoxycarbonyl)-4'-phenyl]-butyl]-1-cyclopentan-1-1H-benzimidazol-2,3,4,5-tetrahydro-2-oxo-1H-benzaphin-1-acetic acid			Antihypertensive, diuretic	Hypertension, general
SLV-308	2(3H)-Benzoxazolone, 7-(4-methyl-1-piperazinyl)-, monohydrochloride	269718-83-4		Antiparkinsonian	Parkinson's disease
Sml53 (lexidronam	Samarate(5)-153Sm, (((1,2-ethanediylibis(nitrilobis(methylene)))(tetraakis(phosphonato))(8)-N,N',O,P,O'',O''P''), pentasodium, (OC-6-21)- [CAS]	160369-78-8		Analgesic, other	Pain, cancer
S-Methylmethionine	N-(Aminomethyl)-11-chloro-5,6,7,8-tetrahydro-8-oxo-4H-pyrrrol[3,2,1-k][1]benzazocine-2-carboxamide monomethanesulfonate monohydrate	4727-40-6			
SMP-300	(4S)-4,7,11-triethyl-3,4,12,14-tetrahydro-4,10-dihydro-3,14-dioxo-1H-pyranof[3',4':6,7]indolizino[1,2-b]quindin-9-yl			Antianginal	Angina, general
SN-38	100286-90-6			Formulation, optimized, liposomes	Cancer, colorectal
SNAP-7941	((+)-methyl(4S)-3-[(3-[4-[3-(acetylamino)phenyl]-1-piperidinyl]propyl)amino] carbonyl)-4-(3,4-difluorophenyl)-6-(methoxymethyl)-2-oxo-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate hydrochloride)				
SOA-132	2-Naphthalene carboxamide, N-[2-[4-(diphenylmethoxy)-1-piperidinyl]ethyl]-3-hydroxy-5-(3-pyridinylmethoxy)- [CAS] 143964-80-1			Anxiolytic	Anxiety, general
				Formulation, inhalable, topical	Asthma

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication	
sobidotin	L-valinamide, N,N-dimethyl-L-valyl-N-[2-methoxy-4-[2-[1-methoxy-2-methyl-3-oxo-3-[2-(phenylethyl)amino]propyl]-1-(2-methoxypropyl)-4-oxobutyl]-N-methyl-, [2S-[1[R*(R'),2S*],2R*(S*,2S*)]-[CAS]	149606-27-9 498-71-5	WO 9303054	Anticancer, other	Cancer, lung, non-small cell	
Sobrerol	subuzoxane	Carbonic acid, 1,2-ethanediyibis[2,6-dioxo-4,1-piperazinediy]methylenebis(2-methylpropyl) ester [CAS]	98631-95-9	EP 140327	Anticancer, other	Cancer, lymphoma, T-cell
Sodium Arsanilate		127-85-5				
Sodium Arsphenamine		1936-28-3				
Sodium Chloride						
Sodium Dibunate		14992-59-7				
Sodium Folate		6484-89-5				
Sodium Formaldehydesulfonoxylate		149-44-0				
Sodium Glycerophosphate		1334-74-3				
Sodium Hyaluronate						
Sodium Iodomethamate		519-26-6				
Sodium Nitrite		7632-00-0				
Sodium Nitroprusside		14402-89-2				
sodium oxybate	Butyric acid, 4-hydroxy monosodium salt [CAS]	502-85-2		Psychostimulant	Narcolepsy	
Sodium Phenolsulfonate		1300-51-2				
sodium phenylbutyrate	Butyric acid, 4-phenyl-, sodium salt- [CAS] 1716-12-7			Formulation, other	Hyperammonaemia	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sodium phosphate	Sodium phosphate monobasic monohydrate + sodium phosphate dibasic anhydrous		US 6162464	Formulation, oral, other	Surgery adjunct
sodium prasterone sulfate	3β-hydroxy-5-androsten-17-one(sodium sulfate dihydrate)		EP 380036	Formulation, mucosal, topical	Labour, induction
Sodium Propionate	Benzoic acid, 2-hydroxy-, monosodium salt [CAS]	137-40-6			
sodium salicylate		54-21-7			
Sodium Tetradecyl Sulfate		139-88-8			
sofalcone	Acetic acid, [5-[(3-methyl-2-butenoxy)oxy]-2-[3-[4-[(3-methyl-2-butenoxy)oxy]phenyl]-1-oxo-2-propenyl]bromo]y-[CAS]	64506-49-6	GB 1523241	Antiucler	
Solasulfone	Butanedioic acid compd with (1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolininecarboxylate (1:1) [CAS]	133-65-3			
solfenacin	D-Glucitol, hexa-3-pyridinecarboxylate [CAS]	242478-38-2			
Sorbinicate		6184-06-1	BE 883352	Hypolipaemic/Antiatherosclerosis	
Sorbitol		50-70-4			
Sorivudine		77181-69-2			
sotalol	Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]-[CAS] 930-20-9 959-24-0			Antiarrhythmic	
Soterenol		13642-52-9			
Sozoiodolic Acid	L-Glutamic acid, N-(N-acetyl-L-Alpha-aspartyl)- [CAS] 3706-85-2 80619-64-3	554-71-2		Formulation, mucosal, topical	Conjunctivitis
spaglumic acid					
sparfloxacin	3-Quinoliniccarboxylic acid, 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-1,4-difluoro-4-oxo-, cis- [CAS] 111071-86-8	EP 221463	Quinolone antibacterial	Infection, respiratory tract, general	
Sparteine		90-39-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SR-146131	1H-Indole-1-acetic acid, 2-[[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)-2-thiazolylamino]carbonyl]-5,7-dimethyl-[CAS]	221671-61-0	WO 9915525	Anorectic/Antiobesity	Obesity
SR-271425	N-[1-[2-(diethylamino)ethyl]amino]-7-methoxy-9-oxo-9H-thioxanthren-4-ylmethyl]formamide			Anticancer, alkylating	Cancer, general
SR-27897	1H-Indole-1-acetic acid, 2-[[4-(2-chlorophenyl)-2-thiazolylamino]carbonyl]-[CAS]	136381-85-6	EP 432040	Anticancer, other	Cancer, pancreatic
SR-31747	Cyclodexanamine, N-(3-(3-chloro-4-cyclohexylphenyl)-2-propenyl)-N-ethyl-, hydrochloride, (Z)- [CAS]	132173-07-0	EP 376850	Anticancer, other	Cancer, myeloma
SR-58611	Acetic acid, [(<i>T,S</i>)-7-[(2 <i>R</i>)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-5,6,7,8-tetrahydro-2-naphthalenyl]oxy]-ethyl ester, hydrochloride [CAS]	121524-09-2	EP 303546	GI inflammatory/bowel disorders	Irritable bowel syndrome
SS732	(R)-(-)-2-(4-difluorophenyl)-1-(ethylsulfonyl)-1,1-difluoro-3-(1H-1,2,4-triazol-1-yl)-2-propanol	US 5385900	Formulation, mucosal, topical	Infection, ocular	
SS-750	Propanamide, N,N'(diftiodi-2,1-ethanediylibis(3-amino)- [CAS]	US 6083968	Antifungal		Infection, fungal, general
β-alanine	(2 <i>S</i> ,4 <i>R</i>)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1 <i>H</i> -indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide	646-08-2		Anticancer, immunological	Cancer, myeloma
SSR-149415	2-(7-chloro-5-methyl-4-oxo-3-phenyl-4,5-dihydro-3 <i>H</i> -pyridazine)[4,5- <i>S</i>]indol-1-yl]-N,N-dimethylacetamide	WO 0155130	Antidepressant		Depression, general
SSR-180575					Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
SSR-181507	(3-Exo)-8-benzoyl-N-[[(2S)-7-chloro-2,3-dihydro-1,4-benzodioxin-2-yl]methyl]-8-azabicyclo[3.2.1]octane-3-methamine HCl		US 6221879	Neuroleptic	Schizophrenia
SSR-591813	(5aS,8S)-10aR)-5a,6,9,10-tetrahydro,7H,11H-8,10a-methanopyrido[2',3'-5,6]pyranof[2,3-d]azepine			Dependence treatment	Addiction, nicotine
SST-101	D-Glucitol, 1,4:3,6-dianhydro-dinitrate [CAS]	87-33-2		Formulation, transdermal, other	Angina, general
SSY-726	(-)-(R)-3-Methyl-3-(methylsulfonyl)-1-(1,2,4-triazol-1-yl)-2-[4-(trifluoromethyl)phenyl]-2-butanol		US 5147886	Antifungal	Infection, fungal, general
ST-200 stachyflin	1-Propanaminium, 2-(acetyl/oxy)-3-carboxy-N,N,N-trimethyl-, chloride, (R)- [CAS] 5080-50-2		DE 3015635 WO 9711947	Cognition enhancer Antiviral, other	Dementia, senile, general Infection, influenza virus
Stallimycin		636-47-5			
Stampidine			US 6350736	Antiviral, anti-HIV	Infection, HIV/AIDS
Stannous Pyrophosphate		15578-26-4			
Stannosopfin	(OC(=O)-13)-Dihydrogen dichloro[7,12-diethyl-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoato(4-)N21,N22,N23,N24]stannate(2-)		106344-20-1	Hepatoprotective	Hyperbilirubinaemia
Stanolone		521-18-6			
Stanozolol		10418-03-8 (2 <i>H</i> form); 302-96-5 (1 <i>H</i> form)			
Staph aureus ther STAT4 inhibitors			US 6376652 WO 9629341	Genomics-based drug discovery Immunosuppressant	Infection, MRSA Unspecified

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
stavudine	Thymidine, 2',3'-didehydro-3'-deoxy- [CAS] 3056-17-5	EP 501511	Antiviral, anti-HIV		Infection, HIV/AIDS
Stenbolone	Glycine, N-[1-oxo-2-[(2-thienylcarbonyl)thiopropyl]- [CAS]	5197-58-0			
stepronin	72324-18-6	US 4242354	Antitussive		
Stibocaptate	27279-76-1			Cough	
Stibophen	15489-16-4				
Stilbamidine	122-06-5				
stiripentol	1-Penten-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl- [CAS]	49763-96-4	Antiepileptic		Epilepsy, general
Streptodornase	37340-82-2				
Streptomycin	57-92-1				
Streptonicozid	5667-71-0				
Stretonigrin	3930-19-6				
Streptozocin	18883-66-4				
strontium ranelate	3-Thiopheneacetic acid, 5-[bis(carboxymethyl)amino]-2-carboxy-4-cyano- strontium salt (1:2)- [CAS]	135459-87-9	EP 415850	Osteoporosis treatment	Osteoporosis
strontium-89 chloride	Strontium chloride (89SrCl2) [CAS]	38270-90-5			Pain, cancer
Succimer	304-55-2				
Succinimide	123-56-8				
Succinylcholine	55-94-7				
Succinylcholine	71-27-2				
Succinylsulfathiazole	116-43-8				
Succisulfone	5934-14-5				
Suclofenide	30279-49-3				
	Aluminum, hexadeca- μ -hydroxytetacosahydroxy[μ 8-[1,3,4,6-tetra-O-sulfo- β -D-fructofuranosyl]-Alpha-D-glucopyranoside tetraakis(hydrosulfato)(8-)]hexadeca- [CAS]				
sucratofate	54182-58-0	JP 58208233	Antilulcer, Formulation, oral, other		Ulcer, general
sufentanil	Propanamide, N-[4-(methoxymethyl)-1-(2-thienylmethyl)-4-piperidinyl]-N-phenyl- [CAS]	56030-54-7	US 3898834	Analgesic, other, formulation implant	Pain, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sulbactam	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-, 4,4-dioxide, (2S-cis)- [CAS]	68873-14-8	GB 2000138	Antibiotic, other	Infection, general
sulbactam + ampicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[phenylsulfonyl]amino-, [2S-[2Alpha,5Alpha,6(S*)]- [CAS]	117060-71-6	US 4234579	Antibiotic, other	Infection, general
sulbenicillin					
Sulbentine	Propanoic acid, 2-methyl-, dithiobis[3-[1-[(4-amino-2-methyl-5-pyrimidinyl)methyl]formylamino]ethylidene]-3,1-propanediyl ester [CAS]	28002-18-8 47744-40-5	GB 1289358	Penicillin, injectable	Infection, pseudomonal
		350-12-9			
subbutamine					
sulconazole	1H-Imidazole, 1-[2-[(4-chlorophenyl)methyl][thio]-2-(2,4-dichlorophenyl)ethyl], (+/-)- [CAS]	61-318-90-9 61-318-91-0	US 4055652	Antifungal	Unspecified
Sulesomab		167747-19-5			
Sulfabenzamide		127-71-9			
Sulfacetamide		144-80-9			
Sulfachloropyridazine		80-32-0			
Sulfachrysoidine		485-41-6			
Sulfacytine		177784-12-2			
Sulfadiazine		68-35-9			
Sulfadicramide		115-68-4			
Sulfadimethoxine		122-11-2			
Sulfadoxine		2447-57-6			
Sulfaethidole		94-19-9			
Sulfaguanidine		57-67-0			
Sulfaguanolate		27031-08-9			
Sulfalene		152-47-6			
Sulfaloxic Acid		14376-16-0			
Sulfamerazine		127-79-7			
Sulfamereter		651-06-9			
Sulfamethazazine		57-68-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sulfamethizole		144-82-1			
Sulfamethomidine		3772-76-7			
Sulfamethoxazole		723-46-6			
Sulfamethoxypyridazine		80-35-3			
Sulfametrole		32909-92-5			
Sulfamidochrysoidine		103-12-8			
Sulfamoxole		729-99-7			
Sulfanilamide		63-74-1			
Sulfanilic Acid		121-57-3			
Sulfanilylurea		547-44-4			
Sulfaperine		599-88-2			
Sulfaphenazole		526-08-9			
Sulfaproxiline		116-42-7			
Sulfapyrazine		116-44-9			
Sulfapyridine		144-83-2			
Sulfarside		1134-98-1			
Sulfarsphenamine		618-82-6			
Sulfasalazine	Benzoic acid, 2-hydroxy-5-[(4-[2-pyridylamino]sulfonyl)phenyl]azol]-[CAS] 599-79-1			Formulation, oral, enteric-coated	Arthritis, rheumatoid
Sulfasomizole		632-00-8			
Sulfasyazine		1984-94-7			
Sulfathiazole		72-14-0			
Sulfathiourea		515-49-1			
Sulfinalol		66264-77-5			
Sulfapyrazone		57-96-5			
Sulfiram		95-05-6			
Sulfisomidine		515-64-0			
Sulfisoxazole		127-69-5			
Sulfobromophthalein		71-67-0			
Sulfonethylmethane		76-20-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Sulfoniiazide		3691-81-4			
Sulfonmethane		115-24-2			
Sulfurdazine		14759-06-9			
Sulfoxone		144-75-2			
sulindac	cis-5-fluoro-2-methyl-1-[{p-methylsulfonyl}benzylidene]indene-3-acetic acid	38194-50-2	US 3725548	Anti-inflammatory	Inflammation, general
Suisatin		54935-03-4			
Sulisobenzzone		4065-45-6			
Sulmarin		29334-07-4			
Sulmazole		73384-60-8			
Suloctidil		54063-56-8			
Sulphan Blue		129-17-9			
suipride	Benzamide, 5-(aminosulfonyl)-N-[1-ethyl-2-pyromidinyl)methyl]-2-methoxy-[CAS] 15676-16-1			Alimentary/Metabolic, other	
suprostone	5-Heptenamide, 7-[3-hydroxy-2-(3-hydroxy-4-phenoxy-1-butene)-5-oxocyclopentyl]-N-(methylsulfonyl)- [IR-[Alpha]a(Z),2B[1E,3R*],3A[Alpha]]- [CAS] 60325-46-4		US 4024179	Prostaglandin	Abortion
sultamicillin	4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 6-((aminophenylacetyl)amino)-3,3-dimethyl-7-oxo-, (((3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-yl)carbonyloxy)methyl ester, S, S-dioxide, (2S)-(2.R*,5S*),5, alpha.,6.beta.(S*))-[CAS] 117060-71-6 76497-13-7				Infection, general
Sulthiame		61-56-3	GB 2044255	Penicillin, oral	
Sultopride	Benzamide, N-[(1-ethyl-2-pyrididinyl)methyl]-5-(ethylsulfonyl)-2-methoxy-[CAS]	53583-79-2	FR M5916	Neuroleptic	Psychosis, general
Sultosilic Acid		57775-26-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
sumanitrole	4H-Imidazo[4,5-1]quinolin-2(1H)-one, 5,6-dihydro-5-(methylamino)-, (5R)-, (2Z)-2-butenedioate (1:1) [CAS]	179386-44-8	WO 9514020	Antiparkinsonian	Parkinsons disease
sumatriptan	1H-[Indole-5-methanesulfonamido, 3-[2-(dimethylamino)ethyl]-N-methyl-1-butenedioate (1:1)- [CAS]	103628-46-2 103628-48-4	EP 147107	Antimigraine	Migraine
SUN-N8075	1-(4-amino-2,3,5-trimethylphenoxo)-3-{4-[4-(4-fluorobenzyl)phenyl]piperazin-1-yl}propan-2(s)-ol dimethanesulfonate			Neuroprotective	Infarction, cerebral
suplatast	Sulfonium, 13-[4-(3-ethoxy-2-hydroxypropoxy)phenylamino]-3-oxopropylidemethyl-, [CAS]	94055-76-2	JP 59167564	Antiasthma	Asthma
Suprofen		40828-46-4			
Suramin		129-46-4			
surfactant TA	Beractant [CAS]	108778-82-1	WO 9117766	Lung Surfactant	Respiratory distress syndrome, general
Suriclonine		533813-83-5			
Suxibuzone		27470-51-5			
SYM-1010	L-Glutamic acid, 4-methyl-, (4R)- [CAS]	31137-74-3	US 5830988	Antiepileptic	Epilepsy, general
SYM-2081	4-(Aminophenyl)-1-methyl-6,7-(methylenedioxy)-N-butyl-1,2-dihydropthalazine-2-carboxamide			Analgesic, other	Pain, general
SYM-2207				Neuroprotective	Ischaemia, cerebral
Symclosene		87-90-1			
Syn-1253	1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(4-methyl-1,2,3-triazol-1-yl)pyrrolidin-1-yl]-4-oxo-1,4-dihydroquinoline 3-carboxylic acid			Quinolone antibacterial	Infection, peritoneum
Syn-2190	1-Azetidinesulfonic acid, 3-[(2E)-[(1,4-dihydro-1,5-dihydroxy-4-oxo-2-thienylacetyl)methoxyimino]-2-(2S,3S)- [CAS]	214963-75-4	WO 9847895	Antibacterial, other	Infection, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Syn-2869	3H-1,2,4-Triazol-3-one, 4-(4-((1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-1-piperazineyl)phenyl)-2,4-dihydro-2((4-(trifluoromethoxy)phenyl)methyl)- [CAS]	210562-98-4	US 6153616	Antifungal	Infection, Aspergillus
Synephrine		94-07-5			
Syrosingopine		84-36-6			
T-1095	1-Propanone, 3-[5-(benzofuran)-1-(2-hydroxy-6-((6-O-methoxycarbonyl)-3-D-glucopyranosyl)oxy)-4-methylphenyl]- [CAS]	209746-59-8	EP 850948	Antidiabetic	Diabetes, general
T-1249	L-Phenylalaninamide, N-acetyl-L-tryptophyl-L-glutaminyl-L-Alpha-glutamy-L-tryptophyl-L-Alpha-glutamy-L-glutaminyl-L-leucyl-L-isoleucyl-L-threonyl-L-alanyl-L-glutamyl-L-alanyl-L-leucyl-L-glutaminyl-L-leucyl-L-Alpha-glutamyl-L-isoleucyl-L-glutamyl-L-lysyl-L-Alpha-glutamyl-L-Alpha-glutamyl-L-lysyl-L-Alpha-glutamyl-L-asparagineyl-L-tyrosyl-L-Alpha-glutamyl-L-leucyl-L-glutamyl-L-lysyl-L-leucyl-L-Alpha-glutamyl-L-aspartyl-L-lysyl-L-trytophy-L-ananyl-L-seryl-L-leucyl-L-trytophy-L-Alpha-glutamyl-L-tryptophyl- [CAS]	251562-00-2	WO 9959615	Antiviral, anti-HIV	Infection, HIV/AIDS
T-3912	1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid			Quinolone antibacterial	Infection, dermatological
T-588	Benz[b]thiophene-5-methanol, Alpha-((2-(diethylamino)ethoxy)methyl)-, hydrochloride, (R)- [CAS]	142935-03-3	EP 565965	Cognition enhancer	Alzheimer's disease
T-67	Benzenesulfonamide, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)- [CAS]	195533-53-0		Anticancer, other	Cancer, liver
T-82			US 57190951	Cognition enhancer	Alzheimer's disease

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
TA-2005	2-(1 <i>H</i>)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R*,R*)]- [CAS] 137888-11-0	US 4579854			Asthma
TA-2005	2-(1 <i>H</i>)-Quinolinone, 8-hydroxy-5-[1-hydroxy-2-[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-, monohydrochloride, [R-(R*,R*)]- [CAS]	WO 189480		Formulation, inhalable, solution	Asthma
TA-993	1,5-Benzothiazepin-4(5 <i>H</i>)-one, 3-(acetoxymethyl)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-8-methyl-7-(4-methylphenyl)-(2 <i>R</i> ,3 <i>R</i>)-rel-(<i>r</i>), (2 <i>Z</i>)-2-butenedioate [CAS] 122024-98-0	JP 01045376		Antithrombotic	Peripheral vascular disease
tabimorelin	(R)-Alpha-[(E)-5-Amino-N,5-dimethyl-2-hexamidoj-N-methyl-N-[<i>t</i> (<i>R</i>)-Alpha-(methylcarbamoyl)phenethyl]-2-naphthalenespropionamide	170851-70-4 193079-69-5		Releasing hormones	Growth hormone deficiency
tacalcitol	9,10-Secocolesterol-5,7,10(19)-triene-1,3,24-triol, (1 <i>Alpha</i> ,3 <i>B</i> ,5 <i>Z</i> ,7 <i>E</i> ,24 <i>R</i>)- [CAS] 53129-94-3	EP 129003		Antipsoriasis	Keratosis
tacedinaline	Benzamide, 4-(acetamido)-N-(2-aminophenyl)- [CAS]	112522-64-2	DE 3613571	Anticancer, other	Cancer, pancreatic
tacrine	9-Acridinamine, 1,2,3,4-tetrahydro- [CAS] 1684-40-8	EP 332147		Cognition enhancer	Alzheimer's disease
Tadalafil	Pyrazino[1'2':1,6]pyrido[3,4-b]indole-1,4-dione, 6-[1,3-benzodioxol-5-yl]-2,3,6,7,12,12a-hexahydro-2-methyl-, (6 <i>R</i> -trans) [CAS]	US 6143746		Male sexual dysfunction	Impotence
tafenquine	1,4-Pantanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]- [CAS]	171596-29-5			Infection, malaria
tatuposide	(S)-N-[2-(1,6,7,8-Tetrahydro-2 <i>H</i> -inden-5,4-bfuran-8-yl)]propionamide	US 80065-55-0 WO 179067-42-6	US 4617394 WO 9612727	Anticancer, other	Cancer, general
TAK-375				Hypnotic/Sedative	Insomnia

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
TAK-427	2-[6-[3-(Diphenylmethoxy)-piperidino]imridazo[1,2-b]pyridazin-2-yl]-2-methylpropionic acid dihydrate			Antipruritic/fiflamm, allergic	Eczema, atopic
TAK-559	(E)-4-[4-[5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzoylimino]-4-phenylbutyric acid			Antidiabetic	Diabetes, general
Taka-Diastase		9001-19-8			
Talamppanel	7H-1,3-Dioxolo[4,5-h][2,3]benzodiazepine,7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-(8R)-[CAS]	161832-65-1	US 5639751	Antiepileptic	Epilepsy, general
Talampicillin		47747-56-8			
talaporfin	N-[(2S,3S)-18-Carboxy-2-(2-carboxyethyl)-13-ethyl-2,3-dihydro-3,7,12,17-tetrahydronaphthalene-18-vinyl porphyrin-20-yl]acetyl-L-aspartic acid			Radio/chemosensitizer	Cancer, lung; general
Talastine		220201-34-3			
Talbutal		16188-61-7			
Talinolol		115-44-6			
		57460-41-0			
talipexole	4H-Thiazolo[4,5-d]azepin-2-amine, 5,6,7,8-tetrahydro-6-(2-propenyl)-[CAS]	101626-70-4 36085-73-1	DE 3503963	Antiparkinsonian	Schizophrenia
talnetant	4-Quinolinecarboxamide, 3-hydroxy-2-phenyl-N-[(1S)-1-phenylpropyl]-[CAS]	174636-32-9	WO 9532948	GI inflammatory/bowel disorders	Irritable bowel syndrome
talniflumate	3-Pyridinecarboxylic acid, 2-[3-(trifluoromethyl)phenyl]aminol, 1,3-dihydro-3-oxo-1-isobenzofuryl ester [CAS]	66898-62-2	BE 858864	Anti-inflammatory	Inflammation, ocular
tatirelin	L-Prolinamide, N-[(hexahydro-1-methyl-2,6-dioxa-4-pyrimidinyl)carbonyl]-L-histidyl-(S)--[CAS]	103300-74-9	JP 61033197	Neurological	Dyskinesia, general
tamoxifen	Ethanamine, 2-[4-(12-diphenyl-1-butene)-1-phenoxy]-N,N-dimethyl-, (Z)-[CAS]	10540-29-1	US 4536516	Anticancer, hormonal	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tamsulosin	Benzeneulfonamide, 5-[2-[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxy-, (R)- [CAS]	106133-20-4 802223-99-0	EP 34432	Prostate disorders	Benign prostatic hyperplasia
tandospirone	4,7-Methano-1H-isindole-1,3(2H)-dione, hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-, (3aAlpha,4B,7B,7aAlpha)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) [CAS]	112457-95-1 87760-53-0	EP 82402	Anxiolytic	Anxiety, general
Tannoform		9010-29-1			
Taprostene		108945-35-3			
Iariquidar	3-Quinolinecarboxamide, N-[2-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl]phenyl]amino]-4,5-dimethoxyphenyl]- [CAS]	206873-63-4	WO 9817648	Radio/chemosensitizer	Cancer, lung, non-small cell
TAS-103	6-[2-(Dimethyl-amino)ethyl]amino]-3-hydroxy-7H-indeno[2,1-g]quinolin-7-one dihydrochloride	174634-09-4	WO 9532187	Anticancer, other	Cancer, lung, non-small cell
Tasosartan		145733-36-4			
Taurocholic Acid		81-24-3			
Taurolidine		19388-87-5			
tazanolast	Acetic acid, oxo[[3-(1H-tetrazol-5-yl)phenyl]amino]-, butyl ester [CAS]	82988-25-1	US 4778816	Antisthma	
tazarotene	3-Pyridinecarboxylic acid, 6-[3,4-dihydro-4,4-dimethyl-2H-1-benzothiopyran-6-yl]ethynyl]-, ethyl ester [CAS]	118292-40-3	EP 284288	Antipsoriasis	Psoriasis
Tazobactam		89786-04-9			
tazobactam + piperacillin			JP 58225091	Antibiotic, other	Infection, general
TBC-37/1		374680-51-0		Cardiovascular	Heart failure
TCH-346	N-Methyl-N-propargyl-[O-aminomethyl-dibenzo[b,h]oxepin			Neuroprotective	Amyotrophic lateral sclerosis
tebipenem	5-Hexenoic acid, 4-hydroxy-, polymer with 4-ethyl-1H-imidazole [CAS]	82200-24-6		Beta-lactam antibiotic	Infection, streptococcal

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
teadenoson	Adenosine, N-[3(R)-tetrahydro-3-furyl]-[CAS]	204512-90-3	WO 9808855	Antiarrhythmic	Tachycardia, supraventricular
tecastemizole	1H-Benzimidazol-2-amine, 1-(4-fluorophenyl)methyl)-N-4-piperidinyl-[CAS]	75970-99-9	US 4219559	Antiallergic, non-asthma	Rhinitis, allergic, seasonal
Technetium 99mTc Bicisate		121281-41-2			
Technetium 99mTc Wertiatide		125224-05-7; 104348-91-6			
Technetium 99mTc Sestamibi		109581-73-9			
Technetium 99mTc Teboroxime		104716-22-5			
Teclothiazide		4267-5-4			
Tectozan	Spirocyclopentane-1,9-[3,7]diazabicyclo[3.3.1]octane], 3',7'-bis(cyclopropylmethyl)- [CAS]	5560-78-1			
tedisamil		90961-53-8	EP 102833	Antiarrhythmic	Fibrillation, atrial
Teflurane		124-72-1			
tegafur	2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)- [CAS]	177902-23-7	GB 1168391	Anticancer, antimetabolite	Cancer, general
(tegafur + uracil)	2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, mixt. with 2,4(1H,3H)-pyrimidinedione- [CAS]	74578-38-4	EP 224885	Anticancer, antimetabolite	Cancer, breast
tegaserod	Hydrazinecarboximidamide, 2-((5-methoxy-1H-indol-3-yl)methylene)-N-pentyl-, (Z)-2-butenedioate [CAS]	189188-57-6 145158-71-0		GI inflammatory/bowel disorders	Irritable bowel syndrome
Teicoplanin	β -L-2'-deoxythymidine	61036-64-4			
telbivudine		3424-98-4		Antiviral, other	Infection, hepatitis-B virus
Telenzepine		80880-90-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
telithromycin	3-De((2,6-dideoxy-3-C-methyl-3-O-methyl-Alpha-L-ribo-hexopyranosyl)oxy)-11,12-dideoxy-6-O-methyl-3-oxo-12,11-(oxycarbonyl)((4-(3-pyridinyl)-1H-imidazol-1-yl)butyl)imino)-[CAS] 3,4-Thiazolidinedi-carboxylic acid, 3-ethyl ester, (R)- [CAS]	191114-48-4	EP 680967	Macrolide antibiotic	Infection, respiratory tract, general
telmesteine	(1,1'-Biphenyl)-2-carboxylic acid, 4-((1,4-dimethyl-2-propyl(2,6-bi-1H-benzimidazol)-1'-yl)methyl)- [CAS]	122946-43-4		COPD treatment	Bronchitis, chronic
telmisartan		144701-48-4	EP 502314	Antihypertensive, renin system	Hypertension, general
telomerase inhibitor			WO 9941261	Anticancer, other	Cancer, general
temazepam	7-chloro-1,3-dihydro-3-hydroxy-1-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one	846-50-4	US 3197467	Hypnotic/Sedative	Insomnia
temeverine	Benzeneacetic acid, Alpha-cyclohexyl-Alpha-hydroxy-, 4(diethylamino)-1,1-dimethyl-2-butynyl ester, [CAS]	129927-33-9	GB 2222828	Urological	Pollakisuria
temocapril	1,4-Thiazepine-4(5H)-acetic acid, 6-[(ethoxycarbonyl)-3-phenylpropyl]amino[tetrahydro-5-oxo-2-(2-thienyl)-, [2S-[2A]alpha,6S(R')]- [CAS]	102090-90-4 110221-44-8 111902-57-9	US 4495188	Antihypertensive, renin system	Hypertension, general
Temocillin		66148-78-5			
temporofin	Phenol, 3,3',3'',3'''-(2,3-dihydro-2H,23H-porphine-5,10,15,20-tetrayl)tetrakis-[CAS] 1122341-38-2		EP 337601	Radio/chemosensitizer	Cancer, head and neck
temozolamide	[Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-[CAS]	85622-93-1	DE 3231255	Anticancer, alkylating	Cancer, brain, general
tenatoprazole	1H-Imidazo[4,5-b]pyridine, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfonyl)-[CAS]	113712-98-4	US 4808596	Antitulcer	Ulcer, gastric
Teneptepiase		191588-94-0			
Tenidap		120210-48-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
teniposide	Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5H)-one, 5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienyl)methylene]-β-D-glucopyranosyl]oxy]-[5R-[5Alpha,5aβ,8aAlpha,9S-(R*)]-[CAS] 29767-20-2	US 3524844		Anticancer, other	Cancer, lymphoma, non-Hodgkin's
tenofovir	Phosphonic acid, (((1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy)methyl)-[CAS] 2,4,6,8-tetraoxa-5-phosphonananedioic acid, 5-(2-(6-amino-9H-purin-9-yl)-1-methylmethoxymethyl) bis(1-methyllethyl)ester, 5-oxide (R)-, (E)-2-butenedioate tenofovir disoproxil	147127-20-6		Antiviral, anti-HIV	Infection, HIV/AIDS
Tenonitroxole	2H-Trieno[2,3-e]-1,2-thiazine-3-carboxamide, 4-hydroxy-2-methyl-N-2-pyridiny-, 1,1-dioxide [CAS] 59804-37-4	GB 1519811		Antiviral, anti-HIV	Infection, HIV/AIDS
tenoxicam		3810-35-3			
Tenuazonic Acid	5,9,13,17-Nonaδecaen-2-one, 6,10,14,18-tetramethyl-[CAS] 610-88-8				
tepranone	Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]-[CAS] 3796-63-2	6809-52-5		Antifilarcer	
terazosin	Piperazine, 1-(4-amino-6,7-dimethoxy-2-furanyl)carbonyl-[CAS] 63074-08-8	70024-40-7			
terbinafine	1-Naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-, (E)-[CAS] 63590-64-7	US 4112097		Antihypertensive, adrenergic	Hypertension, general
terbutaline	1,3-Benzenediol, 5-[2-((1,1-dimethylethyl)amino)-1-hydroxyethyl]-[CAS] 78628-80-5	EP 91161-71-6	24587	Antifungal	Infection, dermatological
terconazole	Piperazine, 1-[4-[[2-(2,4-dichlorophenyl)-2-(1H-2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy]phenyl]-4-(1-methyllethyl)-, cis-[CAS] 23031-25-6	US 67915-31-5		Formulation, mucosal, topical	Dysmenorrhoea
		US 4358449		Antifungal	Vaginitis

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
terfenadine	1-Piperidinebutanol, Alpha-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethoxy)- [CAS]	50679-08-8	US 3878217	Antiallergic, non-asthma	
terguride	Urea, N,N-diethyl-N-[8(Alpha)-6-methylergolin-8-yl]- [CAS]	37686-84-3	EP 159522	Antiprostaglandin	Hyperprolactinaemia
Terlipressin		14636-12-5			
Terodilime		15793-40-5			
Terofenamate		29098-15-5			
Terpin		80-53-5			
tertolol	2-Propanol, 1-[(3,4-dihydro-2H-1-benzodioxepan-8-yl)oxy]-3-[(1,1-dimethylethyl)amino], hydrochloride, (+)- [CAS]	33580-30-2 83688-84-0 34784-64-0	GB 1308191	Antihypertensive, adrenergic	Hypertension, general
tert-Pentyl Alcohol		75-85-4			
tesaglitazar	(2S)-2-ethoxy-3-[4-[2-[4-[(methylsulfonyloxy)phenoxy]ethoxy]phenyl]propanoic acid			Antidiabetic	Diabetes, Type II
tesmifene	Ethanamine, N,N-Diethyl-2-(4-(phenyl)methoxy)phenoxy)- [CAS]	S2981-78-7 968-93-4		Radio/chemosensitizer	Cancer, breast
Testolactone					
Testosterone	androst-4-en-3-one, 17-hydroxy-, (17 β) - [CAS]	58-22-0 5949-44-0		Formulation, transdermal, systemic	Hormone replacement therapy
terbamate		80763-47-5	DE 2748794	Anxiolytic	Addiction, alcohol
Tetrabarbital		76-23-3			
Tetrabenazine		58-46-8			
Tetracaine		136-47-0			
Tetrachloroethylene		127-18-4			
tetracine	Benzocic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester [CAS]	94-24-6		Formulation, transdermal, systemic	Pain, general
tetracycline	2-Naphthacencarboxamide, 4-(dimethylamino)-, 1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo- [4S-(4Alpha,4aAlpha,5aAlpha,6S,12aAlpha)]- [CAS]				Infection, oral
		60-54-8		Formulation, oral, other	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tetrahydrozoline		84-22-0			
Tetrandrine		518-34-3			
Tetrantoin		52094-70-9			
Tetrazepam		10379-14-3			
Tetrofosmin		127502-06-1			
tetroxoprim	2,4-Pyrimidinediamine, 5-[{3,5-dimethoxy-4-(2-methoxyethoxy)phenyl]methyl]-[CAS]	53808-87-0 74515-38-1	US 3992379	Trimethoprim and analogues	Infection, general
Tevenel®	Cytidine, 2'-deoxy-2'-(fluoromethylene)-, (2E)- [CAS]	4302-95-8			
tezacitabine		130306-02-4	US 5616702	Anticancer, antimetabolite	Cancer, colorectal
tezosentan	2-Pyridinesulfonamide, N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(2-(1H-tetrazol-5-yl)-4-pyridinyl)-4-pyrimidinyl)-5-(1-methylethyl)- [CAS]	180384-57-0		Cardiostimulant	Oedema, general
thalidomide	1H-Spiro[ole-1,3][2H]-dione, 2-(2,6-dioxo-3-piperidinyl)- [CAS]	50-35-1		Dermatological	Infection, dermatological
Thenaldine		86-12-4			
Thenyldiamine		91-79-2			
Theobromine		83-67-0			
Theofibrate		54-504-70-0			
theophylline	1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl- [CAS]	58-55-9 5957-84-0		Formulation, modified-release, other	Asthma
Thiabendazole		148-79-8			
Thiacetazone		104-06-3			
thiacylmserine	Carbamic acid, [4-(1-methylethyl)phenyl]-, (3aS,8aS)-3,3a,8,8a-tetrahydro-3a,8-dimethyl-2H-thieno[2,3-b]indol-5-yl ester [CAS]	145209-51-4		Cognition enhancer	Alzheimer's disease
Thiobarbital		467-36-7			
Thiamine		59-43-8			
Thiamine		154-87-0			
Thiamine		67-16-3			
Thiamiprime		5581-52-2			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Thiamphenicol		15318-45-3			
Thiamylal		77-27-0			
Thiazesim		5845-26-1			
Thiazinamium		58-34-4			
Thiazoliributazone		54749-86-9			
Thiazolsulfone		473-30-3			
Thibenzazoline		6028-35-9			
Thiethylperazine		1420-55-9			
Thimerfonate		5964-24-9			
Thimerosal		54-64-8			
Thiobarbital		77-32-7			
Thiobutabarbital		2095-57-0			
Thiocarbamizine		91-71-4			
Thiocarbarsone		120-02-5			
Thiocolchicine		2730-71-4			
Thiocresol		26445-03-4			
Thioctic Acid		62-46-4			
Thioglycerol		96-27-5			
Thioguanine	L-Tryptophanyl-glycyl-glycine	154-42-7			
Thiomectreg					
Thiopental		71-73-8			
Thiopropazate		84-06-0			
Thioproperazine		316-81-4			
Thioridazine		50-52-2			
Thiothixene		5591-45-7			
Thiovir	Thiophosphonoformic acid				
Thiphenamil		82-99-5			
Thiram		137-26-8			
Thionyzamine		63-56-9			
Thozalinone		655-05-0			
Thromboplastin		9035-58-9			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Thurly Nicotinate		70-19-9	US 6245750	Anticancer, other	Cancer, colorectal
Thymectacin		39-83-8			
Thymol		695568-55-0			
Thymopentin		578-20-1			
Thymyl N-Isobutylcarbamate					
Thyropropic Acid		51-26-3			
Throxine		51-48-9			
Tiadenol		6964-20-1			
Iagabine	3-Piperidinecarboxylic acid, 1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-, (R)- [CAS]	115103-54-3	WO 8700171	Antiepileptic	Epilepsy, general
Tiamenidine		31428-61-2			
Tianeptine	Heptanoic acid, 7-[3-chloro-6,11-dihydro-6-methylbenzo[c,f][1,2]thiazepin-11(y)amino], S, S-dioxide [CAS]	72797-41-2 66981-73-5	GB 1269551	Antidepressant	Depression, general
Tiapride	Benzamide, N-[2-(diethylamino)ethyl]-2-methoxy-5-(methylsulfonyl)- [CAS]	51012-32-9	GB 1394563	Neuroleptic	
Thaprofenic acid	2-Thiopheneacetic acid, 5-benzoyl[Alpha-methyl- [CAS]	33005-95-7	GB 1331505	Antiarthritic, other	
Tiaramide		32527-55-2			
Tazofurin	4-Thiazolecarboxamide, 2-β-D-ribofuranosyl- [CAS]	60084-10-8	EP 54432	Anticancer, antimetabolite	Cancer, leukaemia, chronic myelogenous
Tibezonium		54663-47-7			
Tibolone	19-Norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-7-methyl-, (7Alpha,17Alpha)- [CAS]	5630-53-5	EP 389035	Menopausal disorders	Hormone replacement therapy
Ticarcillin		34787-01-4			
Ticlopidine	Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-[CAS]	53885-35-1 56142-85-3	GB 1554424	Antithrombotic	
Ticrynafen	4-(3-hydroxy-3-phenyl-3-thien-2-yl-propyl)-4-methylmorpholinium	40180-04-9 6252-32-2 74-12-7			Antispasmodic
tiemonium					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tigecycline	2-Naphthacencarboxamide, 4,7-bis(dimethylamino)-9-[[[(1,1-dimethylethyl)aminooacyl]amino]-1,4,4a,5,5a,6,11,11a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-(4S,4aS,5aR,12aS)- [CAS]	220620-09-7	EP 582829	Tetracycline	Infection, general
Tigemonam		102507-71-1			
Tigloidine		495-83-0			
Tildine		20380-58-9			
Tilisolol		85136-71-6			
tilmoxib	Benzeneulfonamide, 4-[4-cyclohexyl-2-methyl-5-oxazolyl]-2-fluoro- [CAS]	180200-68-4	WO 9619463	Alimentary/Metabolic, other	Polyp
tituronic acid	Phosphonic acid, [[(4-chlorophenyl)thiol]methylene]bis- [CAS]	89987-06-4	EP 100718	Osteoporosis treatment	Paget's disease
Timenitin		86482-18-0		Antibiotic, other	Infection, general
timepidium	Piperidinium, 3-[di-2-thienylmethylenyl]-5-methoxy-1,1-dimethyl-, [CAS]	35035-05-3	GB 1358446	Antispasmodic	
Timiperone		57648-21-2			
timolol	(-)-1-(t-butylamino)-3-[[(4-morpholin-1,2,5-thiadiazol-3-yl)oxy]-2-propanoimaleate (1:1) salt	26839-75-8 26921-17-5	GB 1253709	Antihypertensive, adrenergic, antiglaucoma	
Timonacin		444-27-9			
Tin Ethyl EtioPURpurin		113471-15-1			
tinazoline	1H-Imidazole, 3-[(4,5-dihydro-1H-imidazol-2-yl)thio]- [CAS]	62882-99-9	US 3376311	Vasodilator, peripheral	
Tinidazole		19387-91-8			
Tinoridine		24237-54-5			
Tiocarlide		910-86-1			
Tioclomarol		22619-35-8			
tiocnazole	1H-Imidazole, 1-[2-[2-chloro-3-thienyl]methoxy]-2-[2,4-dichlorophenyl]ethyl]- [CAS]	61675-64-7 65899-73-2	US 4062966	Antifungal	Infection, fungal, general
tiopronin	Glycine, N-(2-mercapto-1-oxopropyl)- [CAS]	1953-02-2	US 3246025	Urological	Homocystinuria

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tiotropium	3-Oxa-9-azoniatriacyclo[3.3.1.0 _{2,4}]nonane, 7-((hydroxydi(2-thienyl)acetyl)oxy)-9,9-dimethyl-, [CAS]	136310-93-5	EP 418716	COPD treatment	Chronic obstructive pulmonary disease
Tioxolone		4991-65-5			
Tipepidine		5169-78-8			
tipifarnib	2(1H)-Quinolone, 6-(amino(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl)-4-(3-chlorophenyl)-1-methyl [CAS]	192185-68-5 192185-72-1	WO 9716443	Anticancer, other	Cancer, breast
tipranavir	N-[3-1(R)-[4-Hydroxy-2-oxo-6(R)-[2-phenyl(ethyl)]-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide	174484-41-4		Antiviral, anti-HIV	Infection, HIV/AIDS
tiquizium	2H-Quinolizinium, 3-(di(2-thienylmethylene))octahydro-5-methyl-, [CAS]	71731-58-3	US 4205074	Antispasmodic	
trapazamine	1,2,4-Benzotriazin-3-amine, 1,4-dioxide- [CAS]	27314-97-2 5424-06-6	DE 2204574	Radio/chemosensitizer	Cancer, lung, non-small cell
Tiratricol		51-24-1			
trilazad	Pregna-1,4,9(11)-triene-3,20-dione, 21-[4-(2,6-di- <i>p</i> -pyridinyl)-4-pyrimidinyl]-1-piperazinyl]-16-methyl-, (16Alpha)-, [CAS]	110101-65-0 110101-67-2	WO 8701706	Neuroprotective	Haemorrhage, subarachnoid
tirofiban	L-Tyrosine, N-[butylsulfonyl]-O-[4-(4-piperidinyl)butyl]-, [CAS]	142373-50-2 144494-65-5	EP 478363	Antithrombotic	Infarction, myocardial
tiotropamide	Benzepropanamide, Alpha-(benzoylamino)-4-[2-(diethylamino)ethoxy]-N,N-dipropryl-, (+)-, [CAS]	55837-29-1	DE 2503992	Antispasmodic	Muscle spasm, general
Titanium Sulfate	Pregn-4-ene-3,20-dione, 21-[2-(2-dimethyl-1-oxopropyl)thio]-11,17-dihydroxy-, (11B)- [CAS]	13825-74-6			
titocortol		61951-99-3	GB 1475795	Antiallergic, non-asthma, mucosal, topical	Rhinitis, allergic, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tizanidine	2,1,3-Benzothiadiazol-4-amine, 5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-[CAS]	51322-75-9	GB 1429926	Muscle relaxant	Spastic paraparesis
TLK-199	Glycine, L-Gamma-glutamyl-S-(phenylmethyl)-L-cysteiny1-2-phenyl-, diethyl ester, (2R)- [CAS]	168682-53-9	US 5679643	Immunostimulant, other	Myelodysplastic syndrome
TLK-286	Glycine, L-Gamma-glutamyl-3-[2-((bis(bis(2-chloroethyl)aminophosphoryl)oxy)ethyl)sulfonyl]L-alanyl-2-phenyl-, (2R)- [CAS]	158382-37-7	US 5545621	Anticancer, other	Cancer, ovarian
TNF- β analogue			RU 2035185	Anticancer, immunological	Cancer, general
TNP-470	Pregna-1,4-diene-3,20-dione, 9-fluoro-11 β ,17,21-trihydroxy-16,beta.-methyl-, 17-butylate 21'-propionate [CAS]	129298-91-5			
TO-186	O-3-amino-3-deoxy-Alpha-D-glucopyranosyl-(1 β)-O-(2,6-di-amino-2,3,6-trideoxy-Alpha-D-ribo-hexopyranosyl-(1 β)-2-deoxy- [CAS]	5534-02-1		Antipruritic/inflamm, allergic	
tocramycin	Propanamide, 2-amino-N-[2,6-dimethylphenyl]- [CAS]	32986-56-4		Formulation, inhalable, topical	Infection, respiratory tract, general
tocainide		41708-72-9	US 4218477	Antiarrhythmic	Fibrillation, ventricular
Tocamphyl		5634-42-4			
toladesine	8-Chloroadenosine 3'5'-cyclic phosphate	41941-56-4		Anticancer, other	Cancer, colorectal
Tocoretinate		40516-48-1			
Todralazine		14679-73-3			
Tofenacin		15301-93-6			
tofamilast	5H-Pyrazolo[3,4-c]-1,2,4-triazolo[4,3-a]pyridine, 9-cyclopentyl-7-ethyl-6,9-dihydro-3-(2-thienyl)-	185954-27-2		Antiasthma	Asthma
tofisopam	5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-[CAS]	22345-47-7	GB 1334271	Anxiolytic	Anxiety, general
Tolazamide		1156-19-0			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tolazoline		59-98-3			
Tolbutamide		64-77-7			
tolcapone	Methanone, (3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)- [CAS]	134308-13-7	EP 237929	Antiparkinsonian	Parkinson's disease
tolociclate	Carbamothioic acid, methyl(3-methylphenyl)- O-(1,2,3,4-tetrahydro-1,4-methanoneaphthalen-6-yl) ester [CAS]	50838-36-3	GB 1364407	Antifungal	Infection, dermatological
Tolcyclamide	Benzenesulfonic acid, 4-ethenyl-, homopolymer,	664-95-9			
tolevamer	Benzoic acid, 2-[3-chloro-2-(methylphenyl)amino]- [CAS]	28038-50-8		Antibacterial, other	Infection, Clostridium, general
tofenamic acid		13710-19-5	DE 1543295	Anti-inflammatory	Inflammation, general
Tolindate		27877-51-6			
Toliprolol		2933-94-0			
Toimetin		26171-23-3			
Tolnaftate		2398-96-1			
Tolonidine		4201-22-3			
Tolonium		92-31-9			
toloxatone	2-Oxazolidinone, 5-[hydroxymethyl]-3-(3-methylphenyl)- [CAS]	29218-27-7	GB 1250538	Antidepressant	
Tolperisone		728-88-1			
Tolpropamine		5632-44-0			
Tolrestat		82964-04-3			
tolserine	Carbamic acid, (2-methylphenyl)-(3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrol[2,3-b]indol-5-yl ester [CAS]	145209-30-9		Cognition enhancer	Alzheimer's disease
tolterodine	Phenol, 2-[3-(bis(1-methylethyl)amino)-1-phenylpropyl]-4-methyl-, (R)- [CAS]	124937-51-5	EP 325571	Urological	Incontinence
tolvaptan	Benzamide, N-[4-[(7-chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methyl- [CAS]	150683-30-0	EP 450097	Cardiovascular	Heart failure

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tolycaine		36886-58-6			
Topiramate	Beta-D-Fructopyranose, 2,3,4,5-bis-O-(1-methylethylidene)-sulfamate [CAS]	97740-79-4	EP 533483 US 5733880	Antiepileptic Anticancer, other	Epilepsy, generalized, tonic-clonic Cancer, general
topoisomerase inhibitors					
topotecan	1H-Pyran[3'4':6'7]indolizino[1-2'b]quinoline-3,14(4H,12H)-dione, 9-[dimethylamino)methyl]-4-ethyl-4,10-dihydroxy-, (S)- [CAS]	123948-87-8	EP 321122	Anticancer, other	Cancer, ovarian
torasemide	3-Pyridinesulfonamide, N-[{1-(methylamino)carbonyl}-4-{3-(methylphenyl)amino}- [CAS]	56211-40-6	US 4018929	Antihypertensive, diuretic	Hypertension, general
torcetrapib	ethyl (2R,4S)-4-[[3,5-bis(trifluoromethyl)benzyl][methoxycarbonyl]amino]-2-ethyl-6-(trifluoromethyl)-3,4-dihydroquinoline-1(2H)-carboxylate	262353-17-0			Atherosclerosis
torcitabine					
toremifene	Ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1N,N-dimethyl-, (Z)- [CAS] 89778-26-7 butenyl)phenoxy]-N,N-dimethyl-, (Z)- [CAS] 89778-27-8	EP 95875	Antiviral, other Anticancer, hormonal		Infection, hepatitis-B virus Cancer, breast
Tositumomab		56211-40-6 208921-02-2			
tosufloxacin	1,8-Naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, [CAS] 115864-29-9	US 4704459	Quinolone antibacterial		Infection, urinary tract
tramadol	Cyclohexanol, 2-[{dimethylamino)methyl]-1-27203-92-5 (3-methoxyphenyl)-, cis-(+)- [CAS] 36232-47-0				
Tramazoline	1H-Indole-2-carboxylic acid, 1-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]octahydro-, (2S-[1(R*)(R*)],2Alpha,3aAlpha,7aS]- [CAS] 87679-71-8 87679-37-6	1082-57-1			Pain, general
trandolapril		DE 3151690	Antihypertensive, renin system		Hypertension, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tranexamic acid	Cyclohexanecarboxylic acid, 4-(aminomethyl)-, trans- [CAS]	1197-18-8	US 3950405	Antifibrinolytic	Menstrual disorder, general
trantast	Benzoic acid, 2-[3-(3,4-dimethoxyphenyl)-1-oxo-2-propenyl]amino]- [CAS]	53902-12-8	US 3940422	Vulnery	Wound healing
trans-retinoic acid	Retinoic acid [CAS]	302-79-4		Anticancer, other	Cancer, general
Tranylcypromine	[1,2,4]Triazolo[1,5-a]pyrimidin-7-amine, N,N-diethyl-5-methyl- [CAS]	155-09-9			
trapidil	15421-84-8	DD 55956	Vasodilator, coronary		
Trastuzumab		180288-69-1			
travoprost	5-Heptenoic acid, 7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butene)icyclopentyl)-, 1-methylethylester [1R(1Alpha,Z,2S(1E,3R*),3Alpha,5Alpha)[CAS]	157283-68-6		Formulation, mucosal, topical	Glaucoma
Traxanox		58712-69-9			
traxoprodil	1-Piperidineethanol, 4-hydroxy-Alpha-[4-hydroxyphenyl]-Beta-methyl-4-phenyl-, (AlphaS, (S)- [CAS]	134234-12-1 188591-67-5		Analgesic, other	Pain, general
trazodone	1,2,4-Triazolo[4,3-a]pyrimidin-3(2H)-one, 2-[3-(4-(3-chlorophenyl)-1-piperazinyl)propyl]- [CAS]	19794-93-5 25332-39-2	US 4215104	Antidepressant	
Tremacatira		155576-45-7			
Trenbolone		10161-33-8			
Triengestone		5192-84-7			
treosulfan	1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, [S-(R*, R*)]- [CAS]	299-75-2	WO 8401506	Anticancer, alkylating	
trepitubone	Benzenebutanoic acid, 2,4,5-trifethoxy-Gamma-oxo- [CAS]	4-1826-92-0	GB 1387733	Antispasmodic	
treprostinal	Prosta-5,13-dien-19-oic acid, 6,9-epoxy-11,15-dihydroxy-, [5Z,9Alpha,11Alpha,13E,15S]- [CAS]	35121-78-9 61849-14-7	US 6054486	Formulation, parenteral, other	Hypertension, pulmonary
tretinoin	Retinoic acid [CAS]	302-79-4		Formulation, dermal, topical	Acne

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
tretinoquinol	6,7-isooquinolinedio[1,2,3,4-tetrahydro-1-[3,4,5-trimethoxyphenyl]methyl]-, (S)-[CAS]	18559-59-6 30418-38-3 21650-42-0	ZA	6802416	Antiasthma
TRH	TRI 50b [CAS]	24305-27-9 226214-49-9		Antithrombotic	Thrombosis, general
Triacetin		102-76-1			
Triamcinolone		76-25-5			
Acetonide					
Triamcinolone					
Benetonide					
Triamcinolone		31002-79-6			
Hexacetonide					
Triamcinolone		5611-51-8			
Triamterene	Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[{1-methylethylidene}bis(oxy)}-, (11S,16Alpha)-[76-25-5][CAS]	124-94-7		Formulation, inhalable, topical	Asthma
Triapine	Triapine [CAS]	396-01-0 236392-56-6	US	6458816	Anticancer, antimetabolite
Triaziquone		68-76-8			Cancer, leukaemia, general
Triazolam	8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine	28911-01-5	US	3980790	Hypnotic/Sedative Insomnia
Tribenoside		10310-32-4			
Trichlorfon		52-68-6			
Trichlormethiazide		733-67-5			
Trichlormethine		5555-77-1			
Trichloroethylene		79-01-6			
Triclobisonium		79-90-3			
Triclocarban		101-20-2			
Triclofenol Piperazine		5714-82-9			
Triclofos		306-52-5			
Triclosan		3380-34-5			
Tricromyl		85-90-5			
Tridihexethyl Iodide		125-99-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
trentine	1,2-Ethanediamine, N,N2-bis(2-aminoethyl)- [CAS]	58260-01-4 112-24-3		Metabolic and enzyme disorders	Wilson's disease
Triethanolamine		102-71-6			
Triethylenemelamine		51-18-3			
Triethylenephosphoramide		545-55-1			
Triethylenetriphosphophoramidate		52-24-4			
Trifluoperazine		117-89-5			
Trifluperidol		749-13-3			
Trifluopromazine		146-54-3			
trifluridine	Thymidine, Alpha,Alpha,Alpha-trifluoro-[CAS]	70-00-8	US 3201387	Antiviral, other	Infection, herpes virus, general
trifusal	Benzoic acid, 2-(acetoxy)-4-(trifluoromethyl)- [CAS]	322-79-2	US 4098252	Antithrombotic	Thrombosis, general
Trihexyphenidyl		52-49-3			
trilostane	Androst-2-ene-2-carbonitrile, 4,5-epoxy-3,17-dihydroxy-, (4Alpha,5Alpha,17Beta)-[CAS]	13647-35-3	US 3298255	Anticancer, hormonal	Cancer, breast
Trimazosin		35795-16-5			
trimebutine	Benzoic acid, 3,4,5-trimethoxy-, 2-(dimethylamino)-2-phenylbutyl ester, (Z)-2-[34140-59-5 39133-31-8]	DE 2151716			
Trimecacline		616-68-2			
Trimeprazine		84-96-8			
Trimetazidine		5011-34-7			
Trimethadione		127-48-0			
Trimethaphan		68-91-7			
Trimethobenzamide		138-56-7			
Trimethoprim		738-70-5			
Trimetozine		635-41-6			
trimetrexate	2,4-Quinazolinediamine, 5-methyl-6-[[3,4,5-trimethoxyphenyl)aminomethyl]- [CAS]	52128-35-5 82952-64-5	US 4391809	Antifungal	Infection, Pneumocystis jiroveci

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
trimipramine	5H-Dibenzo[b,f]azepine-5-propanamine, 10,11-dihydro-N,N β -trimethyl-, (Z)-2-butenedioate (1:1) [CAS]	521-78-8 739-71-9			Antidepressant
Trimoprostil		69900-72-7			
Trioxsalen		3902-71-4			
tripamide	Benzamide, 3-(aminosulfonyl)-4-chloro-N-(octahydro-4,7-methano-2H-isindol-2-yl)-(3aAlpha,4Alpha,7Alpha,7aAlpha)- [CAS]				
Triparanol		73803-48-2			
		JP	7305585	Antihypertensive, diuretic	Hypertension, general
Tripeleannamine		78-41-1			
Triprolidine		91-81-6			
triptorelin	Luteinizing hormone-releasing factor (pG), 6-D-triptophan- [CAS]	486-12-4 724508-66-3 57773-63-4	US 4010125	Releasing hormones	Cancer, prostate
tritiazine	Morpholine, 4-[thioxo(3,4,5-trimethoxyphenyl)methyl]- [CAS]	35619-65-9	US 3862138	Antulcer	
Tritoqualine		14504-73-5			
TRK-530	Phosphonic acid, [[4-(methylthio)phenyl]thiomethylene]bis-disodium salt [CAS]	151425-92-2	WO 9410181	Antiarthritic, other	Arthritis, rheumatoid
TRK-820	2-Propanamide, N-[5Alpha,6Beta]-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphan-6-yl]-3-(3-furyl)-N-methyl-, monohydrochloride, (2E)- [CAS]	152658-17-8	WO 9315081	Antipruritic/inflamm, non-allergic	Pruritus
Troclosene		2244-21-5			
trofostamide	3,2-(chloroethyl)-2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorin 2-oxide	22089-22-1	GB 1188159	Anticancer, alkylating	
Troglitazone		97322-87-7			
Troleandomycin		2751-9-9			
Trolnitrate		588-42-1			
tromantadine	N-(1-adamantyl)-2-(2-dimethylamine ethoxy)acetamide	53783-83-8	DE 1941218	Antiviral, other	Infection, herpes simplex virus
Tromethamine		77-86-1			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Tuaminoheptane		123-82-0			
Tubercidin		69-33-0			
Tubocurarine Chloride		57-94-3			
tulobuterol	Benzenemethanol, 2-chloro-Alpha-[(1,1-dimethylethyl)amino)methyl]- [CAS] 41570-61-0	DE 2244737	Antiasthma	Asthma	
TV-3326	N-(Propargyl)-(3R)-aminooindan-5-yl)-ethyl-methyl carbamate		Cognition enhancer	Alzheimer's disease	
TY-11223	Acetic acid, [2-[2,3,3a,6,7,7a-hexahydro-2-hydroxy-1-(3-hydroxy-4,4-dimethyl-1,6-nona diynyl)-1H-inden-5-yl]ethoxy]-, [1S-[1Alpha(R*)/2S-3aAlpha,7aAlpha]]-[CAS] 6,7,8,9-Tetrahydro-2-methyl-5H-cyclohepta[b]pyridine-3-carbonyl/guanidine maleate	US 140694-43-5	US 4837342	Antithrombotic	Unspecified
TY-12533	D-Glucitol, 1,4:3,6-di-anhydro-, dinitrate [CAS]	US 6258829	Antiarrhythmic		Unspecified
TYB-3215		87-33-2			
Tybamate		4268-36-4		Formulation, modified-release, other	Angina, general
tyloxapol	4-(1,1,3,3-Tetramethylbutyl)phenol polymer with formaldehyde and oxirane [CAS]	25301-02-4			
Tymazoline		24243-97-8			
Tyramine		51-67-2			
Tyropanoate		7246-21-1			
Ubenimex		58970-76-6			
ufenamate	Benzoic acid, 2-[[3-(trifluoromethyl)phenyl]amino], butyl ester [CAS]	67330-25-0	BE 861852	Antipruritic/antiflamm, non-allergic	
Undecylenic Acid		112-38-9			
Unoprostone		120373-36-6			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
UR-8880	4-[4-Chloro-5-(3-fluoro-4-methoxyphenyl)imidazol-1-imidazol-1-yl]benzenesulfonamide- [CAS]	66-75-1		Anti-inflammatory	Inflammation, general
Uracil Mustard	1,2,3-Propanetricarboxylic acid, 2-hydroxy-, potassium sodium salt (5:6:6), hydrate [CAS]	55049-48-4	US 4400535	Urological	
Uralt-J	2,4(1H,3H)-Pyrimidinedione, 6-[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl- [CAS]	34661-75-1	GB 1309324	Antihypertensive, adrenergic	Hypertension, general
urapidil	Urea [CAS]	57-13-6		Antipsoriasis	
Uredepa		302-49-8			
Urethan		51-79-6			
Uridine 5'-Triphosphate		63-39-8			
Urinastatin		80449-31-6			
ursodeoxycholic acid	3Alpha,7Beta-dihydroxy-5Beta-cholan-24-oic acid [CAS]	128-13-2		Formulation, other, Cirrhosis, primary biliary, hepatic dysfunction, biliary calcus	Cirrhosis, primary biliary
Ursodiol		128-13-2	US 6063773	Formulation, mucosal, topical	Contraceptive, female
Ustercell		20231-81-6			
Uzarin					
valaciclovir	L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]ethyl ester [CAS]	124832-26-4	EP 308065	Antiviral, other	Infection, herpes simplex virus
Valacyclovir		124832-26-4			
valdecoxib	Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)- [CAS]	181695-72-7	US 5859257	Antiarthritic, other	Arthritis, rheumatoid
Valdetamide		512-48-1			
Valethamate		90-22-2			
valganciclovir	L-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-3-hydroxypropyl ester [CAS]	175665-59-5 175665-60-8	EP 694547	Antiviral, other	Infection, cytomegalovirus
Valnoctamide		4171-13-5			

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
valomaciclovir	L-Vanine (3R)-3-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-ylmethyl)-4-(1-oxooctadecyl)oxybuty ester [CAS] 195156-77-5			Antiviral, other	Infection, herpes simplex virus
valproate	Pentanoic acid, 2-propyl-, [CAS]	76584-70-8	US 4988731	Antiepileptic	Epilepsy, generalized, tonic-clonic
Valproic Acid		1069-66-5			
Valpromide		99-66-1			
		2430-27-5			
valrocamide	Pentanamide, N-(2-amino-2-oxoethyl)-2-propyl-, [CAS]	92262-58-3	US 5585358	Antiepileptic	Epilepsy, general
	Pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trideoxy-7-methoxy-6,11-dioxo-4-((2,3,6-trIDEOXY-3-((trifluorooacetyl)amino)-Alpha-L-lyxo-hexopyranosyl)Oxy)-2-naphthalenyl)-2-oxoethyl ester (2S-cis)-[CAS]	56124-62-0	US 4035566	Anticancer, antibiotic	Cancer, bladder
valrubicin	L-Vanine, N-(1-oxopropyl)-N-[2-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl][methyl]-[CAS]	137862-53-4	EP 443983	Antihypertensive, renin system	Hypertension, general
Valspodar		121594-18-7			
vardenafil	Piperazine, 1-(3-(1,4-dihydro-5-methyl[4-oxo-7-propylimidazo(5,1-f)(1,2,4-triazin-2-yl)-4-ethoxyphenyl)sulfonyl)-4-ethyl- [CAS] 224785-90-4			Male sexual dysfunction	Sexual dysfunction, male, general
varespladib	Acetic acid, ((3-(aminooxocetyl)-2-ethyl-1-(2,6-dimethyl-4-(3-nitrophenyl)-2-[4-(diphenylmethyl)-1-piperazinyl]phenyl)ethyl)116308-55-5 methyl ester, [CAS]	172733-42-5	EP 675110	Septic shock treatment	Sepsis
Varicella Virus Vaccine					
varatindipine	3,5-Pyridinedicarboxylic acid, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-2-[4-(diphenylmethyl)-1-piperazinyl]phenyl]ethyl)116308-55-5 methyl ester, [CAS]	133743-71-2	EP 257616	Neuroprotective	Hypertension, general
VEA			US 6007817	Radio/chemosensitizer	Cancer, general

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
vecuronium	Piperidinium, 1-[<i>(2R,3A</i> Alpha, <i>5A</i> Alpha,16 <i>B</i> ,17 <i>B</i>]-3,17-bis(<i>acetoxy</i>)-2-(<i>1-piperidiny</i>)androstan-16-yl-1-methyl-, [CAS]	50700-72-6	US 4237126	Muscle relaxant	Anaesthesia, adjunct
Velnacrine	Cyclohexanol, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-, [CAS]	104675-29-8			
venlafaxine	Benzeneacetonitrile, Alpha-[3-[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl-1,3,4-dimethoxy-Alpha-(1-methylethyl)-, [CAS]	93413-69-5	GB 2227743	Antidepressant	Depression, general
Veralipride	Benzeneacetonitrile, Alpha-[3-[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl-1,3,4-dimethoxy-Alpha-(1-methylethyl)-, [CAS]	66644-81-3			
verapamil	23H-Benzol[b]porphine-9,13-dipropanoic acid, 18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-, monomethyl ester, trans-, [CAS]	52-53-9			
verteporfin	Piperazine, 1-(3,4-dimethoxybenzoyl)-4-(1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)-, [CAS]	129497-78-5	US 5238940	Ophthalmological	Macular degeneration
vesnarinone	81840-15-5	GB 2086896	Cardiotonic		
Vetrabutine	Benzene carboximidamide, N,3,4,5-tetrahydroxy-, [CAS]	3735-45-3			Heart failure
VF-233	05933-74-7	US 4623659	Cardiovascular		
VI-D134	9H-Purin-6-amine, 9-β-D-arabinofuranosyl-, [CAS]	24356-66-9	US 6403597	Male sexual dysfunction	Reperfusion injury
vidarabine	5536-17-4	GB 1159290	Antiviral, other		Premature ejaculation
vigabatrin	68506-86-5 60643-86-9	GB 1472535	Antiepileptic		Infection, herpes virus, general
vilazodone	163521-12-8	EP 648767	Antidepressant		Epilepsy, partial (focal, local)
Viloxazine	46817-91-8				Depression, general
Viminol	21363-18-8				
Vinbarbital	125-44-0				
Vinblastine	865-21-4				
vinburmine	Eburnamenin-14/[15H]-one, (3Alpha, 16Alpha)-, [CAS]	474-00-0 4880-88-0	DE 1932245	Cognition enhancer	

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Vincamine		1617-90-9			
Vinconate		70704-03-9			
Vincristine	Vincleukoblastine, 22-oxo-, sulfate (1:1) (salt) [CAS]	2068-78-2 57-22-7	EP 207831	Formulation, parenteral, other	Cancer, general
Vindesine	Vincleukoblastine, 3-(aminocarbonyl)-O4-deacetyl-3-de(methoxycarbonyl)- [CAS]	53643-48-4 59917-39-4	GB 1463575	Anticancer, other	Cancer, leukaemia, acute - lymphocytic
vinflunine	Aspidospermidine-3-carboxylic acid, 4-(acetoxymethyl)-6,7-didehydro-15-[2R,4R,6S,8S]-4-(1,1-difluoroethyl)-1,3,4,5,6,7,8,9-octanhydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-blindolo[8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2S,3S,4R,5Alpha,12S,19Alpha)- [CAS]	162652-95-1	FR 2707988	Anticancer, other	Cancer, general
vinorelbine	C-Norvincleukoblastine, 3',4'-didehydro-4'-deoxy- [CAS]	71486-22-1	EP 10458	Anticancer, other	Cancer, lung, non-small cell
vinpocetine	Eburnammine-14-carboxylic acid, ethyl ester, (3Alpha,16Alpha)- [CAS]	42971-09-5	GB 1405127	Cognition enhancer	Cognitive disorder, general
Vinyl Ether		109-93-3			
Vinylbital		2430-49-1			
Viquidil		84-55-9			
Viridin		3306-52-3			
Visnadine		477-32-7			
Vitamin A		68-26-8			
Vitamin B12	Vitamin B12 [CAS]	68-19-9		Formulation, transmucosal, nasal	Anaemia, general
Vitamin C	L-Ascorbic acid [CAS]	50-81-7		Formulation, modified-release, <=24hr	Nutrition
Vitamin D ₂		50-14-6			
Vitamin D ₃		67-97-0			
Vitamin K ₃		83-70-5			
Vitamins, Prenatal					

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
VLA-4 antagonists	((R,S)-4-(4-(Amino-imino-methyl)-phenyl)-3-((4-biphenyl)-methyl)-4-methyl-2,5-dioxoimidazolidin-1-yl)-acetyl-L-N-methyl-aspartyl-L-phenylglycine		EP 842943	Antiasthma	Asthma
VNP-40101M	1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine		US 6040338	Anticancer, alkylating	Cancer, general
voglibose	D-epi-Inositol, 3,4-dideoxy-4-[2-hydroxy-1-(hydroxymethyl)ethyl]aminoj-2-C-[hydroxymethyl]- [CAS]	83480-29-9	EP 56194	Antidiabetic	Diabetes, Type II
voriconazole	4-Pyrimidineethanol, Alpha-(2,4-difluorophenyl)-5-fluoro-β-methyl-Alpha-(1H-1,2,4-triazol-1-ylmethyl)-, (R-(R*,S*))-[CAS]	137234-62-9	EP 440372	Antifungal	Infection, fungal, general
Vorozole	7-[3-[4-(2-Quinolinylmethyl)-1-piperazinyl]propoxy]-3,4-dihydro-2H-1,4-benzodiazine-3-one	129731-10-8			
VUF-K-8788				Antiasthma	Asthma
Warfarin		81-81-2			
WF-10	Tetrachlorodecaoxide [CAS]	92047-76-2		Radio/chemoprotective	Chemotherapy-induced injury, bone marrow, general
WMC-79	2-[3-{4-[3-(6-oxo-6H-2,10b-diaza-acanthrenyl-5-ylamino)propyl]-piperazin-1-yl}propyl]-5-nitro-2-azaphenylene-1,3-dione				
wound healing matrix				Anticancer, other	Cancer, colorectal
WP-170			US 5897880	Formulation, transdermal, patch	Ulcer, diabetic
xaliproden	Pyridine, 1,2,3,6-tetrahydro-1-[2-(napthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]- [CAS]	90494-73-4 135554-020-8	US 6531121	Cytokine	Unspecified
xamoterol	4-Morpholinocarboxamide, N-[2-hydroxy-3-(4-hydroxyphenoxyl)propyl]aminoethyl]- (+/-)-73210-73-8	EP 101381		Neuroprotective	Amyotrophic lateral sclerosis
		GB 2002748		Cardiostimulant	
		GB 81801-12-9			Heart failure

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Xanomeline		131986-45-3			
Xanthinol Niacinate		437-74-1			
Xemilofiban		149820-74-6			
Xenbucin		959-10-4			
Xibenol		81584-06-7			
Xibromol	Phenol, 4,5-dimethyl-2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-, exo-[CAS]	13741-18-9	GB 1206774	Antibacterial, other	Infection, general
Ximelagatran	Glycine, N-[(R)-cyclohexyl]-2-(((2S)-2-(((4-(hydroxyanino)iminomethyl)phenyl)methyl)amino)carbonyl)-1-azetidiny)-2-oxoethyl ethyl ester [CAS]	192939-46-1			
Ximoprofen		56187-89-4			Thrombosis, venous
Xipamide	Benzamide, 5-(aminosulfonyl)-4-chloro-N-(2,6-dimethylphenyl)-2-hydroxy- [CAS]	14293-44-8	US 3567777	Antihypertensive, diuretic	
Xorphanol	Morphinan-3-ol, 17-(cyclobutylmethyl)-8-methyl-6-methylene-, 8(B)- [CAS]	77287-89-9		Analgesic, other	Pain, cancer
XR-5118	2,5-Piperazinedione, 3-[15-[2-(dimethylaminomethyl)ethyl]thio]o-2-thienyl]methylen-6-(phenyl)methylene-, imonoylchloride, (3Z,6Z)- [CAS]	174766-49-5	WO 9532190	Anticancer, other	Cancer, general
XR-5944	N,N'-(1,2-Ethanediyl)bis(imino-2,1-ethanediyly)bis(9-methylphenazin-1-carboxamide)		EP 934278	Anticancer, other	Cancer, general
Xylometazoline		526-36-3			
Xylose		58-86-6			
YH-1885	2-Pyrimidinamine, 4-(3,4-dihydro-1-methyl-2(1H)-isoquinoliny)-N-(4-fluorophenyl)-5,6-dimethyl-, monohydrochloride [CAS]	178307-42-1	WO 9605177	Antitulcer	Ulcer, GI, general
YM-511	Benzonitrile, 4-[[4-(bromophenyl)methyl]-4H-1,2,4-triazol-4-ylamino]- [CAS]	148869-05-0	WO 9305027	Anticancer, hormonal	Cancer, breast

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
YM-598	potassium(E)-N-[6-methoxy-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]-2-phenylethanesulfonamide			Anticancer, other	Cancer, prostate
Yohimbine	Adenosine, 2-(1-octynyl)- [CAS] 90596-75-1	US 5270304		Anti-inflammatory	Inflammation, general
YT-146	Thiazolidine, 3-((2,3-dihydro-1H-inden-2-yl)acetyl)-4-(1-pyrmidinyl carbonyl), (R)- [CAS]	130849-58-0	EP 372484	Cognition enhancer	Dementia, senile, general
Z-321	(1H-Indene-5-acetic acid, 2-[(4-chlorophenyl)sulfonyl]amino)methyl]-2,3-dihydro, monosodium salt) [CAS]	146731-14-8	JP 92506077	Antithrombotic	Peripheral vascular disease
Zafirlukast	Carbamic acid, [3-[2-methoxylaminocarbonyl]phe nylmethyl]-1-methyl-1H-indol-5-yl]-cyclpentenyl ester [CAS]	107753-78-6	EP 199543	Antifasthma	Asthma
zalcitabine	Cytidine, 2',3'-dideoxy- [CAS]	7481-89-2	US 4879277	Antiviral, anti-HIV	Infection, HIV/AIDS
Zaldaride		109826-26-8			
zaleplon	Acetamide, N-[3-(3-cyanopyrazolo[1,5-alpyrimidin-7-yl]phenyl)-N-ethyl]- [CAS] Dibenzoz[b,f]thiepin-2-acetic acid, [10,11-dihydro-Alpha-methyl-10-oxo- [CAS]	151319-34-5	EP 776898	Hypnotic/Sedative	Insomnia
zaltoprofen	5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycerol-D-galacto-non-2-enonic acid [CAS]	74711-43-6	JP 55053282	Anti-Inflammatory	
zanamivir	1-Propanone, 3-{(1-(phenylmethyl)-4-piperidinyl)-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)}- [CAS]	139110-80-8	WO 9116320	Antiviral, other	Infection, influenza virus
zanapezil		142852-50-4	EP 487071	Cognition enhancer	
Zatebradine		85175-67-3			
ZD-0473	Platinum, amminechloro(2-methylpyridine)-(SP-4-3)- [CAS]	181630-15-9	EP 727430	Anticancer, alkylating	Cancer, ovarian
ZD-0947	N-acetylcolchimol-C-phosphate		WO 95283388	Urological	Overactive bladder
ZD-6126				Anticancer, other	Cancer, general
ZD-9331	1H-Tetrazole-5-butanoic acid, Alpha-((1-(1,4-dihydro-2,7-dimethyl-4-oxo-6-quinazolinyl)methyl)-2-propynylamino)-2-fluorobenzoyl)amino) (S)- [CAS]	153537-73-6	GB 2264946	Anticancer, antimetabolite	Cancer, pancreatic

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zebulazine	2-(1H-Pyrimidinone, 1-β-D-ribofuranosyl-[CAS]	3690-10-6		Anticancer, other	Cancer, general
zelandopam	7,8-isquinolinediol, 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydro-[CAS]	138086-00-7	JP 03190818	Vasodilator, renal	Hypertension, general
Zenarestat		112733-06-9			
Ziconotide		107452-89-1			
zidovudine	Thymidine, 3'-azido-3'-deoxy- [CAS]	30516-87-1	US 4724232	Antiviral, anti-HIV	Infection, HIV/AIDS
	Urea, N-(1-benzol[b]thien-2-ylmethyl)-N-hydroxy- [CAS]	111406-87-2	EP 279263	Antiasthma	Asthma
Zimeldine		56775-88-3			
zinc acetate	hexakis(m-acetato)-1m4-oxotetrazinc	12129-82-7		Antiviral, other	Infection, herpes simplex virus prophylaxis
zinc acexamate	Hexanoic acid, 6-(acetylamino)-, zinc salt (2:1)- [CAS]	70020-71-2	EP 369088	Antifulcer	Ulcer, duodenal
zinc ibuprofenate		78416-80-5		Anti-inflammatory, topical	Inflammation, dermal
Zinc p-Phenolsulfonate		127-82-2			
Zinc Salicylate		16283-36-6			
Zinostatin		9014-2-2			
zinostatin stimalamer		123760-07-6	EP 136791	Anticancer, antibiotic	Cancer, liver
Zipeprrol		34758-83-3			
ziprasidone	2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-[CAS]	122883-93-6 146339-27-7	EP 281309	Neuroleptic	Schizophrenia
zofenopril	L-Proline, 1-(3-(benzoylthio)-2-methyl-1-oxopropyl)-4-(phenylthio)-[I(R*)-2Alpha,4Alpha]-[CAS]	75176-37-3 81872-10-8 819338-43-4	GB 2028327	Antihypertensive, renin system	Hypertension, general
	L-Proline, 1-(3-(benzoylthio)-2-methyl-1-oxopropyl)-4-(phenylthio)-[I(R*)-2Alpha,4Alpha]- + 6-Chloro-3,4-dihydro-2H-1,2,4-benzothiazide-7-sulfonamide 1,1-dioxide [CAS]				
zofenopril + HCTZ	Phosphonic acid, [1-Hydroxy-2-[(1H-imidazol-1-yl)methylene]bis-[CAS]	1118072-93-8		Formulation, fixed-dose combinations	Hypertension, general
zoledronic acid		165800-06-6	EP 531253	Osteoporosis treatment	Hypercalcemia of malignancy

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
zolimidine	2-(p-methylisufonylphenyl)imidazo[1,2-alpyridine	1222-57-7	US 3318880	Antiucler	Gastritis
zolmitriptan	2-Oxazolidinone, 4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)-, (S)- [CAS]	139264-17-8	WO 9118897	Antimigraine	Migraine
zolpidem	Imidazo[1,2-al]pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-(R-(R°,R°))-2,3-dihydroxybutanedioate (2:1) [CAS]	99294-93-6 48-0	EP 50563	Hypnotic/Sedative	Insomnia
Zomepirac	Zomepirac	33369-31-2			
zonampanel	1(2H)-Quinoxalineacetic acid, 3,4-dihydro-7-(1H-imidazol-1-yl)-6-nitro-2,3-dioxo-[CAS]	210245-80-0		Neuroprotective	Ischaemia, cerebral
zoniporide	1H-pyrazole-4-carboxamide, N-(aminoimino methyl)-5-cyclopropyl-1-(5-quindinyl)-,	249296-45-5		Cardiovascular	Unspecified
zonisamide	1,2-Benzisoxazole-3-methanesulfonamide [CAS]	68291-97-4 68291-98-5	GB 2025931	Antiepileptic	Epilepsy, generalized, tonic-clonic
zopiclone	1-Piperazinecarboxylic acid, 4-methyl-, 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrazolo[3,4-b]pyrazin-5-yl ester [CAS]	43200-80-2	GB 1358680	Hypnotic/Sedative	Insomnia
Zopolrestat	Zopolrestat	110703-94-1			
Zorubicin	Zorubicin	54083-22-6			
zosuquidar	1-Piperazineethanol, 4-(1,1-difluoro-1,1a,6,10b-tetrahydrodibenzofa, e)cyclopropan[cyclohexen-6-yl]-Alpha-[5-quinolinyl oxy(methyl)].6(R-(1a4)pha,6(Alpha,10bAlpha). [CAS]	167465-36-3			Cancer, leukaemia, acute myelogenous
zotepine	Ethanamine, 2-[(8-chlorodibenz[b,f]hepin-10y)oxy]-N,N-dimethyl-[CAS]	26615-21-4	GB 1247067	Neuroleptic	Schizophrenia
ZP-123	Ethanamine, 2-[4-(1,2-diphenyl-1-butene)phenoxy]-N,N-dimethyl-, (Z)- [CAS]	WO 0162775		Antiarrhythmic	Arrhythmia, general
Z-tamoxifen	Z-tamoxifen	10540-29-1		Anticancer, hormonal	Cancer, colorectal

Table IV

API Generic Name	API Chemical Name	CAS No.	Patent Reference	Example of Therapeutic Use	Example of Indication
Zuclopentixol	1-Piperazineethanol, 4-[3-(2-chloro-9H-thioxanthan-9-ylidene)propyl]-, (Z)-[CAS]	53772-83-1 982-24-1 85721-05-7 64053-00-5	EP	270282 Neuroleptic	Psychosis, general

CLAIMS:

1. A pharmaceutical co-crystal composition, comprising: an API and a co-crystal former, wherein both the API and the co-crystal former are solids at room temperature and the API and co-crystal former are hydrogen bonded to each other.
2. The pharmaceutical co-crystal composition according to claim 1, wherein the co-crystal former is selected from a co-crystal former of Table I or Table II.
3. The pharmaceutical co-crystal composition according to claim 1, wherein the API is selected from an API of Table IV.
4. The pharmaceutical co-crystal composition according to claim 1, wherein the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II.
5. A pharmaceutical co-crystal composition, comprising: an API, a co-crystal former, and a third molecule, wherein the API and the co-crystal former are solids at room temperature, and wherein the API and the third molecule are bonded to each other, and further wherein the co-crystal former and the third molecule are hydrogen bonded to each other.
6. A pharmaceutical co-crystal composition, comprising: an API and a co-crystal former, wherein the API is liquid and the co-crystal former is solid at room temperature, and wherein the API and the co-crystal former are hydrogen bonded to each other.
7. The pharmaceutical co-crystal composition according to claim 6, wherein the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II.
8. A pharmaceutical co-crystal composition, comprising: two APIs, wherein one or both of the APIs are solids at room temperature, and wherein the two APIs are hydrogen bonded to each other.

9. The pharmaceutical co-crystal composition according to claim 8, wherein each API is selected from an API of Table IV.

10. A pharmaceutical co-crystal composition, comprising: two co-crystal formers, wherein both co-crystal formers are solids at room temperature, and wherein both co-crystal formers are hydrogen bonded to each other.

11. The pharmaceutical co-crystal composition according to claim 10, wherein each co-crystal former is selected from a co-crystal former of Table I or Table II.

12. The pharmaceutical co-crystal composition according to claim 1, wherein the API and the co-crystal former form an inclusion complex.

13. A pharmaceutical co-crystal composition, comprising: an API and a co-crystal former; wherein the API has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp₂ amine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine, and the co-crystal former has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp₂ amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine, such that the drug and co-crystal forming compound are capable of co-crystallizing from a solution phase under crystallization conditions and a hydrogen bond is formed between a hydrogen bond donor and a hydrogen bond acceptor.

14. The pharmaceutical composition according to claim 1, wherein (i) one of the API and co-crystal forming compound has at least one hydrogen bond donor group and (ii) the other has at least one hydrogen bond acceptor group.

-
15. The pharmaceutical composition according to claim 14, wherein the difference in pKa between the API and the co-crystal forming compound does not exceed 2.
 16. The pharmaceutical composition according to claim 1, wherein the API is selected from celecoxib, carbamazepine, itraconazole, olanzapine, topiramate and modafinil.
 17. The pharmaceutical composition according to claim 1, wherein the API is selected from 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin, and ibuprofen.
 18. The pharmaceutical composition according to claim 1, which further comprises a pharmaceutically acceptable diluent, excipient or carrier.
 19. A co-crystal comprising carbamazepine and saccharin.
 20. A co-crystal comprising carbamazepine and nicotinamide.
 21. A co-crystal comprising carbamazepine and trimesic acid.
 22. A co-crystal comprising celecoxib and nicotinamide.
 23. A co-crystal comprising olanzapine and nicotinamide.
 24. A co-crystal comprising celecoxib and 18-crown-6.
 25. A co-crystal comprising itraconazole and succinic acid.
 26. A co-crystal comprising itraconazole and fumaric acid.
 27. A co-crystal comprising itraconazole and tartaric acid.
 28. A co-crystal comprising itraconazole and malic acid.

29. A co-crystal comprising itraconazoleHCl and tartaric acid.
30. A co-crystal comprising modafinil and malonic acid.

31. A co-crystal comprising modafinil and benzamide.
32. A co-crystal comprising modafinil and mandelic acid.
33. A co-crystal comprising modafinil and glycolic acid.
34. A co-crystal comprising modafinil and fumaric acid.
35. A co-crystal comprising modafinil and maleic acid.
36. A co-crystal comprising topiramate and 18-crown-6.
37. A co-crystal comprising 5-fluorouracil and urea.
38. A co-crystal comprising hydrochlorothiazide and nicotinic acid.
39. A co-crystal comprising hydrochlorothiazide and 18-crown-6.
40. A co-crystal comprising hydrochlorothiazide and piperazine.
41. A co-crystal comprising acetaminophen and 4,4'-bipyridine.

42. A co-crystal comprising phenytoin and pyridone.

43. A co-crystal comprising aspirin and 4,4'-bipyridine.
44. A co-crystal comprising ibuprofen and 4,4'-bipyridine.

45. A co-crystal comprising flurbiprofen and 4,4'-bipyridine.

46. A co-crystal comprising flurbiprofen and trans-1,2-bis(4-pyridyl) ethylene.
47. A co-crystal comprising carbamazepine and p-phthalaldehyde.

48. A co-crystal comprising carbamazepine and 2,6-pyridinecarboxylic acid.
49. A co-crystal comprising carbamazepine and 5-nitroisophthalic acid.
50. A co-crystal comprising carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid.
51. A co-crystal comprising carbamazepine and benzoquinone.
52. A process for the production of a pharmaceutical co-crystal composition, which process comprises:
 - (1) providing an API which has at least one functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp₂ amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
 - (2) providing a co-crystal former which has at least one complementary functional group selected from the group consisting of: ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp₂ amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
 - (3) grinding, heating, or contacting in solution the API with the co-crystal former under crystallization conditions; so as to form a solid phase;
 - (4) isolating co-crystals formed thereby; and

(5) incorporating the co-crystals into a pharmaceutical composition; wherein the API is a liquid or solid at room temperature and the co-crystal former is a solid at room temperature, and wherein the API and co-crystal former are hydrogen bonded to each other.

53. The process according to claim 52, wherein:

- (a) the co-crystal former is selected from a co-crystal former of Table I or Table II;
- (b) the API is selected from an API of Table IV;
- (c) the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II;
- (d) the API and the co-crystal former form an inclusion complex;
- (e) (i) one of the API and co-crystal forming compound has at least one hydrogen bond donor group; and
(ii) the other has at least one hydrogen bond acceptor group;
- (f) the difference in pKa between the API and the co-crystal former does not exceed 2;
- (g) the API is selected from the group consisting of celecoxib, carbamazepine, itraconazole, olanzapine, topiramate, and modafinil;
- (h) the API is selected from the group consisting of 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin, and ibuprofen; or
- (i) the pharmaceutical co-crystal composition further comprises a pharmaceutically acceptable diluent, excipient, or carrier.

54. The process for the production of a pharmaceutical co-crystal composition, which process comprises:

- (3) providing an API which has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp₂ amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

-
- (4) providing a co-crystal former which has at least one complementary functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp₂ amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
 - (3) grinding, heating, or contacting in solution the API with the co-crystal former under crystallization conditions; so as to form a solid phase;
 - (4) isolating co-crystals formed thereby; and
 - (5) incorporating the co-crystals into a pharmaceutical composition; wherein the API is a liquid or solid at room temperature and the co-crystal former is a solid at room temperature, and wherein the API and a third molecule are bonded to each other, and further wherein the co-crystal former and the third molecule are hydrogen bonded to each other.

55. The process according to claim 52, wherein: the API is a liquid at room temperature.

56. The process according to claim 55, wherein the API is selected from an API of Table IV and the co-crystal former is selected from a co-crystal former of Table I or Table II.

57. A process for the production of a pharmaceutical co-crystal composition, which process comprises:

- (1) providing an API which has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp₂ amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;
- (2) providing another API which has at least one complementary functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone,

thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp₂ amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(3) grinding, heating, or contacting in solution the APIs under crystallization conditions; so as to form a solid phase;

(4) isolating co-crystals formed thereby; and

(5) incorporating the co-crystals into a pharmaceutical composition; wherein one or both of the APIs are solids at room temperature, and wherein the two APIs are hydrogen bonded to each other.

58. The process according to claim 57, wherein each API is selected from an API of Table IV.

59. A process for the production of a pharmaceutical co-crystal composition, which process comprises:

(1) providing a co-crystal former which has at least one functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp₂ amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

(2) providing another co-crystal former which has at least one complementary functional group selected from the group consisting of ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphonic acid, phosphinic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, sp₂ amine, thiocyanate, cyanamide, oxime, nitrile, diazo, organohalide, nitro, s-heterocyclic ring, thiophene, n-heterocyclic ring, pyrrole, o-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, and pyridine;

-
- (3) grinding, heating, or contacting in solution the co-crystal formers under crystallization conditions; so as to form a solid phase;
 - (4) isolating co-crystals formed thereby; and
 - (5) incorporating the co-crystals into a pharmaceutical composition; wherein both co-crystal formers are solids at room temperature, and wherein both co-crystal formers are hydrogen bonded to each other.

60. The process according to claim 59, wherein each co-crystal former is selected from a co-crystal former of Table I and Table II.

61. The process according to claim 52, wherein the co-crystal is selected from the group consisting of carbamazepine:saccharin, carbamazepine:nicotinamide, carbamazepine:trimesic acid, celecoxib:nicotinamide, olanzapine:nicotinamide, celecoxib:18-crown-6, itraconazole:succinic acid, itraconazole:fumaric acid, itraconazole:tartaric acid, itraconazole:malic acid, itraconazoleHCl:tartaric acid, modafinil:malonic acid, modafinil:benzamide, modafinil:mandelic acid, modafinil:glycolic acid, modafinil:fumaric acid, modafinil:maleic acid, topiramate:18-crown-6, 5-fluorouracil:urea, hydrochlorothiazide:nicotinic acid, hydrochlorothiazide:18-crown-6, hydrochlorothiazide:piperazine, acetaminophen:4,4'-bipyridine, phenytoin:pyridone, aspirin:4,4'-bipyridine, ibuprofen:4,4'-bipyridine, flurbiprofen:4,4'-bipyridine, flurbiprofen:trans-1,2-bis(4-pyridyl) ethylene, carbamazepine:p-phthalaldehyde, carbamazepine:2,6-pyridinecarboxylic acid, carbamazepine:5-nitroisophthalic acid, carbamazepine:1,3,5,7-adamantane tetracarboxylic acid, and carbamazepine:benzoquinone.

62. A process for the production of a pharmaceutical composition, which comprises:

- (1) contacting in solution an API with a co-crystal forming compound, under crystallization conditions, so as to form a solid phase;
- (2) isolating the solid phase;
- (3) testing the solid phase for the presence of co-crystals of the API and the co-crystal forming compound; and
- (4) incorporating the co-crystals when formed in step (3) into a pharmaceutical composition.

63. A process for the production of a pharmaceutical composition, which comprises:

- (1) providing (i) an API or a plurality of different APIs, and (ii) a co-crystal forming compound or a plurality of different co-crystal forming compounds, wherein at least one of the API and the co-crystal forming compound is provided as a plurality thereof;
- (2) screening for co-crystals of APIs with co-crystal forming compounds by subjecting each combination of API and co-crystal forming compound to a step comprising
 - (a) contacting in solution the API with the co-crystal forming compound under crystallization conditions so as to form a solid phase;
 - (b) isolating the solid phase; and
 - (c) testing the solid phase for the presence of co-crystals of the API and the co-crystal forming compound; and
- (3) incorporating the co-crystals when formed in step (c) into a pharmaceutical composition.

64. A process for modulating the solubility of an API for use in a pharmaceutical composition, which process comprises:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal;
- (3) testing the co-crystal for modulated solubility as compared to the API; and
- (4) incorporating the co-crystal having modulated solubility into a pharmaceutical composition.

65. A process for modulating the dose response of an API for use in a pharmaceutical composition, which process comprises:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal;
- (3) testing the co-crystal for modulated dose response as compared to the API; and
- (4) incorporating the co-crystal having modulated dose response into a pharmaceutical composition.

66. A process for modulating the dissolution of an API for use in a pharmaceutical composition, which process comprises:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal;
- (3) testing the co-crystal for modulated dissolution as compared to the API; and
- (4) incorporating the co-crystal having modulated dissolution into a pharmaceutical composition.

67. A process for modulating the bioavailability of an API for use in a pharmaceutical composition, which process comprises:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal;
- (3) testing the co-crystal for modulated bioavailability as compared to the API; and
- (4) incorporating the co-crystal having modulated bioavailability into a pharmaceutical composition.

68. A process for increasing the stability of an API for use in a pharmaceutical composition, which process comprises:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal, wherein the co-crystal has increased stability as compared to the API; and
- (3) incorporating the co-crystal having increased stability into a pharmaceutical composition.

69. A process for the incorporation of a difficult to salt or unsaltable API for use in a pharmaceutical composition, which process comprises:

-
- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
 - (2) isolating the co-crystal;
 - (3) incorporating the co-crystal having a difficult to salt or unsaltable API into a pharmaceutical composition.

70. A process for decreasing the hygroscopicity of an API for use in a pharmaceutical composition, which process comprises:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal, wherein the co-crystal has decreased hygroscopicity as compared to the API; and
- (3) incorporating the co-crystal having decreased hygroscopicity into a pharmaceutical composition.

71. A process for crystallizing an amorphous API for use in a pharmaceutical composition, which process comprises:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal;
- (4) incorporating the co-crystal into a pharmaceutical composition.

72. A process for decreasing the form diversity of an API for use in a pharmaceutical composition, which process includes:

- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
- (2) isolating the co-crystal wherein the co-crystal has decreased form diversity as compared to the API; and
- (3) incorporating the co-crystal having decreased form diversity into a pharmaceutical composition.

73. A process for modulating the morphology of an API for use in a pharmaceutical composition, which process includes:

-
- (1) contacting in solution the API with a co-crystal forming compound under crystallization conditions, so as to form a co-crystal of the API and the co-crystal forming compound;
 - (2) isolating the co-crystal, wherein the co-crystal has a different morphology as compared to the API; and
 - (3) incorporating the co-crystal having modulated morphology into a pharmaceutical composition.

74. The co-crystal of claim 1, specifically excluding co-crystals selected from the group consisting of: nabumetone:2,3-naphthalenediol, fluoxetine HCl:benzoic acid, fluoxetine HCl:succinic acid, acetaminophen:piperazine, acetaminophen:theophylline, theophylline:salicylic acid, theophylline:p-hydroxybenzoic acid, theophylline:sorbic acid, theophylline:1-hydroxy-2-naphthoic acid, theophylline:glycolic acid, theophylline:2,5-dihydroxybenzoic acid, theophylline:chloroacetic acid, bis(diphenylhydantoin):9-ethyladenine acetylacetone solvate, bis(diphenylhydantoin):9-ethyladenine 2,4-pentanedione solvate, 5,5-diphenylbarbituric acid:9-ethyladenine, bis(diphenylhydantoin):9-ethyladenine, 4-aminobenzoic acid:4-aminobenzonitrile, sulfadimidine:salicylic acid, 8-hydroxyquinolinium 4-nitrobenzoate:4-nitrobenzoic acid, sulfaproxyline:caffeine, retro-inverso-isopropyl (2R,3S)-4-cyclohexyl-2-hydroxy-3-(N-((2R)-2-morpholinocarbonylmethyl-3-(1-naphthyl)propionyl)-L-histidylamino)butyrate:cinnamic acid monohydrate, benzoic acid:isonicotinamide, 3-(2-N',N'-(dimethylhydrazino)-4-thiazolylmethylthio)-N''-sulfamoylpropionamidine:maleic acid, diglycine hydrochloride ($C_2H_5NO_2:C_2H_6NO_2^+Cl^-$), octadecanoic acid:3-pyridinecarboxamide, cis-N-(3-methyl-1-(2-(1,2,3,4-tetrahydro)naphthyl)-piperidin-4-yl)-N-phenylpropanamide hydrochloride:oxalic acid, trans-N-(3-methyl-1-(2-(1,2,3,4-tetrahydro)naphthyl)-piperidin-4-ylum)-N-phenylpropanamide oxalate:oxalic acid dihydrate, bis(1-(3-((4-(2-isopropoxyphenyl)-1-piperazinyl)methyl)benzoyl)piperidine) succinate:succinic acid, bis(p-cyanophenyl)imidazolylmethane:succinic acid, cis-1-((4-(1-imidazolylmethyl)cyclohexyl)methyl)imidazole:succinic acid, (+)-2-(5,6-dimethoxy-1,2,3,4-tetrahydro-1-naphthyl)imidazoline:(+)-dibenzoyl-D-tartaric acid, raclopride:tartaric acid, 2,6-diamino-9-ethylpurine:5,5-diethylbarbituric acid, 5,5-diethylbarbituric acid:bis(2-

aminopyridine), 5,5-diethylbarbituric acid:acetamide, 5,5-diethylbarbituric acid:KI₃, 5,5-diethylbarbituric acid:urea, bis(barbital):hexamethylphosphoramide, 5,5-diethylbarbituric acid:imidazole, barbital:1-methylimidazole, 5,5-diethylbarbituric acid:N-methyl-2-pyridone, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)-pyrimidine:5,5-diethylbarbituric acid, bis(barbital):caffeine, bis(barbital):1-methylimidazole, bis(beta-cyclodextrin):bis(barbital) hydrate, tetrakis(beta-cyclodextrin):tetrakis(barbital), 9-ethyladenine:5,5-diethylbarbituric acid, barbital:N'-(p-cyanophenyl)-N-(p-iodophenyl)melamine, barbital:2-amino-4-(m-bromophenylamino)-6-chloro-1,3,5-triazine, 5,5-diethylbarbituric acid:N,N'-diphenylmelamine, 5,5-diethylbarbituric acid:N,N'-bis(p-chlorophenyl)melamine, N,N'-bis(p-bromophenyl)melamine:5,5-diethylbarbituric acid, 5,5-diethylbarbituric acid:N,N'-bis(p-iodophenyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(p-tolyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(m-tolyl)melamine, 5,5-diethylbarbituric acid:N,N'-bis(m-chlorophenyl)melamine, N,N'-Bis(m-methylphenyl)melamine:barbital, N,N'-bis(m-chlorophenyl)melamine:barbital tetrahydrofuran solvate, 5,5-diethylbarbituric acid:N,N'-bis(t-butyl)melamine, 5,5-diethylbarbituric acid:N,N'-di(t-butyl)melamine, 6,6'-diquinolyl ether:5,5-diethylbarbituric acid, 5-t-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid, N,N'-bis(4-carboxymethylphenyl)melamine:barbital ethanol solvate, N,N'-bis(4-t-butylphenyl)melamine:barbital, tris(5,17-N,N'-bis(4-amino-6-(butylamino)-1,3,5-triazin-2-yl)diamino-11,23-dinitro-25,26,27,28-tetrapropoxycalix(4)arene):hexakis(diethylbarbituric acid) toluene solvate, N,N'-bis(m-fluorophenyl)melamine:barbital, N,N'-bis(m-bromophenyl)melamine:barbital acetone solvate, N,N'-bis(m-iodophenyl)melamine:barbital acetonitrile solvate, N,N'-bis(m-trifluoromethylphenyl)melamine:barbital acetonitrile solvate, aminopyrine:barbital, N,N'-bis(4-fluorophenyl)melamine:barbital, N,N'-bis(4-trifluoromethylphenyl)melamine:barbital, 2,4-diamino-5-(3,4,5-trimethoxybenzyl)pyrimidine:barbital, hydroxybutyrate:hydroxyvalerate, 2-aminopyrimidine:succinic acid, 1,3-bis((6-methylpyrid-2-yl)amino)carbonyl)benzene:glutaric acid, 5-t-butyl-2,4,6-triaminopyrimidine:diethylbarbituric acid, bis(dithiobiuret-S,S')nickel(II):diuracil, platinum 3,3'-dihydroxymethyl-2,2'-bipyridine dichloride:AgF₃CSO₃, 4,4'-bipyridyl:isophthalic acid, 4,4'-bipyridyl:1,4-naphthalenedicarboxylic acid, 4,4'-bipyridyl:1,3,5-cyclohexane-tricarboxylic acid, 4,4'-bipyridyl:tricaballylic acid, urotropin:azelaic acid, insulin:C8-HI (octanoyl-N^e-LysB29-human insulin), isonicotinamide:cinnamic acid, isonicotinamide:3-hydroxybenzoic acid, isonicotinamide:3-N,N-dimethylaminobenzoic acid, isonicotinamide:3,5-bis(trifluoromethyl)-benzoic acid, isonicotinamide:d,l-mandelic acid,

isonicotinamide:chloroacetic acid, isonicotinamide:fumaric acid monoethyl ester,
isonicotinamide:12-bromododecanoic acid, isonicotinamide:fumaric acid,
isonicotinamide:succinic acid, isonicotinamide:4-ketopimelic acid,
isonicotinamide:thiodiglycolic acid, 1,3,5-cyclohexane-tricarboxylic
acid:hexamethyltetramine, 1,3,5-cyclohexane-tricarboxylic acid:4,7-phenanthroline, 4,7-
phenanthroline:oxalic acid, 4,7-phenanthroline:terephthalic acid, 4,7-phenanthroline: 1,3,5-
cyclohexane-tricarboxylic acid, 4,7-phenanthroline:1,4-naphthalenedicarboxylic acid,
pyrazine:methanoic acid, pyrazine:ethanoic acid, pyrazine:propanoic acid, pyrazine:butanoic
acid, pyrazine:pentanoic acid, pyrazine:hexanoic acid, pyrazine:heptanoic acid,
pyrazine:octanoic acid, pyrazine:nonanoic acid, pyrazine:decanoic acid, diammine-(deoxy-
quanyl-quanyl-N⁷,N⁷)-platinum:tris(glycine) hydrate, 2-aminopyrimidine:p-
phenylenediacetic acid, bis(2-aminopyrimidin-1-i um)fumarate:fumaric acid, 2-
aminopyrimidine:indole-3-acetic acid, 2-aminopyrimidine:N-methylpyrrole-2-carboxylic
acid, 2-aminopyrimidine:thiophen-2-carboxylic acid, 2-aminopyrimidine:(+)-camphoric acid,
2,4,6-Trinitrobenzoic acid: 2-aminopyrimidine, 2-aminopyrimidine:4-aminobenzoic acid, 2-
aminopyrimidine:bis(phenoxyacetic acid), 2-aminopyrimidine:(2,4-dichlorophenoxy)acetic
acid, 2-aminopyrimidine:(3,4-dichlorophenoxy)acetic acid, 2-aminopyrimidine:indole-2-
carboxylic acid, 2-aminopyrimidine:terephthalic acid, 2-aminopyrimidine:bis(2-nitrobenzoic
acid), 2-aminopyrimidine:bis(2-aminobenzoic acid), 2-aminopyrimidine:3-aminobenzoic
acid, 2-hexeneoic acid:isonicotinamide, 4-nitrobenzoic acid:isonicotinamide, 3,5-
dinitrobenzoic acid:isonicotinamide:4-methylbenzoic acid, 2-amino-5-nitropyrimidine:2-
amino-3-nitropyridine, 3,5-dinitrobenzoic acid:4-chlorobenzamide, 3-dimethylaminobenzoic
acid4-chlorobenzamide, fumaric acid:4-chlorobenzamide, oxine:4-nitrobenzoic acid,
oxine:3,5-dinitrobenzoic acid, oxine:3,5-dinitrosalicylic acid, 3-[2-(N',N'-
dimethylhydrazino)-4-thiazolylmethylthio]-N²-sulfamoylpropionamidine:maleic acid, 5-
fluorouracil:9-ethylhypoxanthine, 5-fluorouracil:cytosine dihydrate, 5-
fluorouracil:theophylline monohydrate, stearic acid:nicotinamide, cis-1-{{[4-(1-
imidazolylmethyl)cyclohexyl]methyl}imidazole:succinic acid, CGS18320B:succinic acid,
sulfaproxyline:caffeine, 4-aminobenzoic acid:4-aminobenzonitrile, 3,5-dinitrobenzoic
acid:isonicotinamide:3-methylbenzoic acid, 3,5-dinitrobenzoic acid:isonicotinamide:4-
(dimethylamino)benzoic acid, 3,5-dinitrobenzoic acid:isonicotinamide:4-hydroxy-3-
methoxycinnamic acid, isonicotinamide:oxalic acid, isonicotinamide:malonic acid,
isonicotinamide:succinic acid, isonicotinamide:glutaric acid, isonicotinamide:adipic acid,
benzoic acid:isonicotinamide, mazapertine:succinate, betaine:dichloronitrophenol,

betaine:pyridine:dichloronitrophenol, betaine:pyridine:pentachlorophenol, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:methyl 2,4-dihydroxybenzoate, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxypropiophenone, 4-{2-[1-(2-hydroxyethyl)-4-pyridylidene]-ethylidene}-cyclo-hexa-2,5-dien-1-one:2,4-dihydroxyacetophenone, squaric acid:4,4'-dipyridylacetylene, squaric acid:1,2-bis(4-pyridyl)ethylene, chloranilic acid:1,4-bis[(4-pyridyl)ethynyl]benzene, 4,4'-bipyridine:phthalic acid, 4,4'-dipyridylacetylene:phthalic acid, bis(pentamethylcyclopentadienyl)iron:bromanilic acid, bis(pentamethylcyclopentadienyl)iron:chloranilic acid, bis(pentamethylcyclopentadienyl)iron:cyananilic acid, pyrazinotetrathiafulvalene:chloranilic acid, phenol:pentafluorophenol, co-crystals of itraconazole, and co-crystals of topiramate.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10





Figure 11

TransForm Pharmaceuticals, Inc.


[DMXRAPID\Administrator]d:\DATA\ Monday, Jul 08, 2002 08:17a (MD)\JADES)

**Figure 12**

Sample: MM_90_110_A
Size: 1.8060 mg
Method: Ramp

DSC

File: \...\Vitraconazole\MM_90_110_A.001
Operator: MM
Run Date: 08-Jul-02 08:11
Instrument: DSC Q1000 V5.1 Build 191

**Figure 13**




Figure 14




Figure 15




Figure 16




Figure 17




Figure 18

Sample: MM_109_15_Tar
Size: 1.2140 mg
Method: Ramp

DSC

File: Y:\...ultraconazole\MM_109_15_Mal.001
Operator: MM
Run Date: 01-Aug-02 14:18
Instrument: DSC Q1000 V5.1 Build 191




Figure 19




Figure 20




Figure 21




Figure 22




Figure 23




Figure 24




Figure 25




Figure 26

Celecoxib Forms with Poloxamer 407 and Hydroxypropylcellulose
Dissolution in 5X diluted simulated gastric fluid (fasted state) at 37C





Figure 27



Dissolution profiles into 0.1 N HCl at 25 °C

Sporanox Beads (amorphous freebase) (Rectangle)

L-Malate (Inverted triangle)

L-Tartrate (Oval)

Succinate (Triangle)

Crystalline Freebase (Diamond)

Figure 28




Figure 29




Figure 30




Figure 31

Molecular structure of the Olanzapine-nicotinamide-H₂O-IPOAc crystal:




Figure 32A





Figure 32B



The Olanzapine molecules occupy the spaces shown above and are hydrogen bonded to the water molecules.




Figure 32C

The arrangement of the Olanzapine molecules is similar to that observed from the methanol solvate and the published structures for the hydrates. The water molecules bridge the Olanzapine moieties resulting in hydrogen-bonded zigzag sheets.




Figure 32D




Figure 33




Figure 34




Figure 35




Figure 36




Figure 37







Figure 38




Materials Data, Inc.

Tuesday, Sep 02, 2003 11:11a (MDI/JADE5)

Figure 39

**Figure 40****Figure 41**

**FIND PEAKS:**

Spectrum: MO-157-72C_Modafinil-Malonic

Region: 3432 200

Absolute threshold: 566.428

Sensitivity: 60

Peak list:

Position:	1004	Intensity:	48630.113
Position:	222	Intensity:	41631.178
Position:	633	Intensity:	50431.465
Position:	265	Intensity:	27932.348
Position:	1032	Intensity:	25424.109
Position:	1183	Intensity:	23465.441
Position:	814	Intensity:	21696.129
Position:	1601	Intensity:	20374.211
Position:	480	Intensity:	18917.469
Position:	718	Intensity:	18779.322
Position:	757	Intensity:	18691.541
Position:	361	Intensity:	16080.872
Position:	917	Intensity:	12651.293
Position:	1104	Intensity:	11708.740
Position:	889	Intensity:	11172.533
Position:	412	Intensity:	11137.416
Position:	1225	Intensity:	8027.109
Position:	1251	Intensity:	8844.633
Position:	1368	Intensity:	8262.702
Position:	1442	Intensity:	5738.694
Position:	1731	Intensity:	5730.659
Position:	1293	Intensity:	5700.056
Position:	3085	Intensity:	1935.514
Position:	2849	Intensity:	1012.835

Exposure time: 2.00 sec

Number of exposures: 15

Number of background exposures: 15

Grating: 360 lines/mm

Spectrograph aperture: 100 µm slit

Figure 42




Figure 43




Figure 44A




Figure 44B




Figure 45A




Figure 45B




Figure 46A



Figure 46C




Figure 46B




Figure 46D

Figure 47A




Figure 47C





Figure 47B




Figure 47D




Figure 48A




Figure 48C




Figure 48B




Figure 48D




Figure 49A




Figure 49B




Figure 50A




Figure 50B




Figure 51




Figure 52




Figure 53A




Figure 53B




Figure 53C




Figure 54A




Figure 54B




Figure 55A




Figure 55B




Figure 56A




Figure 56B




Figure 57A




Figure 57B




Figure 58A




Figure 58B




Figure 59




Figure 60

Sample: 100% L-Lactide
Date: 1-31-04
Cylinders: 10 mm
Gardner reference: Polymerside were used and




Figure 61






Figure 62

(Figure 63)


1. One-dimentional (linear) hydrogen-bonded chains:




2. Isolated rings:



3. Extended Networks:



4. Isolated triads:



INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 03/27772

A. CLASSIFICATION OF SUBJECT MATTER		
IPC 7 A61K9/14 C07C233/00 C07D233/00 A61K31/00		
<p>According to International Patent Classification (IPC) or to both national classification and IPC</p>		
<p>B. FIELDS SEARCHED</p> <p>Minimum documentation searched (classification system followed by classification symbols)</p> <p>IPC 7 A61K C07C C07D</p>		
<p>Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched</p>		
<p>Electronic data base consulted during the international search (name of data base and, where practical, search terms used)</p> <p>EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data</p>		
<p>C. DOCUMENTS CONSIDERED TO BE RELEVANT</p>		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	<p>WO 03/074474 A (ZAWOROTKO MICHAEL J ; MOULTON BRIAN (US); UNIV MICHIGAN (US); RODRIGUE) 12 September 2003 (2003-09-12)</p> <p>the whole document paragraphs [0006], [0008], [0023], [0038], [0043], [0052], [0055], [0056]; claims 1,5-11,21-24,28; examples 1-9</p> <p>-----</p> <p>-/-</p>	1-4, 13-16, 18,52, 53,62-74
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C.		<input checked="" type="checkbox"/> Patent family members are listed in annex.
<p>* Special categories of cited documents :</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>		
<p>Date of the actual completion of the international search</p> <p>10 February 2004</p>		<p>Date of mailing of the international search report</p> <p>21.06.2004</p>
<p>Name and mailing address of the ISA</p> <p>European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epoml, Fax: (+31-70) 340-3016</p>		<p>Authorized officer</p> <p>Luangkhot, N</p>

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 03/27772

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Description of document, with indication, where appropriate, of the relevant passages the whole document page 1, lines 18-23 page 14, line 27 - page 15, line 6 claims 1-5, 19, 37-45	Relevant to claim No.
P,X	WO 03/033462 A (KIM KIBUM ; UNIV MICHIGAN (US); LANG MEIDONG (US); MATZGER ADAM J (US)) 24 April 2003 (2003-04-24)	1-4, 13-16, 18,22, 24,52, 53,62-74
X	WO 01/51919 A (TRANSFORM PHARMACEUTICALS INC ; CIMA MICHAEL J (US); LEMMO ANTHONY V () 19 July 2001 (2001-07-19)	1-4, 13-16, 18,52, 53,62-74
Y	the whole document page 1, lines 10-19 page 63, lines 11-16 page 63, line 23 - page 64, line 25 page 65, lines 3-6 pages 66,68 page 16, lines 4-20 claims 1,6,11 page 35, line 15	22,24
X	WEISSBUCH I ET AL: "Understanding and control of nucleation, growth, habit, dissolution and structure of two- and three-dimensional crystals using 'tailor-made' auxiliaries" 1995, ACTA CRYSTALLOGRAPHICA. SECTION B, STRUCTURAL SCIENCE, MUNKSGAARD, COPENHAGEN, DK, PAGE(S) 115-148 , XP002960386 ISSN: 0108-7681	1-4, 13-16, 18,52, 53,62-74
Y	the whole document abstract page 145, column 2, paragraph 2	22,24
X	WO 01/42222 A (MIYAKE PATRICIA J ; FERRO LEONARD J (IL); PHARMACIA CORP (US)) 24 June 2001 (2001-06-14)	22,24
Y	the whole document pages 60,61; examples 1,2 page 1, lines 19-27 page 4, lines 5-19 page 5, line 15 - page 6, line 8 page 10, line 30 - page 14, line 19 page 48, lines 9-18 page 50, line 9 - page 56, line 34 page 60, line 11 - page 64, line 4 claims 1,57-175	22,24

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/27772

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 8.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple Inventions in this International application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-4, 13-16, 18, 52-53, 62-74 (all in part), 22 and 24 (whole)

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-4,13-16,18, 52-53, 62-74 (all in part), 22 and 24 (whole)

A co-crystal comprising celecoxib, and nicotinamide or 18-crown-16; its use in a pharmaceutical composition and method of preparation

- 1.1. claims: 1-4,13-16,18, 52-53, 62-74 (all in part), 22 (whole)

A co-crystal comprising celecoxib and nicotinamide; its use in a pharmaceutical composition and method of preparation

- 1.2. claims: 1-4, 13-16,18, 52-53, 62-74 (all in part), 24 (whole)

A co-crystal comprising celecoxib and 18-crown-16; its use in a pharmaceutical composition and method of preparation

2. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 19 (whole)

A co-crystal comprising carbamazepine and saccharin, its use in a pharmaceutical composition and method of preparation

3. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 20 (whole)

A co-crystal comprising carbamazepine and nicotinamide, its use in a pharmaceutical composition and method of preparation

4. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 21 (whole)

A co-crystal comprising carbamazepine and trimesic acid, its use in a pharmaceutical composition and method of preparation

5. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 47 (whole)

A co-crystal comprising carbamazepine and p-phthaldehyde, its use in a pharmaceutical composition and method of preparation

6. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 48 (whole)

A co-crystal comprising carbamazepine and 2,6-pyridinecarboxylic acid, its use in a pharmaceutical composition and method of preparation

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

7. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 49 (whole)

A co-crystal comprising carbamazepine and 5-nitroisophthalic acid, its use in a pharmaceutical composition and method of preparation

8. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 50 (whole)

A co-crystal comprising carbamazepine and 1,3,5,7-adamantane tetracarboxylic acid, its use in a pharmaceutical composition and method of preparation

9. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 51 (whole)

A co-crystal comprising carbamazepine and benzoquinone, its use in a pharmaceutical composition and method of preparation

10. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 25 (whole)

A co-crystal comprising itraconazole and succinic acid, its use in a pharmaceutical composition and method of preparation

11. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 26 (whole)

A co-crystal comprising itraconazole and fumaric acid, its use in a pharmaceutical composition and method of preparation

12. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 27 (whole)

A co-crystal comprising itraconazole and tartaric acid, its use in a pharmaceutical composition and method of preparation

13. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 28 (whole)

A co-crystal comprising itraconazole and malic acid, its use in a pharmaceutical composition and method of preparation

14. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 29 (whole)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A co-crystal comprising itraconazole and tartaric acid, its use in a pharmaceutical composition and method of preparation

15. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 23 (whole)

A co-crystal comprising olanzapine and nicotinamide, its use in a pharmaceutical composition and method of preparation

16. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 36 (whole)

A co-crystal comprising topiramate and 18-crown-16, its use in a pharmaceutical composition and method of preparation

17. claims: 1-4,16,18, 52-53, 62-74, 13-16 (all in part), 30-35 (whole)

A co-crystal comprising modafinil, and malonic acid or benzamide or mandelic, glycolic, fumaric or maleic acid, its use in a pharmaceutical composition and method of preparation

18. claims: 1-4, 13-15,17,18, 52-53, 62-74 (all in part), 37 (whole)

A co-crystal comprising 5-fluorouracil and uread, its use in a pharmaceutical composition and method of preparation

19. claims: 1-4, 13-15,17,18, 52-53, 62-74 (all in part), 38-40 (whole)

A co-crystal comprising hydrochlorothiazide, and nicotinic acid or 18-crown-6 or piperazine, its use in a pharmaceutical composition and method of preparation

20. claims: 1-4,13-15,17,18, 52-53, 62-74 (all in part), 41 (whole)

A co-crystal comprising acetaminophen and 4,4'-bipyridine, its use in a pharmaceutical composition and method of preparation

21. claims: 1-4,13-15,17,18, 52-53, 62-74 (all in part), 43 (whole)

A co-crystal comprising aspirine and 4,4'-bipyridine, its use in a pharmaceutical composition and method of preparation

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

22. claims: 1-4,13-15,17,18, 52-53, 62-74 (all in part), 45-46 (whole)

A co-crystal comprising flurbiprofen, and 4,4'-bipyridine or trans-1,2-bis(4-pyridyl)ethylene, its use in a pharmaceutical composition and method of preparation

23. claims: 1-4,13-15,17,18, 52-53, 62-74 (all in part), 42 (whole)

A co-crystal comprising phenytoin and pyridone, its use in a pharmaceutical composition and method of preparation

24. claims: 1-4,13-15,17,18, 52-53, 62-74 (all in part), 44 (whole)

A co-crystal comprising ibuprofen and 4,4'-bipyridine, its use in a pharmaceutical composition and method of preparation

25. claims: 5,54-56 (whole), 62-74 (in part)

A pharmaceutical co-crystal composition comprising a/ a solid active pharmaceutical ingredient (API), b/ a solid co-crystal former, c/ a third molecule, wherein the API and the third molecule are bonded to each other, and the co-crystal former and the third molecule are hydrogen bonded to each other; and its method of preparation

26. claims: 6-7 (whole), 62-72 (in part)

A pharmaceutical co-crystal composition comprising a/ an active pharmaceutical ingredient (API), b/ a co-crystal former, wherein (a) is liquid and (b) is solid at room temperature, and (a) and (b) are hydrogen bonded to each other; and its method of preparation

27. claims: 8-9,57-58 (whole), 62-74 (in part)

A pharmaceutical co-crystal composition comprising a1/ a solid active pharmaceutical ingredient (API), a2/ a second solid API, wherein (a1) and (a2) are hydrogen bonded to each other; and its method of preparation

28. claims: 10-12, 59-61 (whole), 62-72 (in part)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A pharmaceutical co-crystal composition comprising b1/ a solid co-crystal former, b2/ a second solid co-crystal former, wherein (b1) and (b2) are hydrogen bonded to each other; and its method of preparation

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 03/27772

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03074474	A	12-09-2003	WO 03074474 A2 US 2003224006 A1	12-09-2003 04-12-2003
WO 03033462	A	24-04-2003	US 2003113802 A1 WO 03033462 A2	19-06-2003 24-04-2003
WO 0151919	A	19-07-2001	AU 2930501 A BR 0107456 A CA 2396079 A1 CZ 20022332 A3 EP 1248869 A2 JP 2003519698 T NZ 519984 A SK 9742002 A3 WO 0151919 A2 US 2003162226 A1 US 2002048610 A1	24-07-2001 08-10-2002 19-07-2001 15-01-2003 16-10-2002 24-06-2003 26-03-2004 04-02-2003 19-07-2001 28-08-2003 25-04-2002
WO 0142222	A	14-06-2001	AU 1805901 A AU 1930301 A AU 1931001 A AU 1931101 A AU 2041201 A AU 750978 B2 AU 2057101 A BG 105808 A BG 105873 A BR 0008058 A BR 0008059 A BR 0008060 A BR 0008088 A CA 2362673 A1 CA 2362675 A1 CA 2362815 A1 CA 2362816 A1 CN 1376146 T CN 1379669 T CN 1411447 T CZ 20012875 A3 CZ 20013162 A3 CZ 20013163 A3 CZ 20013210 A3 EA 3639 B1 EA 3612 B1 EA 3464 B1 EE 200100414 A EE 200100419 A EP 1175214 A2 EP 1165072 A2 EP 1150959 A1 EP 1150960 A1 HR 20010582 A1 HR 20010589 A1 HU 0200409 A2 HU 0200580 A2 HU 0201450 A2 HU 0201463 A2 JP 2003523954 T	18-06-2001 18-06-2001 18-06-2001 18-06-2001 18-06-2001 01-08-2002 18-06-2001 30-09-2002 30-04-2002 26-03-2002 26-03-2002 05-02-2002 09-04-2002 14-06-2001 14-06-2001 14-06-2001 14-06-2001 14-06-2001 23-10-2002 13-11-2002 16-04-2003 13-02-2002 12-06-2002 12-06-2002 13-03-2002 28-08-2003 26-06-2003 26-06-2003 16-12-2002 16-12-2002 30-01-2002 02-01-2002 07-11-2001 07-11-2001 31-08-2002 31-08-2002 29-06-2002 28-11-2002 28-12-2002 28-05-2004 12-08-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/US 03/27772

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0142222	A	JP 2003516353 T	13-05-2003
		JP 2004500358 T	08-01-2004
		JP 2003516394 T	13-05-2003
		MA 25868 A1	01-10-2003
		NO 20013855 A	05-10-2001
		NO 20013858 A	08-10-2001